var title_f34_33_35344="Dexamethasone: Pediatric drug information";
var content_f34_33_35344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexamethasone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618515\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12644928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/51/5941?source=see_link\">",
"       Dexamethasone (ophthalmic): Pediatric drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/18/6442?source=see_link\">",
"       Dexamethasone (systemic): Pediatric drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13214 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-122.72.76.133-B89E15691A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35344=[""].join("\n");
var outline_f34_33_35344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/51/5941?source=related_link\">",
"      Dexamethasone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?6/18/6442?source=related_link\">",
"      Dexamethasone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35345="Patient information: Central line infections (The Basics)";
var content_f34_33_35345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17165\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/8/10368\">",
"         Central line",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/16/34050\">",
"         Patient information: Going home from the hospital (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/50/33569\">",
"         Patient information: Sepsis in adults (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Central line infections (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/central-line-infections-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15868497\">",
"      <span class=\"h1\">",
"       What is a central line?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A central line is a small tube that goes into one of your large veins, most often in the neck, chest, or arm (",
"      <a class=\"graphic graphic_figure graphicRef82134 \" href=\"mobipreview.htm?10/8/10368\">",
"       figure 1",
"      </a>",
"      ). Your doctors and nurses can use the central line to draw blood or to give you medicines and fluids.",
"     </p>",
"     <p>",
"      If you have a central line, you will probably be staying in the hospital. In some cases, though, people go home with a central line.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868514\">",
"      <span class=\"h1\">",
"       What are the signs of a central line infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The signs of a central line infection include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Redness or swelling around the site of the central line",
"       </li>",
"       <li>",
"        Bad smelling pus around the site of the central line",
"       </li>",
"       <li>",
"        The skin around the site is warm to the touch",
"       </li>",
"       <li>",
"        Fever of 100.4&deg;F (38&deg;C) or higher",
"       </li>",
"       <li>",
"        Chills",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Be sure to tell your doctor or nurse right away if you have increased pain at the central line site or if it feels warm or starts to smell.",
"     </p>",
"     <p>",
"      A central line infection can be very serious. It can lead to an infection in the blood.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868529\">",
"      <span class=\"h1\">",
"       What happens if my central line gets infected?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your central line gets infected, your doctors and nurses will give you antibiotics to fight the infection. They might have to remove or replace the central line, but that is not always necessary.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868546\">",
"      <span class=\"h1\">",
"       What can I do to prevent a central line infection?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Wash your hands often with soap and water or alcohol-based hand cleaner.",
"       </li>",
"       <li>",
"        Do not touch the central line or the skin around the central line with your bare hands.",
"       </li>",
"       <li>",
"        Make sure your doctors and nurses wash their hands or use alcohol-based hand cleaner before they touch you. It is OK to remind them if they forget!",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The doctors and nurses caring for you will also take steps to prevent infection.",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The doctors or nurses will change the bandage around your central line on a regular basis. Be sure to tell them if it gets wet or dirty between regular changes.",
"       </li>",
"       <li>",
"        The doctors and nurses will check your central line every day for signs of infection or other problems.",
"       </li>",
"       <li>",
"        The doctors and nurses will take out your central line as soon as you no longer need it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868561\">",
"      <span class=\"h1\">",
"       What should I do if I leave the hospital with a central line?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you go home with a central line, be sure to ask when and how you can bathe, how to care for the central line, and how to change the bandage around it. Do the following things to reduce the risk of infection:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Always wash your hands with soap and water or alcohol based cleaner before caring for your central line.",
"       </li>",
"       <li>",
"        Wear new, disposable gloves when caring for your central line.",
"       </li>",
"       <li>",
"        Watch carefully for any signs of infection (listed above) and call your doctor or nurse right away if you have any of the signs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15868576\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33569?source=see_link\">",
"       Patient information: Sepsis in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=see_link\">",
"       Patient information: Going home from the hospital (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?34/33/35345?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17165 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-49B032D4AE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35345=[""].join("\n");
var outline_f34_33_35345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868497\">",
"      What is a central line?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868514\">",
"      What are the signs of a central line infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868529\">",
"      What happens if my central line gets infected?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868546\">",
"      What can I do to prevent a central line infection?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868561\">",
"      What should I do if I leave the hospital with a central line?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15868576\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17165\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/8/10368\">",
"      Central line",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?33/16/34050?source=related_link\">",
"      Patient information: Going home from the hospital (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35346="Robot surg immersive syst";
var content_f34_33_35346=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79637&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Robot-assisted laparoscopy surgical system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 308px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE0AgQDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6lJOTzRk+tB6mkoAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkooAXJ9aMn1pKKAFyfWjJ9aSigBcn1oyfWkqO4nit4zJPIkaDqznAoAlyfWjJ9arW97a3Klre5hkUHBKuDipDPCOssY+rCgCXJ9aMn1qAXVuWCieIsTgAOCTU1AC5PrRk+tJRQAuT60ZPrSUUAKCfWigUUAB6mkpT1NJQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFYfiaaaIW6wSNGW3ZIOOmP8a3KwPFH+stB7P8A+y0AecP8QQNJe/e1u3j8xoo4xJl5CM5wPTjrSt47ihjje+t5LQvHvCyTfNk9BjGTn2z74rynTNU+2X01nCVeOJ3EQI3+WSWJwvrjP6etYcAjfxS1vdQ3z6X92Sc5VpGHUglRjnn26EnrXmQxNSSl71reW57awNNWTW9+v3I9Vv8A4r2cEfmCISLkgkMSRjqMdc/XH6GrmneKfEGrxJdWOmWlvZMo+a5LF2OOwUjj61yeuab4QtLFJVS4ZNhjVpG3uOMZHQdB1AzxVPV/ifY6Jo5s9MsL6ZVgCq+0pt4xkk5Ofzrpp1Lq8569jnr0XtSpNebuez+Eb6a/tNNvLlYlmkkG4R8KPnxxyew9a9Hryn4YSy6n4X8OzhAslxEkzAt90H5j9a9WrqPM23CiiigAooooAUUUCigAPU0lKeppKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoorn/F2p3emQW7WewF2IbI56dqAOgorgbXxVeiVDO52bhuBReRnnoBXSL4m05/uO7HvhelAG1RVKw1O2vmdIHJdBkqeoFXaACs/xBeyadol9dwKrSwws6h+mQO9aFZfimNpfDepoiszNbyAKoyT8poA80s/iFrErMty1umACDHDn9Ca0F8a3zD/j6x9Ldf8AGvPnPlvnkZFSaPpLX7NE1/cIq4YsWYnvxwQcc/oPSmkrCO+/4Ti8iO4z+YP7pt1x+jCug0rxklzZJLPBtdmIGDjP4c/zrgf+EJuJIt8OotcEcqrAqDyD1yfSk1uG407wheKxMV1FGw3IwypJ6g/jSk0ldFQTlKx6UfFEWDi3Of8Ae/8ArVwPi0+JdW8QWGo6V4jm0yG1bP2WEkRyrkHa6lSGPB+Y+vCjknhNY1ZluLaaG9uVsoQFWKI5a5YZBY98A5yciqEPinVNRVU0zT7iSHcTv/evxnkbh0x2BDH1JrjWLTipcrs9Putf80d6y+XWS/4e9vyPez4muN5IkhC/3fspJH4+YP5VGfFNyGBMkOzPI+ynP5+bXgugL4i1zV3tL24u7K1CZcv8zsD2z0Bxj+ePTuNN0i103WPs9tNI5it9xDvuOCeCSTnPBrpg5S1lGxzVqcKb5YyTfke3afdLe2UVwisqyLuAbrViub0LVwkNhZtblU8sIZd4wCF6ke+P1rowQRkHI9RVmAtFFNd1jRndgqqMlicAD1NADqK4ib4gWU086WJTyUTelxLkLKMZJQcFgB3FLY+NgEimvRCbSXAjlXdGzE9Plb/EfjWnspWvYnnR21FRW08VzBHNA4eORQykdwalrMoK5DxCzf8ACRbSx2i2QgZ4GWb/AArr68bv/HNg/jnxCl5Dd2dpYGO0WeWJmE0il/M2hQcKMrgnrk+lAHmGhRa/aXn2zTdHtbaJ+Bdz3UTFlPPA3ZHHbGcV0euXGv6lK1vbQ6RbRnAMrXHzbf7y46c/061sW/w9udcsbW7sPEFw9hIqvCbe3C/LjgcsSOOxAPrVxvhTLKkSTajq0gQAHLAbsZ6jpjpx7VxuFSW6t80enSlh6fvc136M8n1DwNfX10supa3odrGqbtv21mEnP8XygLkdwDVfXNFg0qwOy60y8yAhht7sSH1z9zOAM9Bkjoa9rtPhRBEZmdtSmaZdjl5ogCOeMbeBz0qeP4R2RtpYXNy8cgAdZZUO7HTovUevWsVhZPRpfeds80V9JN/JIvfCAAeHvD4CBAtmvyg5C/L0r0yuZ8J+GhoFva28JUW1tEIo13FiABgZJrpJHWNS0jBVHUscAV6KVlY8GUuZtjqKbHIkqbo3V19VORTqZIUUUUAKKKBRQAHqaSlPU0lABRRRQAUUUUAFFFFABRRRQAUUU2WRIo2kldURRksxwAPc0AOormNU8e+F9MyLnWbVm/uwMZj/AOOZx+Ncve/GbQYiVtLS/uCO5VUU/iTn9KdmB6fRXjcvxuTOIdD49Xuv6bKh/wCF1Tk8aTCB/wBdif6UcrA9qorx+H4zgnEmkIf925x/7LWnbfF/SnwbmxuYh3KMr/4UWYHptFcZZ/Evwxc433r25PAE0RH8s1vWniPRbsA2+q2T57ecoP5E5pAatFIrKyhlIKnoQetLQAUUUUAFFFFABRRRQAVy3j8qtjasxA/e4/Q/4V1Nc544XdptufScD/x1qAOHguInm8kbt/YbTg/Q1DrLXazR2FrOLJ3hmmeVsKV8vYAuSDtyXyTgkBTjnmtu1RQQQB+VU9UsYtQ3xXETYBO2RH2suRg49iCQRyCOCDQtBk/wpu5mkuTd3puYpIvMid8AhfMdQfXDKEYAkkZYZ6AeiG8th1uIR/wMV5pD4Zgt9Pc2U0rTPgl268ZwvAAAGTwABkk965m9iu4WYF5QR23EU3q9CT2TU9e03TrUzz3UbKDjEbBjn6ZrDvPHukpayOUuCu08rsP6Bs15bHe3W1Q00nTnmpZMy6fMD3BosFzz7VJ4tU1yzlt5nMItnBXLAEg+nrz3rtfh5hfDFjMx/efZEZn7scdz3rynQ9QibW7O1y/mGKcAADadpwc/lXqvw7YN4bsY2YAG2VRk1PQZ6HYljAMEAg9xmuX+I5mPhDUUgAaeR441wuesygnHsMn8K6DR3LWaE9SAT+IrnvHq2s+ieRfyFLaWcCQq7KcZLdV56jtUzaUXfY0hzcy5dzi/D/hq71Lw9JB9stLfUGVgVc+Y6IScnI6Hr+dbVkt/4MilVL5H0aH5XEUZAh2jJAGTye3OWJ5yc1yq6p4K0qW8t4N4HlMWkF3PllHJGRjtgH8a9N8IHw/rGkTRW6WdzHOpFwmd5fd13kjcxOPvHJPXNec6SaShseo6tSOtdX8rI8ef4half3E7acIII3yEdoATHkjA3AjA4GQa2/hLea1feJNduNbu3uVjijSLOAoBZjwBx/DXRa94bg0a/FlpfhJp7Z1Xy5beeVAVPBLAAjIK8nqeDms74bWt1HL4gFykyStJHEPNk8xRgOQFbJyAGAz7VvQVRVEm7oeKlhnRbhGz06k2j6tqX2sx20/lwvcNbRl975fYzkkB12rwRwCc+1e5/Du4e78H6fcSArJIHZ1LFtrb2yMnrg55rym38C3dsHuotVWBc+c6eWG2vtK7k3DhipI5yPbrXrXgKFLfwjp0MSsqRqyqGOTgO3U9zXe2rHiI364j4v6w2meC7yOBh511i3P+yjcMfpjI/Gu3rzXxzaw3WoXcOosDbDbMN38ICjkfr0qJRck0jSDUZJs8Y8PaqE0eGSHyoprX91OzM6BV+8eAQrfUj15451b3XLsuIbXEqujHeVOd6/dG0kk4LDH0/Cs621PT2vbq3iW48ppEEbTERxFS2Au1cMCQPUDrx2Mt3d3MTTxWYFnFBD5cLWyhFkLLjnb8xVR0ya9GjP2lOMjmqx5Kjj5ntnwcu7m88LZv0EV7E/lTRgk7SADjB5HXoea7yvLv2f4L5PCl1NdhfJmuW8p+8gVVBf6Ft4/4DXqNcVRWmzWHwo5P4lz3sHh6NtOmkhla4RWaOQoxU54DDkc4ryWbUbUXEsOrZW7VsP8Aab2DLHg5+Z9x4I6gV6/8Qx/xIY/+vmP+dfMXxv1Sfwd4gtb+3gtrs6j5h2TrlU2LGvY5Oc0kl1KPQotQsFWP7PfW9osZOAlyWHPOcJx1960v+EpdYdn/AAk4AAwComyP/H6+XLr4natOwP2LTYwOgjhK/wAjz+NVx8RtZAYLFZAMMHEbcjOf73sKr3Ban1N/wmcFuWkuvFBZBzgwXBAH1yasL43s5og1tqZnB/iW0nI/mK+Rb/xrqd9D5NxHaNHkEr5ZwfrzzU1n8QdeskCWclrDGBgItshUfRSMfpR7oan1Le+MIUQyT3cscQ6v9lKr0z1ZyOlP8K+IYtb11obG9mlgSASbvLQAkkdGAIIwR0NfKN3478QXalJryIoRgqLaIAjGORtx0r3r9nEm80n+0J+bljJASvyqEQptAQAKOvUdePTlXj0DU7XXhNHeyNBczRyDuuBn68f1r0D4SXFxc+Hrp7u5muJFu2QGRy20BEOBknA5rhPEYY3DbSBzzXd/CEY8OXf/AF+v/wCgJUsZ3FFFFIBRRQKKAA9TSUp6mkoAKKKKACiiigAoqhrepw6Tp8lzN8xHCIDy7dhXFv441B8+Va2yA9N25sfqKAPQ6K8uuPE2uzgiO7SHPZIl/rk1zut3/i+SEnTdS3y+ks7xr/47zQB7jI6xxs8jBUUFmY9AB3r5B8b+JNR8S69eXM13ctYvMWt4Gc7I0/hAXoDjGfeptX1n4jLcNb6raIdPdWWSaCaSViCCMAFs/jtrHhYEEA8jgj0rSmuomVkViPvGn7JMcEGrRHHQUqkA8itCSofNX7ykUCR+xrSidG4JxnsafJYLKMxfI3p2o0AyS79aQXDjuammhkjkKOMGozESOlVyoVyfSILrVdTgsbZlE0xIXccDgEn9Aa7+D4dTBVL6xtb0S3yB+bV59ZSTWN7BdWx2zQuHU+4r3Hw/qkOtaZHcwEKxGJIweY27g1lUuti46mLp/hXU9OIax8R3UD+scZXP5PXSWOp+M9PKhdQstSjH8NzGUb8xz+ZrgNW8YapY69NYzwWsIjYKM5JIPQ9e9U/Hnia9udEj0nSpU+2X+6OZ4sgxRgZYZPGTnH51i5WV2Wld2Ov1L9obStME1vd6e0t7E2w/Zpg8ZYHB59MZ6Z/wo6B+0tpl3qZh1XRZrOzYkLNFOJGX6qQuenUH8DXjml/DydFb7VG8juMhx93gHsef5dKku/CiWDpDIqx42nc+CFbdtz+WDj3rm9rLc6FSifZ3h7XtL8Raet9ot7Fd2zfxIeQfQg8g+xFadfGPwx8ZTeEfGNncCQpp0uILqHIG9PmCtjpuHynPc59TX2FpOpWurWMd3YyiWF+46g9wR2PtW8J8yMJw5WXKKKKsgKz9c046nZiASCJlcOGK7ugPbI9a8/11S2tXpkJkPmsFD8hRnpUuk61f6VE6QRwzIxztfIx9MYAoGdCPC9w8TRterECMb40JYfTJ4/WqvinT4tKtoLi1SYxl9srM5fAPTr05ptt42uN2270lgP70coP6f/XrQl8S2l3A0f2SZ4pFKsrjHHccZoEZGnXAhIxzEw5x/OsL4heHLjUbUXmmTyJKi/MiE4kX6ev86to6WUzozMLXJKu/G3vyar2XiFNQ8/7PdrFp8Gd7E7SeOTnqo7/54EDPMtE0bU7xVut0k9uqEsRyM4/X8K6e1aP7Cyk/w9hj+taWla7PesZ9NtoF0NC0cUjEmWdgfmZFHRR6tySfXOKPiGJbeE3luQYZfvbegJ7j2NNCaPBdDiaPx1bKA21TejJ9MkivXfhfKWsEQ8hbdBj8681sJoo9dnkbbvG7bnrg5zivQ/hW6tZSNuI2wxjjH+1/hSGdTe3Utg3mXGqRWenqQmSoTbnpliTnv6fSsabxZp72e03aXk2QI28hirN0HIGPxo1KCW7vIojdMqTK0jHbkpggYHI45zVK88I3emWInh1Ke6Uck3MhJAx1759f84p6C1OT8d6XqesTaZdXNvJb3Uwk0uSOK2bYkbbgZck8qS6EDj7vBPbsPCtkdCS1h+2TSS2kSRZYbRIqgDlcnAOM4zxW147ErR6C9k8r211qFugaFAwC4LeZuwcjgDnjmuwg+HtvrMcepyareC5lGGJCMDt+UdAOyj8aSae49UYuja1vlYXzF5Cx2yuSSBnofStNLMNdmUNI0ZYnDHjOfYU/XvBVjoulvcnU3+0/djWUKFlP90Drms3T70tZREsVaEhdwPb3r0nyV43RxrmpPU1/Et6lrpYiZtu8bmx2Ucn+ldv4WR4/DmmiWPy5DAjOmMYYjJH5mvMb+Sy1HVLeOeXAjVJJUPSVN5O3PQZ2tnrwa9GtvE+nzRsWdlkX7yAZwOxB7j/A1xzoTj0OiNSMupuVk63oVvqrRyuTHcRjCyAZ49CO4qC58V6RbqGkuSc4GFjYnJ6DgcfyrlPEHivWLiSaLRJ7OzQD5Hli81m9iNwA+ozRCjOT7BKpFHjHj/TLTw/4t1Gz0+2ZCnlb44v3kEpyH4j/AICARjBxnsOc5EM8EqJDqc07wNKGaTaT8u4YTdnHpwScYziu+/skOyS3YDXv3pXViQzEnJ55/OsjWPD1jcXsMt3bQSkBjyu1iRjBJHPH9a9GjQ5I8tzmq1vaNSsfQfg680+50ZIdJSKO3syLby4nDqhCqwAI65VlOevPPNbleV/BC8MSX+kxRottEftCsWZnZmIBySTxgAflXqleZVg4TcWdUJc0bnMfET/kXgfS4i/9Cr5Z/amt2ll8OOrRjmdTuIXqI/Xr0/Dj1r6n+In/ACLTn0ni/wDQxXzr+0BBcTLojWbMLhJHKbGRichR91iB3qOhZ8wUU7bwTxwcV9M/D/4XeD9S8LadfatpiyyXNrDKHW8mDMTGpcsowFO8nABPGOnSkB8yUV9QHwv8Hojua1hKY7z3mc/UHp+Fa8Xw3+Ht3Ypd6bokElu8bsr+dcnPynaQS4xyO4o3A+SK+oP2ZP8AkVQc/wDLxOMYH/TL8e/+ea+dPFNvDaeItRt7ZAkMczKijoBnpX0P+zGD/wAIszfw/aZ1zs7gQn73fr07fjQgZ6B4ifZcPwDknqwHau5+D5z4cu8/8/jf+gJXCeIz+/fnHXqQB09+td18HuPDt4P+nxu2P4EpsDu6KKKQCiigUUAB6mkpT1NJQAUUUUAFFFFAHE/EeXJsIAf77kfkB/WuSiXAroviA4bWoUH8MAz+LGsKJelIZX1IslhMUJWRhsQjqGb5QfzIq8qj0qtqKFltYgP9ZcJ/46d//stXxGaAIzGjqQ6gg9iMisrVPDOmakMzW6CTGA4GCPoRyPwra2EUh4ovYDyvXvBWoafmTTm+1Q9fKkOG/Bv6H865QSL5rQyq0M68NFINrCvoBX7MMiuf8VeEbHXbYkoFmAOyReGQ+x9PatIz7iaPISMdqsWl20DANlk7juPpVfVLK+8P3a2uqrujY/up1Hyv/gfamghgCpyK03IOkMEN9D2II+Vh1X/PpWNPaPBK0ci4YfqPWnaRffZLgCQ5hY4YenvXRapAtxbBlwXj5z/s96adhtXOZEPHStXw7qk2i6gk8THyyQJU7Ovp/hUPkE9BUM8BxgU3qJHo3jDSoPEujJfaRHby6lGnmWkkuQGx/AxUgjnI68H8a8j8J+Ijq+oXB1uBbK/tmMU0YV9ylTjncSc9vwFegfDbUHgu5dNmb5JcyRZPRgOQPqBn/gPvXCftC6LNomt2firTkCW97i2uwo/5agHa31Kgj/gPvXJVp9EbU5JO7Oyn1a2iaK3t0ZrhEMqIy53AdcZwM8/56VlatfreR5hPlmb5lBYZII5GehBz1rm/D8yXVra3CzGdthKy5KBTxgcfjWvp+mtIixXEyptmleJIz8ojZ8qOnpgfgK811mmz1o4ZOKfUw7jw/C0UlwSX7kjLBgG+6cj3xx35r13wjq0/heWymtXd7N4082LORIoGPzHY1mafHa267ZmEobswAHUn+tWNUjT7LGLQALGMKg4GPatcPXip2exz4jDycNNz6DsrqG9tIrm1kEkEqhkYdxU9eT/BXX2klu9EnJyoNxCD/DyAy/mQfzr1ivQaseceWeLXli1a+MewEOSMn2+lY2gX8kzXMer+ZCVI8l44Sdw5zu5Ht6VueOhs1m96AEKef9wVk6Wz6n5g0+Oa48ogP5cbEKT74pDLc91BFko0kgHpGQfyqpq12w0fzYGkiieSMSyDKtHEZFEjeowu7nt17Voxaffx4DWF7/34Y/yFDJLG5WQPG3dHTaR+B5oQHOaF4i8O6PZa/a6qjTQ3cu63RrUOMhOpAXHVsBuSQAcng1z+mWq39hNbbS8Iw4iBIBHrgdQOuP0Navi3THKwLZWjkDcSsMOAOnOFFZ2jM0aE4Kuqj8Kb1ZJ02g6XNaadHBZSOgh3GMn7oLHJ47A/56VUF5FuntL6IxwPlJomH+qb+8PQHr6A4I4JNa/hfWku7byJPlJYr/wIdv8ACodbs/t7l4EVb+IEbNwzKnPBHc/p1FNDPnjxdb3nhzxPd2NxC5jl+aC4H3XTkhvx5GOxBrqfhJe3PlS+bFIkTpGsTHo+N2cfpW/4i8P/ANv6c9s5jW6syZLPccNtIw0TA9geh+no1YXhHdb6FpycqVLZ7Y+ZqVhHZ6rO9teaW6kYeVo2z/dYdv8AgW0/nWzf3KrpksatH9pKfuULAMTt7ZNc94gbdp9tN/zzlVv6/wBKt32nw3mq2lxKzgxQvjaecFSDj35/SgZ8p3N5cve3UdtLKVnzCUVid6bgQvuMqpx7V+hngJI/Dfws8Prf7oVstKgM24YIYRLuGPXORj8K8I8AeGYb3xj4eik8JWMEiS+f/aCzqD5UBUqxQrneSADnHPOT29c+LerK7WmhRMcvi5uCOyAkKv4kZ/4CKlNsb0OI8ZeJ0kaXXNdmW1tUwtskjfKm44Ucc+hJH16CqWlX/nOyxkuFUESZBDD/ABrlfHUq6y0elY3WzENKB3UH/I/KtCNNQL2ljpUcZeQ7p938CdyfQAe/XpmuilN03dGU4qSszpZXkF8swAMRjEZXuCCxz+O4/lR5zw3KtG5Q/wB4EgOvdSf1Hv8AU1DZvJc6zFptpBK+5FUSykDc+cbSDggnIPIx71f1C0uNPm8m9t5YJT/DIuN3uD0P1FepCrGfqcMoOJXupXk3K5BOMqccN0wf0FEU8jxLlskcEH/OR9Dn60wlCu1gyjtxxSxjngg9sj+taEEqSFTnFZerO5PmMTg5Vfp1Y/oPyq3dz/Z4843MeFX1PYVW1MPFKh3FiIwhPuOc/nTStqBo/Dq+k0fWY72YbY3yko/6Zn+eMA/hXvysGUMpBUjII718vzapJFERJg8Yz0r6T0JGj0TT0kUq628YZW6ghRkGvNxsbNSOzDS0aMj4if8AIrze00P/AKMWvDvirfaLawwweJFmS3udyQ3DwiaKM7R/CDu6+x6duK9y+If/ACKlz7Sw/wDo1a+bP2iSqR+G5mSNtk7DmRoyAQM/vAcRjj8ePSuLodJ5jo/gWw8UtcyaJrc1ytuVEoi0soE3Z25y467W/KvVdC03xLpGmWllZRxNHbIqJI2lMXOAMEn7QBnisD9lZXa08XiJN7kWoAPQnE/WvbrS3vDbxteW0Qnbb5qqSVU4528c8+uO9Ju3Qa1OAz4z3AqsSkcDbokY/nc0RReNBH5f2i5CFQhA0qI8D63fWu5lsLuWQ5gREZIzlJjwy7iQB5fQnaCc8jsMct0bT762uC1zGAvl7flnMnPy+qL6Hmkm29gtY+YPGvh7RdM8QXEfiLWtbg1KTErqNHhIw3Qjbc4r1n9nY2C6PKmmtLLFHPOgnlTynkGYiCYwzAHBHOT6dq4H9pcQ/wDCXW5Dp9pEYV0DDcq7VIyOvc12n7MbH/hF5hlsfbbjjfx9y2/h/rVITPRPELfv3AJyeMDvxXd/B/jw9ecY/wBMbt/sJXA+ImHnupI5zwTjPH5fnXefB7/kX74bSMXrdRjPyJQwO8ooopAKKKBRQAHqaSlPU0lABRRRQAUUUUAeZ+L5PM8TXQ7IEUf98g/1qpAucCl1t/M8QageuJmX8jj+lS2w70hkdyoN1Yp3EjP+SMP/AGYVe21TmGdbsV/6YTN+OYx/U1p7eKAKxWonWrbLUTrQBUYUsUhjb1HcU+QYqA0AVfFHh+z8QaVJDcJuRxkMOGU9mB7EV4Pe2dzoGtS6VfsCwG+GToJYz0PsexHY+2M/RVlLsk2Mfkbj8a4j4u+Fzq+iPcWMedSsgZ7Yjq396P6MBj64ParjKwmjy9yMVuaZqTGzRWPKfLz3rlLC9S8soZ0OQyjNXYZPLJweDzWpK0PQ7PTBcafDcqRscH9CQf1FVbiwVDyRWLp2uyW9j5G8gBiR7Zx/9emXGss2cvVJCZpq62FzDdx53QOJMDuAckfj0/Guu+KGkx678PNdsyA7rbtcRFeSXj+cY+u3H415Zcavx96vSpvEVnZeF7OS8lULNZxlgT13IM1FRbFRPl7wPr02n3P2LeBDO3y7uzdP1rvk1LUTqUEUYMjk7VWPJJ/zzXB+APCzeItalt5iY7a3G6aVeSpzwByOT/SvoTw94fstFgJto2luNuDPO2+Rh7n/AAxXMsseIkpp2XU7aWYOhDlau+hNo+lvJEkmoOfMXoingfU9/wAK6GO3gIAwvH+yD/MVRs7qOaWSMArJGASPUEDB/WrCknnNexSwVGlHljFfqefVxVWpLmbL1t/odyLi0ZoZwCu+PhsHqMiug07xjqVnGElKXSDgGXO4fiP65rlo5c8NT3HGRn6itHQp2tYy55PW56fpfivS9T2R3QFvMeizYK59m6fniulXGBtxjtivCOccgMPUV1XgjxG1hcrY3subJ+ELn/VN/RT+n51y1sJZc0DSNS+jPTq898VSiPxFcKGw7BDj22j/AAr0IVka9oFnrMX79THcKPknj4dccj6j2rgNTh/tqwKJXlEJTo+cY7fr0x3zXLeI7+yt5IorPS4lv2k8srEPLaQ9SSucKAASTgelbut6Xd6U0dvqjyrA8qLFdwRlwTngNwdvbk8e/eqeo28l1Mba+it/ND5SXJLLGOr5HIyTtHIPrTjFt2QNpK7MuCxVLY3tlaS2887BmWQFDlcgjGdueeSOvBzjrsRsuqW0VyiuZ7cHfGiDe3tnqOeccc1yp1iewvJLPVxJJYmTbDeIwDjjIJIPIGepwevDDJrT3XFswuYbjerdLq3BwwPaVB7fxL7HiqcXHRiTUldEXjGA3Nq91p8Jj1aEebPGnzLz1G7pv4zgfrxnznRZGbR7WVwAzu7HHuzGvV0lgbTzasiW9uQUOZMiRWwMhvUlsfU/Q1w17bRTIyWoXZvaWMqQRIhJO4EfX9R0zWsqaik07mUZuTaaIL24nuNO+zxMgBPJcnpz/jWhrmpPpuiTX6sfMt7B5FKqD8xwBwfcisTDopBBFQ+L75V8H3kbHnyrZcnpg3CA/oDUSRcR3wZ8Za3q/wAQ/A8Kq5dlu0vCsWEeIhmySBxzg49QPXFen/HPRdctLuXxBpMTXNo0SpOI8s8G3Pzbf7uMc9uc+tY/7NHyXsUKkbV0xW49WMbH/wBCr3DxTrEehaFdX8mC0a4jQ/xueFH5/pmoTsynqfKXhvzLtGvrhAZJGwoB+9jp9O/4Cursry2FlILW4D3CyP8Aatp2ncm3auT/AAfMW9xg5rnNReZXdJAyJMXMkiKQAuMtnAwoJ9OoxjqVPqHwu+GNleW9tr/iO2LSNhrS1JwoiwceYP4gc52njpnPQaRkoy5miJRco8qZf+D/AIeu7i/k8Q6rEURV8uyyoHmg8mQD07DpnJPoa9XubeG6haK5hjmibqkihgfwNSgADA4FZPiPXrTQrRZbpsySNsiiB+Z29BUVarnJzY6dPlSgjzv4j6PHo15YyaXFtiud++MsWwRtwRnoOfWuSW8i27pV2DIAbacNkA5GO3PWtfxF4vh8T3cJt3Qx2xZCY+VBJGee/Qc/SuNv7oHT5RFKFCQR3GFU4CuzBQPxQjrxxXrYRudNNnFXXLNot20ranqpTbiO1kyGHfB4/l+hqe8k33bo/B7VS0l76C0Te8aTsoaQMm4knoOD1xjoKo3+qhNVa0vkFrcnmF92UmX2OBg+qnp79a6WrvQxXmdN4F0dNZ8Z2VtcqPIt83Lr/f24IH0zjPtmvoWvIfgxLby65fM6n7WbYbD6IGG79SlevV5GMk3Ut2O/Dq0bnOfEIf8AFJ3f+/D/AOjUr5w+PyTm10S4g81BBOGeZFGIhzyc/Kf+BEAY9zX0Z8Siw8FaiU+8PLI+vmLXyV4z1fWLPW7m0ASaOQhm85AeCNwBGOQM4H49K5oq+htsH7NFvbTWfix7mCOUxC2ZSybivE3T9Pyr2CwWwu7SK5is4fJmCmMG3G7BXPzccd/0rw3S9a1uCV0sFtLdpBlvKj8vdtBPOOvf86kbxh4kH/LwfwZh/WqdJvZgpeR7VMkG8rBY233Y3XzLJgMEtuydmM4HA6564yMpohgu7oxT2FmB5W//AI8nTn5f76D16da8T/4TPxDyBdMT6CV/8aUeM/Eef9fIf+27/wCNJUmuoOXkN/aPhSHXLJYY0jiwdqoAAPlTPFdf+zMSvhyUHPN3ckfKOfktu/X+lcHq+saheTEarYW93MnH78+YR+JzXoXwRv7iTU5bOXTorJBC8qeWwAwGQEbQOOWz1/AU3C2ornoGv48+Q8ZAIye3H5du9d58H+NBvgBj/S2/9ASuB17md8df/sT/AJ5rvfg9j+wb7GP+Ptv/AEBahlHe0UUUgFFFAooAD1NJSnqaSgAooooAKKKz7zWdPs3KT3UYkHVF+Zh9QM4/GgDzC7ffq16/96eQ/wDjxrQtelYyyCS5lcdGcn8zWtaNSGKADr6f7Fq36uv/AMTWpWVEc6/IfS1T9Xb/AArUHSgBDUbDg1JSGgCnImc1XZSOtX3XmoZBwaAKZqyXE6YbriqxFRvJ5ZOPTNCA+dNTtv7I8beIdKwFjjuTNEB0CSDeAPpkipI3yMHqKsfEpgvxXk2/8tdPRm9yHI/lWfvw+R2rdPQgkmufLcrVWa+KqSTiqV1c5dm965zWtV8tGSM8nitE7IW5PrPiIITHESWqLxB4iur+G3heQ7I41jAz2AxXKxZmuBuOecmup8G6UNa8T2lsw3QqfMk/3Rzj8TgfjWd3OVkVsj2X4a+Hl0jQoFZP9JnAuLgngliOF/AcfUmuuE4KPJH2YEg/SpLJPLUAkkkcn1qireXJdqegBNexCKjFRRzN3ZnaRd7/ABnfxD7gt1OPyrpg4XJY4ry/w/rEMHjnWJLl2UF4LaIAZyWVj/Q16NeSBYQwPBYDP41pITLLSYOV5A7+1TCZgu5fnTvjqKqRkbVOc9qdC/lvj+E1AiyhSUZBDKfXsfQis7XrWdbGWfTSEvIhvQD7r4/hI9D0qS+D2zm4hGRj50/vD/GrVvOlzAskZ3KeP/101pqB6L8HfEjeJfCUc7ZIiby1LH5gMfdb3HI/AV3VecfA3TTpvh/VVxhH1GRkHttX+pNej142JUVVko7HVD4VcKwPEfhqDVoZmt5TZXzrtFxGobp03KevU+h561v0Vim07obSasz5r+J+n6oLWbR/saiVWDSzAlgYxySo64boTyAu7PPXnPDuoy6e8NukssUj4HkytlXzz+7fv3wDyeowK+mfGdnBeaTGs8YY/ardFcD5k3zIpKnscE8ivC/iHbaJpetR27RpeQSJK8dw6II5XXCyIOzON4JZQOcgklTjRzc3qTGCgrI5Pxj4intRZT20TurMShI+VGAOcMMjpkd85PUcVNZavbW2jprEbN/Z0shkmikI3QzE4JHojZPfjr0LkQ3FusuizS6PC8touQ9rcHJHsr9xnpu5/wBoAAV55dTMkCwwxusEi9JRt3+oxzkZBHXtTSb2BySPTb7XLCeAS2aCWNxlXD8EevSuH8Z6kLjwhqMiDCNeQWgOcglQ7nHtwKxhEr28ckabZI1VZYslkOCFDrnkcYyPX8a7tfBfi/QvB8l/e6OsGmLItyZHmicyK4CAbQWI+9nJA7jqRQ7bBG/U9d/Zx8P3ttp8esXKiO3eyS1iB+8+AuW9gNuPrn0ro/jz4i0zQfCcC6mN0tzcKIEBO7K8lhg84Bxg/wB6r/wX0t9M8DwM9xDcG6kNxvizj7qqc575QnoOvQc1D8SfDVt48ubLSE8lJ9Nl+1tdSw+ckLFGVUKZG4ncGxnHyjOelQ7KRT8jlPhd4St/E+zX9Ytkm0xNy2kEqcTNnDSMD/CCMAHuMkcAn2ysvw1o1r4c0C00yzZ2gtkwZJTlpGJyzsfUkkn3NWbjU7C2QvcXtrEg6l5VUfqaT1egLRaluvLvjR4N1vxSLH+wJgkpxbszNsFuC2WlJzk/LlcAZwx9eO5TxPoMn3da038blB/WkfxToS/8xazb/clDfypOm5aWGp8rumeH+JvCVr4QVtIsJZZvOiDPJIcEu+QxGOg4yBz061jS232m61uKNgjx2kMansCoLj9WrufiFe22sa6s1jMJYlWNAwBHILE9frXK6fFnxHq64wJIY19j8pFe3hvdpJeX+R51Z3m2M024E808kKGEvgpjun8Hvym38QwrL8T2UOp2LCZMyQnd749Qf896u2Eig2DYwk0P2c+zpkrz/wB9VLqMZ+/jnHPuO9bPR3RktVY9F/Z+0uxtfDFzewlnvp5zHMXOTGq42oPbBB/H2r1OvKvgMfLtNat+ySxyD6MGH/steq14mJ/iyuejR+BHOfEL/kUL/wCsX/o1K+eviToF4xvNcghW4t4IY8wRAtM+ODhcYOMg9egP4/QvxE/5E7UP+2f/AKMWuDtT8p/D+QrKLa2ND5qh1qRJFZvDutNjsbUjH5GnLqTsuToOtfX7KP8AGvpwGuP+Ii+M3GnnwPPaxEeZ9qFwqHd9zZjcD/t9MVftGKx4vLrcQt2VtD1lT8gP7osDtB5I3kd8DjjtioYvE+mWDI+oaTfLFMp2me1IPB6qN47jH5967ot8aVPDaY/08kf4V6R4Hm8Qjw/F/wAJZ5aatvbzBCV27c/L93jpQ6rYlGx87X3jTw8+0WttNGc5LeTtPsPvkV658N9DvrHVbfVJxGLS7sC0fzfON5jcArjjgetelmaT/no/5mqUzf6ZBk8kN/Slzu1h2MPXTmeX/D2Nd/8AB0D+w9QI6m8JPOf4EH9K881w5uJf8M9jXofwcOdAvv8Ar7Pf/YWoZR31FFFIBRRQKKAA9TSUp6mkoA+ep/Gfxqs9XvY08JxXcCTOE3W2U27jjayuuRjHOTTrr4m/Fu0iL3PgGFFHWQwSbV9yfMwB9TX0HXknxU8QG6v0021uMWts2Zgv8cg7H2H88+gp3AgTxX4gvtNjXV7i1hmYZkSxRo1/3cli2Px5rGnviq7Y+B6CuN1jx1o2m7kub5GkXgpF85B9Djgfiawx8Sbe6ONL0jVb0+qRAD+tTcD1uA4atW3fpWHbSbkViCMjODWnbydKALkD/wDE8lPrbJ/6G9a6tXPxSbdZB/vW/wDJv/r1sI/p0oGWuMUxsCmb+KRmzQAjNVeVuMVI5qu55oAjNZl/KBMwz0AFaTkKpLcADJNclqeoJEss8zhI1DSMx6Ko5/lQB4f471aB/irqUk0yJHbwJArMcAnAYj8yfyqheataJbkx3ULFuOHBriNcvn1XVr/Udu37TO8uD/CGYkCqIHyN15YdT9apSsKx0Wo6qgT5HznpiubnlaVyzEkmp7yNoiqN0HK/SqwocmxklvKsKsShZzx6AV7P8ENFeKzudZuYthuP3UGRyUByzfQnA/4DXnvw68Ow+JfEUdpczpFboPMkUth5AP4V9z69hmvpK3t44I0ggRY4o1CIijAUAYAHtXbg6Lb9ozKpKysW04CkVRuVQXsm7Gxkyc9Mf5FXRjbjPI5xXK/EbURp+gXE8ZYSMBAuPU8/yzXpowPLI7gTeLRIuBv1WHGO4QNXuMi79OjH+yK+dfCbNP4r06InP78yEe+P8B+tfRtrhrJPYYpKV9RyVhmnzbo9rHkHFW3OD7VkWzeXcsvQda1gfMiDDtTZJNE/mRFGHI/lWZIj6fOZ7cFoSf3kY/n9atqSrBh2qwQGAwOGpXsB6l8L7uO68PP5ZB2THp7gHn9a7Cvn3TNS1LQ5J10i8a2+0KOdqsMj2YEfj71n3vi7xS7MJNYu1IODswn/AKCBXn1cJKU209GaqqktT6SrK8S65baBpkt3cK0jqpMcKY3yEdhn9SeBXzbPrGuXIIuNZ1ORfRrpyPyzVKSFrg7rmWWU+ruTSWBfWQnX8jS8R/EXXdcWb7WjpC5BW2Rf3SYIYAjo/IBywP4A4rgvGE2q+JktHvEnmkiYKuV+4mOi+g+ldQbOMcpu/ChUkQ/L0/2qtYKK6kuu30KfgiOS18HvYamGS6EkgTOMlCBjpxjjoay5NAmjZxaSlYnfzGiZsxs3PJXpnk84zXRGR1H3FY05WDjldp9M1osHBdyXXkcfL4daOTzEdoVI+YKWfB9h1x9c/WvXU+Kt6fC82i3mn2krxWjR+eWJE0YUgMF6BhwDyeeeAQK5B4pD9xj+PP8AOpLeNkYl0Tk5OF5Jxj+VV9Vp9he2kdBF8R9f0rS9O06we1t0jiSJI4oBlVUAFjuz+J7k+9YC+IvEio6W2uX0Idy7+U5Qsx6sSOSfc1OtlBJM8hVt7gAnrwOg+nJ/M1ah0+Pjav6VaowWtifaSfUw2W+u2zf3d1dN3M8hYn86uQWC4HyDP0rcjseOVH5VL9jwM7wtWlbYm9yhb2+3Axx9KtBQg5OPxrP1TUYrHIe4UH2Ga5XUfFIAIjff+FXGnKWyIc4x3Z6PbD92rE8D5v51FbsI3muCAGbahb6t/wDXqHQ5muPD9lORzJArfmKNSbydNBzjdNGP/HhUxWtgb0uU5oStreJERut7gTRn0Oc4/PIq/elWthKnKuAR+NMu4yk2pJ/fUuB9QaqaZc/atGHOTGxUn9R+hFW9VclPU7T4Sa7p+jT38eozeR9p8sI5HygruyCe33h7da9lgmjniWWCRJYmGVdGDA/QivkDX9Qls50S3cqxXOB0rqvgv4wvbHxha2N7csbC+PkGMn5Vkb7jAepIC/8AAq4K+E5k6iep10q1rRZ7t8QhnwfqI9k/9GLXz/8AFK7v7W30aPTL6ezkub+3gZ1leNSHJU52n5h0yOCMAjNfQXj4Z8I6j/uqf/H1r5++J/zHw8UYgx6tYs5Dj5QZDgkdhnuP8a806jkZ/CXxP3kr4viCM2FH26T8BkrzTB4O+LW0PF4kaRTyCt6xB/Ss3x78N/E+oXMFzaB9QcbY0SCVWVOCSxZmBBJ29sepGAD7h4KtL7T9CtLbV5S90scaysXLZcIoc5PqwJ/XvTas7AePnQPi/Hwut7v+3lT/ADFRtY/GO3/5iW76zQH+Yq54g8M+If7Yu3vLW6umZmPmRWxkVueCHGeCOg7dKqppmsQSSiCx1GMN0xayL29hxWqpJ9SeYap+NS8xzGQe32Rv6V2/wt1bxBfpNbeLi39q208qNuRFO3bEw4UAfxn8DXHx2vilQBDb62QPRZgD+HSuv+GRvBdXQ1JXS886QyLLlXHyRYyv+7jn6VM6fLrcalc39bGbmT/D2NeifBvP9hahux/x+HHP+wled6yqm7cnrjHTNejfB0j+wr7H/P2f/QFrJlHe0UUUAKKKBRQAHqaSlPU0lAEV3L5FpNL/AHEZvyGa+UNSgF/BsuJJW3cthyCx9T619SeIX8vQNTcfw2sp/wDHDXzBFzt+tJjMvS/Bmj203mm3E8oOd83zY+g6CurggjjUBFAA6ACooeFFWEakBswv8qn2q9BJjFZMD5jX6VbjfFMRob/+JrbHPWGQf+PJ/wDXrWjl4rALgXNs/uy/mM/0rUjkoGaSyA07eKoq9P30ATu9Qk0m6kJABJIAHJJoAztdufJs9gPzSHH4d/8APvXinxa154NCls7U5nvcxcH7sf8AEfx4H/AjXe+L9YVVklLhV5VcnGFHU14Dr+onWtUkuASYR8sX+76/j1oQHMwWhFsQ+d3PHaqBYKnB5zxXuHhD4T3uu6NHqEl3FbRzIXRChZivY9R161zeq/CW5guTb2epRzTA4AeMqD+OT/KmosDzOWaSZ90rFjSKMiu6j8A3mlXrx6/EYCo3KvUOPUGti38OWVzIF2RbFHZBXLVxKpy5Wjrp4R1I8yZ5rp7Tx3Ia1WQy4IHlg5z2PHocH8K+kfCNxqFroNmPENx593t+aTbhl7gN/ex6/wA6xfD+i2lt80UUShOgK9TWrrtzss2EYzKRjavOKyjmVWMk6eiX4nTHL4WanqdK53tC0Tg7+AwPUHv9K8m+MmspbyQ2Mbh2hJYj1Y9M+uB/OpNO8Y3Phky/2nFLJauHMIcH5ZApKhfYnAI98/Xy7UJJ9WupLu9nZrqUl2Ljg5549K+hpYxV6V4aN/geRVw7pT5WdN8LrZZvE0dxuLeVE8hJ9T8v9TXvemyq9u6Z5BP6818+/DlLu38QRJGwVHB3Z6EV7VbXb2xGFDKyjINdVK/IrmM9y8gxLI/oCKu6RLviZW9ayxceZG3yFc981PYSeUVFamdjTkDxufl3Cn2cyyHaPXp6GpXIaNWFVLtfKkjnQYOcOB3FIC1cp5kZ4wynIqGa2jniWfHJ+VvrVs/vI1lXns1VoJNkc6H1yB70ugmimbFT0xSfYW7L+lWhI3IDH86QyMO9FjO5Uawc8Zpq6WmcuR+pq0ZGxnNNMrHvTEJHp1uvUA/hU32a2X+AfkKrmRvWmNIfWiwXLZSAcCNaYTEOiqKpvIefSo2YkU7CuXGnRR1AqN70L0JqkxJzk1FjAJI5qkhXLMmosOB1qrNfSkH5jz2FM2EnJ60yZDy3aqSRLbOU8StJJIueeea5m4YoWCgHNdRq6+ZMRmsgWyAnKk/WuiDsc1SNz1rwjk+FNMDdfJA/KpPEp2aVFj/nun86Z4TI/wCEbsAAMBD/AOhGl8WcaTD7zp/OuRfxPmdL+D5F/UkH2gSAdtp+lc1oB2Jfw5xtccfmD/IV1M53yyKR7VyUH+i+JL+Hqsw3D64BNOOsWhS0kmc/rMRn1WU/wqAv5Cq6K9s6ywOySoQ6OOoI5BH41qX6YvJ/dzVGVcEA+lVHZFM+n9R1Ua78L/7TUBTdWkcrKDkKxI3D8DkfhXgHxx1m60LQdOurcRTobuLNvcRBoyQkhDZGGByFPBGNo989x8LdZ+0/DjxDosr5ksT5sQJ/5ZuckD6MGP8AwIV5v+0ln/hDNNOOPtqc5/6ZyV4Fan7ObielTlzxTPNF+KmoYxLo2kye5e6B/SarA+K84HGiWyn/AKZ312v/ALVrzWkrEs9Nj+Ld+p/49JVX0j1G4H82NWo/jDdgYaDVP+Aapj+cZrymkoA9ak+LzTRNG8XiCPcMb49YQEfT9xXoHwT1d9ajvLtvtMga7l/fXdx5sx/dwgBiAAeAOcdq+Za+hf2bdv8AYtxx832qXBx22RU0Jnf+JX23Ln6evrXhfi7xFrNn4g+yWWq39vaNEshhiuHRC2SC2AcZwB+Ve4eKzid/oK+efHX/ACNaf9cF/wDQmqo7g9jVsfEuv2dzbSWmu6tDJvXlL2UZ59N1foBX50p/rLX/AH1/nX6LHrVVEKIoooFFZFAeppKU9TSUAY/jIlfCGuFTgixnIP8A2zavme1OQK+mvFq7/CutJ/espx/5DavmC2bApMZqxtwKmU1SjerKNSA07Zv3Yqyj1QtG+Uj3qyDTEWZpCpgbPCyD9cr/AFrTilrEuH/0aQ90G8fUc/0q9FJzQBrpIDUqvWcj9MGrEchNAFxTkVj+I9RWC3eENg4zIfRfT8as398tnBu4Mh4VfU/4V5F4+8SGG2uRGwZwCTz99v8AAE0hnKePtafWL/8Asq0cgvzMQfuRjt+P+etc1fQx2d2I1wqFVIHt0/pUmgyWhjWQ3Mcl7P8ANK28bsk5xjOf0rU8VrJbaEJIIhKokHmlkPC4/lnFa8q5RX1PWbT4qaBptjZWq2uoQTpbAMvkq4MZB2D5WJ689AcY7Vhaf460GXWWuru+EIzn99E64/MV4RPdQzx4a0t1k/vIzLke4yRUcEsUZQMZkTIzskDDr/dPB+lSpWGe/wDjLxBaeINakudNljmsogIUdTndgYJ9uc4HpXAeIbSeNDcaZM8Ei/MUX7rfhXDi9mjvDf29zcm4lZnmbgEksT26568jrXVad4ia9t3Q2s9y6qc+TExI474GBmq5Y1FyyQKcoO8WQaH4/ls1Md/AZcHh0P8AMGung8ZaTJB9rlvQm1T+72nfn029/qOK8jeP97IJm8pxyVZSOfStvRJ/DVrHG+o6bqerXRPMKXK20S88chXZv/HevtzxPB029EdccdVirPUTxf4lm17UFeMPDawgrChPOO5PuePyH1q34C02213UZLG+eZD5ZkjdOe4HNdtNr0el6SyeH/AGjaddt928nzeyRD1XzAcN79PauFg0/Wtc1WW8lupZL6P9800rkuCvPB9u1elQoTpNcsTjnU5222eiweHovDMtvOXaRN+GYjkA4rqZJ1i2dxjFZng3XhrWi2dxqMSMzK0UkbDIc5A3D2+X8zXStoFleIjQ3csSqOEbBx+NezFqUUcrvfUzjeggYHAqzaXKyHa67c9DUx8LSp80N0JPZuKgbSdQjP8Ax7gj1DA07CudDp0m+Ly357A0+7XNswPas7TnljicXCFWX0GTVdfF2ly3CWrySF5AcMqE8Zx069eOBU9QaHa/fz2HhxtQtjn7NKjOCeq5wRU2k6vDrMlzJaRnyoyiiboJMoGI+ozg1WBlW4jtJDthnJTpnepBzkHgD654x741bC2isFjsbZQkMKYVfQDAH9cmqasiZbEvl45OKhYfMeKusKjZQakyKpBpmz8at49qbigCsUPTFMKkDpVoio2HtTEV2Q46c0x1wKsyDAqFxwaYitxu6UhOO1KOppdhY5PSmBFg46CoL0+XEc9cVeKYqlexM6scU0SzlrhQ0hJqqYlBOc4q9c/u5MGoNvmEbTWyZmzv/Bb7/Ddr6qXX/wAfNT+KhnS4B/02Q1U8Fkf2KUX+GVh/I/1rQ8Qp5llajr+9Wufaoa/YLVx8t2feuMlkz8RIbc/xRStj1/dEj/0E12d4MXYNcGz5+J9s54XesOf96PB/9CNXSV0/RmdR2t6i3ilriZsZG8/zNZ0vM2309a1rpHWaUYGQ5yCevNUpPIkYFsCQccHmkjRljwrqTaTrZYEiK7he1kx3DdP/AB4KasfHvTLvVvClpFp8ElzPFcxuIYU3yONkgOAOeOvSsO5Uggxn5hyCOxr1fT4otQjtrm+tImkMEbeXNCrFG+bOMjI6mvOzCGqmdWFlo4nyDN4c1uAnztH1KP8A37Vx/Sqkmn3sf+stLhP96Jh/SvtkWtqvCW8UX/XJQn/oOKRraJvvSXTD0N1Lj/0KvNsdR8PMpU4YEH0IpK+3ZNNs5B8ySH/eld/0YkVSm8PadLw8MBHobWBv1MZP60WC58X19Bfs3uF0edSwBa6mIXdycJFnj8RzXf3HgjQZsl7G2Yn+9awY/RB/On+HPD8Hhy5MFhvW0mle4MaxxpEjlVXAA+bovv356UWAr+LW/fv9BXz146b/AIqpP+uC/wDoTV9A+LDmaT6V4P4t0m+utdFzbwmSLYE4YZBBPaqjuD2KsJ/e2n/XRf51+jJ618F+FPAHirxIkE+j6NcXEEc4jeQlUCsMEg7iOxFfelOo0xRFFFAorMoD1NJSnqaSgCnrUZm0a/iHJe3kXH1Uivk63f0719ekAjB5Br4+CGCV4T1jYqfw4pMaNKJs1ZRqoQtVmNqQGpZvkke1XFasu0fEy+h4rRFAE/UYPQ8U6yc+RGCckDafqODUa0ttlWkXsGyPx5/nmmI0on/KpZbhLeIySHgdB3PtVF51gTe5+g7muF8b+MINMt5Hklw4+UbedvsPVqQE/jPxL5IdfMAlIwSD9wf3R715JrSfb0+1SDLBgiswIWPccYLdB19a56+8RT6hqn2iclYgCETOdue59T6mtrT/ABlaWuh3unXFi90tywz8wUAfiD7dvxFOwy3b+GvsTLDHezW14q/OuAQD34Ip02k6qkhkSS0u/l287omI9OMjvXKtdXd7EfssjyMByj8vj2P8X86k02XXPv293Iq56M+Vz9DkUASXmlahDdPK2nzW2e0A3qBj/ZzVUyvG2JIrZ2HUOm1v8/hXpPgOG+1bWLLT9Qni23EyRF448MNzAZ64/SvRPiL+zbrupXEFxoGtWFyEXYYrpGgI5zkEbgf06UtQPDdCsNLuYmm1Fmt23cRRP2/EcZpfGF+rRR2GlMEsVGNqd/Y03UvCWqWFxJbiMG5tiYpkVsjcvBwenUGsh8Qv5d4slvP0IkThv8+tetGmoQtbfqY3uzKW2YnAHzehrT0W1K3aNjDA9xV+OGCSMF5AuOA+3K/mDXR6PbwoUMy+cnZhj/J/OiFCMXcHI7TSI1ms0WQYfA696ux29rbZzEis5wAo5Jxn+WaSxME9osabkAHBzytMmVoWBuULLztkViVzj9DzXdF3M2cVb6bcWV/pVgzSRQ2k0zBgSoeMuxznvkFBj3FWfFHh/ULvSoLpdQZp8ojrMoGxTnncO2cdu/Wu2sp7cmNb233RKdykr8yH1H9RWreWKRIt1akTWcgw2D2PUH0oaTVgueZ+HfCGpFRIPEV3aMcYCSthfVWGfWulh8Iap5jC48W6quFDgB85XuQc847j296teWbadYLgqjEfuLlB8kqjoGA+6wGM4/LGK0ra53wiJ2AnhJKEHII7j/PqaXJFbILsm0rw3NpoDprF9PL0bzZ2wTkgkAHuPrjg1b0zTltPOQ4ULJlGA6oVBIYd/mLfpWemq+T8pbOP0pX1yLBMkgUDue1Uk+hDZuXBiidFjC7cghRxjjpVq13SM8jLyQBu9e/Htz/OvObbxbb32rrb25YxySBDcFTtVema9UgiUQoIzuTHDevvWbnG/KnqKaaWxAV9uKbtzVryj2pPL5ouYlQx88Uwqc1dZMYqtcT28H+umij/AN5gKTkluNK5EUpoTmqVz4i0qAY+0GRhyQiE/r0rnpfiPpInMENteNKDgh0VB/6ET+lZuvTXUtU5PodXMnFVyhYYA5q/DsudIs77lRcR79nXb7Z71FIURBjg55rGWPpR8zRYabKiQDvzSuoLjJAAHWk8+FMmTDIDnDNkfrWJqeo29xqtpHC6AKkhIUgbR8vP61k8xX2YlrCPqy5LreiwoWm1SwQL63CZP4ZqhB4j0fVryLS9Mv4J7+fIRFzg4BJ+bGOgPeuG8e+C01Bm1DRvL+2HJkhU4EvuPRv5/XrnfDWystNv4dRvBcLqELNsXcAi5BXkYznB9aPr8mrpB9WS3Z6vL4NvJyC01rEO+WJP6DFS2nggRKwl1JBk5+WHOP8Ax4VGviQSdCanTUZphlT1rN42s9mNYan2NTSdIh0eF4oLh5xI+9i4AwcAcflVy+t3mhg8sBirBsE4rCBvdwMbEfjUOsXuswwxmO6EaZ2nEa8n8q3oYlzajLczqUbarYs+MNTutL037UlrEZC+xdzkheCckADPTpn8a840jU77UvE9hcTwxJMbuFtyAhWwy9ifQetdFdJeXtrIt9eyyrnIUsSo49PXmqHhfTnGu6UCcR/aoxz1PzivRUuSLZh7NSaTPp/wzDEIY28qPkc/KK3NTvYtLsJrnYAsa5woAzXP6DI0NsFkIyPSrF/qLNEy8Ed8187J6s9FLQ8+1vSNL1jUZtREMNtdy8kxgBd2c7iO7e9C6dMlx5kdyjp5ap5Z4GQSd2cZ74/CuX+Jmomz8Q6WLYyjcjtLDbzeQZCSqoS2CcfK/GO1cR418R67pVpa6p4c1QzW7ofMtbkh2QhypxzkkFCCP/r0Obe4KKWx7EbW57eWf+B//Wphhul6xg/7rCvn/wANfFDxPc6gG1C8EcCk5iEMYDcf7Sluvfd+Fd9bfEC6lZQNpyP7o/xpOaQ7HfkXA6wv+lMLyj70Ug/DP8q5aLxndMOYkI+h/wDiqSfxtepdQJFp8csTn943mlWUewwQfzFHOgszqDOR1R/++TVc3oN1CgR8csW7Djoe+fwqhF4qkklwbBlhx99pRk/RQD/Oqt746trUqJtL1ElpBGoEI+YnoQc7T+eeelPmQWKPikS3F0RGH24wSKoaD4alv9RgiCbpZW2quOFHcn2HWr9/8S/D9otybu3vFMDqjo1vyd2dpHPQgE/hW78H9afW9R1fUre3aLS8Rw28ki4d2yS/0A+T/PRXA9p8LabaaLpcVjYoAi8s2OZGxyx9zj9AO1bg6ViaUxbBrbXpQA4UUCigAPU0lKeppKACvk7xTb/YvFesW+MCO8lC/wC7vOP0xX1jXzL8Xbf7J8RdUwMJL5cq/jGuf1BpMEc/C1W4zkVnQt0q5E1IZdQngjrThLfq2Ukide28YP6VEhqxGaAKt1r8lgy/bUjQHoRnB/nU1l4osZ3cCWHfgDb5oOD/AE61leLrQ3Gn5UZKnNedCBkvZl28lVb+Y/pSA7zxF4qA3pauHcjG9T0+npXmGsWA1S4867llZhwqg8L9BWwykDpVZxQBzz6Barj5pPzrQsdDsUjVzGXb/aOanuDjFWbNswgfWqQDVjji4jRVHoBiq88cbyb2XEn99Ttb8x1/HNWZD8xqrI3zUwOs+G0Oov4s0tdLlt3uftUXli7UlN28YyUwcZ68V9Xi1+IF0PLn1Pw3p6nrLa2k07j6B3C/mDXzV8C4fO8d6V323Ct+XP8ASvsiVtkbOeAoJpAz49CLezXzXDecZZX8xsY3HccnA6cjNcP4j0PVLeZks0+22p5CSLuGPTmup8MzCbT7pSfnS4kUn8c/1FaMj8ZJx2NfS2toziv1PGU0yZZzm2urGU9423L+WcgfnWhb6NrCBZrZoXVm2iRS0WTjOOMAn65rpPFL28+FLvEAciQcc19O/BHwlpa/By1tNRH9o2mqb7u4Fyo2kthflHYAIuD178ZriruNFXNINyPlmwn1vT42kvJ4PKQZJZug/ADP50WHizUL+7eO2MKuqkqrRncwzjnn26HNc3rGoSXMIjR3Fv5hMcZJO0c4Hvwah0u6S11CKdn8uSM8N6ilVc0rQZUbdTtm8Z3Nq2240vcB18mTB/Iirdp8RNPh3c3doWGGSWLKn6inyXWl6sqtdQrDOR99Bw3vViz0bTpMbmjYVyLF1FuaOmjPk8c6Y8xLSxyxsBmPaxBIGAcdQfcGmXHjDzlH2CwuHx0ZY36emWxx9c108Oj6PF0WMH1AqwLHTCeJFqnjZh7JHDrd6zeHJSK2Q93O5vyFWorANhr64luP9knC/kP612K2GnZxvH50stjpaKS0yD6ms5Ymct2NQS2Rz0EttBgRQov0FdHo2s38jGOCXbHGu92boij/ADism8utGs1OwfaJv4VHT8a5rxJrmoaC+nqLUIl8DKHfO3aDjAx378+o9azlVbKsdzc/EG6s2LPZTvaA4aWRV6euAQQK6BfERurSK5t3QROgYYwa801D4eeN9Sv0Mdkba2nAZ98yAKD2IznOOoxXZ674etPB/hfTI57K01G7yY5JJ2lKA8twodR3xyKhVpvTmJ9nHexHqniWJARNc8dw0mK5ifW1uZCLWN5mPQRIzk/kK1PCuo/afEVlbNp+lRQSPhlisYgehx8xBb9a9caSSNfLR5FjHGxWIX8ulRJ9ykux4iumeIrzmHQ9S2N0aSExr+bYpJPh9r15Ks8lvZWzj+N7xGIPqQm417PsVSSFAJ6nFZ1xqenwuVmvLZGHUNKox+tLmHY523s/FaaZa2I1HQ0ht02K0dtO7nH+9gVS1Twj40uCPsnivT3U/djEJgb8yn/s1bF54w0O2yG1GE84zHmT/wBBBqS08ZaBOMJqsII/vhk/9CApfIZwEvw68VtP/wATNdUvYzwfs12s6n/gKsCKoDwvLouohrewu0lKYYSIQevfPT8TXscGv6bIqbNTsZBwMrcIf61e1PUpGsR5Fw/lbh/q5CF6H0NFwPK7fSvErIHi0ufyT/y0YAr/AF/lWdrWlXVjLFc30UEc0xOTDIHDYxncP4W5/HnuDntrnV9PhLNLe2cb/wARaZAf55rndSu7XxDMkGn3KzvCTI+0HgYx1xjriqi1cTRR0sq7qrnGa7TTLMIoZWJFcZDpN6k4Cxv+ArutJhmgt1Wbg+lW0SjdsvJwFcAGn+IrKGXQ7ls7fKQzA4/ujJ/T+dct4qa5GlD7HK0TmQAsrFflwe46c4rkLVbmyuRdfbrgXWCu5XIbHpk8/wCe1b0abbUkyJyS0NmN12HOD3+tRpcPbajazwpveBxMEBxnaQcfjjFZ1tqlujGFxNkdWMZP8vx6VeikVmV4yrFmVcjIPJHrXsNaanL1Pb9O1IFyoaprq6OSDxmuTsrS6hfcGOa6TTLWW6wlwCQe9fOnceRfE+XZ4v0yQuH3IFH+zgtx+Zz/AMCPtXPag00+mRxxxSiJizEY4OWPTA/HnOSSfavZ/Efwu0zWZ4JpLvUIpIn3jy5F/LlTxXQW/hu0t4I4xChVAFUFc4AosB8rRaTJLPlLWTj2rUg0mSFw5ZkPoOa+mzo8GMeVGB6eWKgk8OWcn3raFv8AgApOIHzwkcynCyD8VrUskm3KZDG1ezzeD9Nc5NnFn2qlJ4K0/Py25T/dNLkA4SOV1UYMeB/tVzvjyaeXSo4pEU27ygMSDyccAHp6k/hXo2t+CH8ln03e0ijIRm615V4z03WFscS6VfK8LhifIbBH1AwaVrDLejeHbXU9FWzeBZoZLgyeWA2AEBC+38TnA9zXtXgyFotNt7U26QJCPLREQIAo9h0rhfhNpVyNPuLy5tJEeRwsXmxFWUAHJGecHd/OvX9B0xwwZxirJOl0yEJGDitIDAqKBNiAelS0wFFFAooAD1NJSnqaSgAr59/aBhEfjKymXjzbJQfqHf8AoRX0FXif7R1riTQbwD/ntCx/74K/+zUmB5PC1XIjWbA3Sr0bdKQy+h4qdDVSJqsoaALO1ZE2sMisO60i3k1vBUAPb8f8BY5/9CFbUbVWu22apYP/AHlki/MK3/slAHP6j4cwC0J/CuWv9PlgY7lr1OXBWsTU7aOQHcBQB5XeAg0+xfER9ia19dsAhJT1rnoZPLLqfWmgLUrc1WkbmmyTjPWq0swLUxHtP7N0HneOrFsfKplY/hG39a+rNYfy9JvX/uwOfyU180fssW/m+Inm/wCedtI/5sF/rX0f4mbb4b1Zh2tJj/44acdwZ8X+E3xd6tD6T7vzH/1q3J2RUJcn8K5fR5fI8T3sJOBOm4fUH/65reuJsH5hgdj/AI19LLc4Uc7qsaSyMjAlH46da+w59Wij+Ekur28SwRJojXKRIMBAINwUfTGK+PdVmijkPnygbecjj8q+mPEcrad+zYglUozaPbQlW4I8wIuD7/NXm4xc0orzN6WiZ8SXRYELjkHirNgCSGldFHYuRmotYAScgepplo291G35x7VrLSQLY9y+B/gqw8cXWpWepz3EflW5kSWBh8rblA6ggjBPH611+qfs/a7A7HR9bsbhByonV4T9OAwqf9kWwdI9fvXwMrDGoHvvP9B+dfRlebiP4jNYPQ+Sr34O+PbZiI7OG6A/iiu4wP8Ax4rWYfhp47UkHRpgR/08Q/8AxdfY5GRULwKe1YF3Ph/WdH1rRNc0/R9Wie11G/Ki3iLq2/c20cqSBzxya66P4TeI3Yfa7qziTv8AvGZh+AGP1rd/aFgEXxp+HjDq0kY/Kcf4173Pp4OeKEFzwbRvhxZaUwlumN9OpyN67UH/AAHnP4k/Sm6hcR6LeRDVLM3GmxyK0MgQSNERjg7u/XBz/wDW9qutGDjla5zW/CEWpWzQyOyDO4EDOCKbSA43UfiZo4eRkhvnYseBGo5J4yd1cV4y8Wf8JNBBYW1g0LRy+bvkl5ICnIxjjr69q7fSPhNDaxxx39/LdJCcRBIhEAB0LddxxnnjGTxya3oPhdozXInMU/mjuJmX+VTYLnz3Fc3GnXFrfWY8t1kbYz/NyoHXjB+9V278VeIb1ju1CfJ/55AR4/75Ar6Mt/htoUeD/ZsLMOcvlifzPsK27Lwnp9rjyLK2jx02RAUBc+Tk0vX9XP8Ax7393n+8Hf8AnWtZfDXxLd4/0Ewg95WC4/DrX1jFpUSjG3ip0sY1P3aYXPmOz+CusTAfabq1iyckLubH6VsQ/AkyD/SNSP8AwGH/AOvX0WlsoPC1IIgB0oEfPA+BNog5vLpj7MFH5YrN1P4GMUH2PUpIWBBzJAJR9Oor6bEa/wB2mvCh/gH5UAfL0PwffTx5kd5Hcy8/Lc2wZCfp257Vf+HPw71LQLOe31aeGVWl8xTCST0AwSQPTNfRps4z/AKhl0uJs/LQB5vDpcMK4WIZ9T1qG40uF8n7pr0GbRUOcCsy+0DzUK4P1FO4zybxLcWukrsuAZt6k7UGePU+lcoWjvJ42trJ44wQ0n7w5Yf3c9q77xZ4HvLm5WW3ZGUY3I5IyAfp6Z4qk2hX8cSxrYyAqRjDLz+RrrpOml5mE+ZvyOA1HTWEp+fYF6OVVuD2ORj8sVHDHcR4HmKVUg5jTaRj9K7ebwxrc7ExW6RsWDEyyDB55+7n3q9Y/D3V7pytxJbrG552lm2+4yBXU8WlGzZmqbvsdtpwjldCp3KRkH1FdnplrHsGBzWdonhj7JbRRgnCIEBPXAGK6iztBAuOteSdRA1kCelJ9gHpWlgelLQBmCwFO+wr6Vo0UAZclgMcCqrWBz0rdIBpNooAwv7PPpTl0/PBHFbe0UbRQBmQ6bGuCVFX4YVjGAMVNiigAooooAUUUCigAPU0lB6mvnrxL+0bDbavdWmhaZFPbwSNGt1PISJcHG4KuMA9uenpTSuB9C15b+0TbiTwRbXGQGt71Gye4KspH5kflXC2f7Ql9Kv7zTrDd6qHA/8AQq474meOn8YNa3GpMsUNqjCKCAMFBbGWPPLcAe355TTAxYLkdM1owS5A5rzez8RGOTZMVZfUjY39R+orpLDxBZtgySGEHjMgwv8A3190/nSasM7KFulXYzxWLZXKSoGRwynoQcitWFxxzSAuIeaq6sdos5f+edyn/j2U/wDZ6nU1V1rH9k3L/wDPJfO/74Ib+lMC7I3FZV84weavyvhT0zWHqUwUNzSA5/W3BVq4O/l2XJwetdZrM42nmuC1Ob/SOvamgJWn561GZsms9pj2oWRjyOR60xH1f+ydLbINRlmnhjkEKRqruFLbjk4B6/dr33xcceE9abt9hnP/AJDavz/8P+JINOtniljdzkYCkfqf/wBddDpPja+nvY7KznlghmIWREkbDIeoPY5Ga0pxbkhPYbfbrfW/tIHMLkMPVcf1roiylecEevqOxqLWdPNxvngXL+Vkj1wR/TNQaHeQXOniOVSTFmMY68dq+ieqOIp3wTzQ6xZMZyC6hl/EHqK+j/2kNRaD4YQI6+U95dRI0f8AdwrOR+BUV856gQfljhmVAc5bnPNbnxc+J2o+M9Mt4Lu1t4ILeUuPJDfeK45JPI61xVoOVSD7GkHaLR4rq0oa5Yg9DUliC7J852Z5UVn3DEysT3NTWdwI8qck54A71m5pz1NLaH2R+ylJD/YWtxJjzlliZgOgUq239Q1e7V8n/s7eL7XwVb6qfEEcyLf+UUCAEps3YByR1DE173o3xN8M6rdQW8V3JDLO4jiE0ZAdicAZGR+dcOIi/aM0g9DtaKKKwKPib9p/xPqo+NrwrMsaaKIDZFEGVLRpKWJ7ncx6+gr678D3s2r+CvD+pXjiS6u9Pt55nChQztGrMcDgck18Y/tUJt+NurN/ehtj/wCQlH9K+vvhC/mfC7wo3/UNgX8kA/pS6jOpaIN2qFrNWPIq3RTEU/sUfoKctqq9BVqigCAQinCIelSfhS0AMEYpQg9KdRQAm0UbR6UtFACbRRtHpS0UAJtFGBS0UANKikManqKfRQBWlsoZPvIp/CoDpVqT/qlrQooApJptsnSJfyqwkEaD5UA/CpaKAADFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACiigUUAUPEFlNqOialY2tz9lnubeSGOfbu8pmUgPjIzgnOMjpXxr4w+A/jLwzay3scdrqtnEpeR7KQ70UcklGAP/AHzur7ZPU1k+K7OXUfC2sWVuCZ7mzmhjAIBLMhA68dTTUmgsfnfFM64KtVoXErrhjuFZWs3dxFeiJomhe1jEMsMkexkdTgq3fI6fhWqtncpawzlPlkQPtB5XI6EVopJk2IXhD9VqIWm1t0TNG3qpxVpJOcHr71KrKfaqsIr273Vq+6F8HrkZQn6lSCfzrasvFGo2xAeScqO25WH6rn9azxj2pdoPalyJjuzq7bxuTgSOI/d7cn+T/wBKvN4ojureSJryzKOpQ5iZeCPc1w3loe1BgVvSp9mg5jsrLxMTZLGXhmkiJiMrzhPMK8bsAd+v41Tu9Y83PmT2UX0m3/4VzH2Rey0G09Bil7MfMSavfwsh2yhvcA4rjrqTzJSR0rWvdGupHLLNvGcgN2rP/su6WVVeM7M8suDxS5bBcqDA9z71JGkkzbY1Zj7VZNvFbMfOSWQj/YIFOe/dIGiSMW7nGCMggU72At2Ph+a4I86VYs/wj5mP4Vq+GoydbtDLA8RBPz4KhiFPWq/hdn8q4muZDIw2pEQclc9cenFdFA5t84G1Scgs2W/Ac10UILSTInLodpY3YAYMeV4xjqD/APqrBv7L+ztSa6tz/ol2SWHZJOv681HYTwz7mjkw2PmVhkg9xVgXAX5Tloj1VhkV7cWcrKmpwXtwm+IsxIHA+ZT+XIrnL9LmKJobtFDSbmxnhFzx+I4rtVsIn+ZRKY26JHMSv5dvzri/iG32O4s4bfMWFZiAd24kjrn6VzYq0Yc3YuGrscshhEriQBgD39K1dLFutxHJGiKQcg1hwpJPvyDk9TitLQ98NwzgYZU4yOhBH+fxrhhW12NnE63xpIw0TSGRPklnYu/oVX5R+O5vyrc8L3Ti1g2OyvGwZGB5B9RWP4/vEj8NaLHLkySTtKMDkKFA/wDZxWl4CudCli/4nWvRaQqkfLJbSyuwx1AQY/Mis6tROV2EYu2h9u6Dff2noen3xABubeOYgdiygkfrV+vBI/j94J8M6Haadph1TV2toxGjJAIw2PUuQR+ANc/dftG+ILyY/wBj+FLW3iBwTeTvIfrhQuP1+tcbkjZJnm/7WigfGW5I/is7cn/vkj+lfVXwNmSf4S+F2RgwFmqEg55BII/Svk7xDr174k8Y3+q6pHbR3t3JC7xWzEouxFQY5PQAHr37Hiu/0T4l6zpWnR2Gk6jbQRxliUkWNnJJzn5yODkHio9orlcp9V0V89aV8YdfXiaXTLv2lgaJj9MMAfyNaGofGjVoIR5emacsmed0jnjPOBx/Oq50Tys91orE8M+IrLxBpNte2c0TeZEjyRrIGMTMMlGx0I6fhW0rA1QhaKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAUUUCigAPU0lKeppKAOM174YeDNf1ZtT1bw/Z3F8zh3l+Zd7DuwUgMfqDnvWF4x+C3hbxBGTbWv8AZFwBhZLBVRfxTG0/hg+9eoUUWA+QfEf7OPi21lkbRdS06/gH3d7NDIf+AkFR/wB9V59qnwu+JGkE+f4cvpgO9sq3Gf8Av2Sa+/iAaaYwe1C02A/NvUE13SW26rpF3akdRcW7xH9RVaPXV/5aQsP905r9KzCMGsHVPBfhvVd39paBpV2W5Jms43OfqRmq5mKx+f0OtWjHl2T/AHl/wq/BcxTD91Ij/wC6c19e638A/h9qiN/xI/sUp/5aWc7xkfRclf0rg9Y/ZW0SRGOjeINStJM5X7TGk4H/AHzsNNTYWPB1b61KrjuK7XXP2fviDom99JnsdagXkJHLskI/3ZMD8AxrzvVf7Z8O3P2fxNol9p0mcAywsgP03cH6g1SmhWNQbGoMCtWda6la3OPKnQt/dPyn8jV0MQeDirTFYd9lHpSNBHKAsiLIq8DcMgfSpVlYjBoHAp3ENgt7aLOyBI89dihc/lV+GG1lO0ozORgYJzVIMQRgmt60uyGt8YAQ5wBiqT6IVjGuPtWgXSvHAxLsA0DfIemRzjjp3FaMGqvNbJIumltzbWRJAdp9TkCm+MIW1KKYRnEjbWBzg8EVW0bT7+2tyqKJg2MhmxjnPBxWyxfI+Vsl076o2bSaQucQiJDjI356/QVyfj5F/ta0Z494EZGPoxrtLHT7jcjPFJGON465wa1E0/zJEZrJJSo4MqBj1rLFVnUhypjpxs72OQ8Pal4Qlt4rbU9ElWQ4BlVs59+or0i0+HHhbULSOe3huYUkGQ6ykEj/AIFmpLHTi7h3sbcEfxNGBio9a8WWmmaVFK2n3VylwWSBinlRvjGSCfmxyMELg+tcMbw3Zu1zGH8UfDGgeD/CkesNYSancrIlpai8uGeOMkM2WVSMgBT+OK818Hmw1PVL/UPF9hcSWkkLNAlniEGYsuB7Lt3dAe3Brrnn1XxAGtUjka2fBNtEpKnBBG4c55APPHGa6fw38OmvZFbWL1bKIf8ALNBvkI9P7q/r9KmU3LYaVjzE20C3btptoIVJ+VdxYqP948/ljPpW/pfgzxFrNuPsFlPJGfukLtj/AO+jhf1r6A8P+FfDGgKrWdglxcAf6+5/eOfcZ4B+gFdH5kl1xEm33FSqfcfMfH9x4d1bw3r0tpqahLiCZPPCuGChwhXkcHt0zXTaJ8NdY8QNc39rPapCvlr5ckhDE+Wp44x0xXTfHDRrjS9Uvb6eRHXUbIPFz82+KWBWz9FZfzPpXqHw701LXQFvHZG+1N5kaqfuqFVQD75U/pRy62C+h4befDfxXYqXg065mUDrbESZ/BST+lY0+p6xBYXmh6kJzZ3AVbiyn3JuCsGXI4IwVB4x0r64W4lx8uFWq+o2dpqcPlajawXUX92aMOP1p+z7MObufMnwf1my8EeL4r43d9bac8bx3FuUEm8EfL8wI6Ng9D096+rvDHjLR9eQHTNRt7lj1jVsOPqp5/SvO9U+Fnhi/JMUdxZOTk+RJlT+DZ/TFcZqnwRu45N+i6xbyY5AnVoiPy3A/pR768w91n1FFKHHBqWvlHw/421X4b+L7TT/ABhfSw2qqDIr3UkweI7gHVNxUc91APy/Wvp/QdXsdd0m31LSbqO6sp13Ryxng9j9CDwQeRVxdyWrF+iiiqEFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFACiigUUAB6mkpT1NJQAUUUUAFFFFABRRRQAUmBS0UAJtFV76wtb+2e2vraG5t34eKaMOjfUHg1ZooA8k8X/s/+BPESs8OmtpFzjAl05hGPxQgp+QB968d8S/s1+LdJ3SeFNbt9TgXJWCcmCT2AByh+pIr69ooA/PXWdD8beGmca/4Zv440+9L5DbP+/i5T8qyrfxJavgSpLEfcbh/n8K/R/Fcv4g8AeE/EJZtZ8PaZdSt1la3VZD/AMDGG/WqU2hWPhyC/tJgDHcxYP8Aebaf1rYspI3IKTxHHo44r6O1T9nXwRcb2sI72wJ6JHN5ifiHBJ/Ol8PfBTRtCnVwVuth3IGj2gH1Iyc01UYcqPFH8I6xqNnMiW5hLrtDSnZz/P8AStjwh4A1jT3V76+Hlg8xrl8/nivohPDCZ5xVyPRIIV4QE+9TJ8zuxrRHnmm+HY5FBZNo9StakWg28fLNx7ACuuezGMY4rPu9Kjm+8ZB/utSA5nxFHp1n4d1MyR5QWsu7YRvI2HOCehr4/wBL8ZXVtcWrCysrmOF8+TchpA3sRkYFfZ994et5oniZpSjqVYNhgQeoIIrz60+BPhaDUILk/bWSF9wtzKPLbnO1sgkjn1qWrjudbpthENOh+ywW9nC6B/KQBQuR6DvVHVLNoFLxpNK3pHGTmu2t7QRDEaKPU9SfxqSS0aRSGJpgeaafcavNNsWz+zx9nncfyFdLDpWryKCNZWFfSODP8zVjUdHkjYyR9qs6Rc8eW5wwpAcf8S/DFxfeCtUkubn7ZdQW7GBnjG5eVLBT1Gdo4HUgelaXwysJbrwXpNybthuhH7rA+X6/UYP41n/tBauukfDS6yGLXk8VspVtpB3eZnP0jI/GuT/Zl8UtqUeq6K0RRYEW5Ri+4n7qNn0/gAHsaX2h9D1u8gvo32wTQkf7YNWrNL1UBlWBifQmpo7TzZdxB6+tacdouAPSqEZxM/e2ib6NUTtMASbF/wDgLg1trZAngGrCWI/u0xHy1+0N4M1PXNXtNa0uxvbgiMW00CQs7JgkqwwMkcnI7fjx67+zH4Y1nwz4AmTX1uIJLu6M8NrNkNDHtUcqeVJIJx9O+a9ShtFUjgVcUYGBSsAtFFFMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAUUUCigAPU0lKeppKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAppWnUUAN201kz1qSigCs0ANRtaA1dowKAMqSxBPSoGswOAK2yoppQUAYgtMdjUgt8djWsYx6Unlj0oAyZLTeuCOKyLrw+Hk3xStG3qBXXeWPSk8oegoA8p8cfDx/FmjDTbzUXEKzLMhaMvhhkdNw7MR17034bfCm08GXN3PDdG4luEEfEXlhVByR1PU4/KvWPKX0FOEYFKwGfBYLGOB+dWlt1FWMClpgRpGB2p4ApaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAFFFAooACOTRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigAxRiiigBQKKKKAP//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    da Vinci&reg; S Surgical System",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Intuitive Surgical, Inc, 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35346=[""].join("\n");
var outline_f34_33_35346=null;
var title_f34_33_35347="Keratoacanthoma - face";
var content_f34_33_35347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F55042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F55042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Keratoacanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35347=[""].join("\n");
var outline_f34_33_35347=null;
var title_f34_33_35348="Lichenoid drug eruption hyperpigmentation";
var content_f34_33_35348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59258&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichenoid drug eruption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A lichenoid drug eruption manifesting as violaceous and hyperpigmented papules is present in this patient with dark skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35348=[""].join("\n");
var outline_f34_33_35348=null;
var title_f34_33_35349="Ipratropium and albuterol: Patient drug information";
var content_f34_33_35349=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ipratropium and albuterol: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/51/28469?source=see_link\">",
"     see \"Ipratropium and albuterol: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184255\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Combivent&reg;;",
"     </li>",
"     <li>",
"      Combivent&reg; Respimat&reg;;",
"     </li>",
"     <li>",
"      DuoNeb&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F184256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Ipra-Sal;",
"     </li>",
"     <li>",
"      Combivent UDV;",
"     </li>",
"     <li>",
"      Gen-Combo Sterinebs;",
"     </li>",
"     <li>",
"      ratio-Ipra Sal UDV;",
"     </li>",
"     <li>",
"      Teva-Combo Sterinebs",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13319002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691417",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to open the airways in lung diseases where spasm may cause breathing problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702321",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ipratropium, albuterol, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to soya lecithin or alike food products such as soybeans or peanuts, talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701537",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to any type of nuts or seeds, talk with your doctor. Some products have nuts in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697166",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an overactive thyroid, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697334",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have prostate disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2858939",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid driving and doing other tasks or actions that call for you to be alert until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to get the breathing attack under control.",
"       <b>",
"        Get help right away.",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698996",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Peak flow measurement low.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699112",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016673\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694582",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your puffer (inhaler) use checked with your doctor at each visit. Read and follow facts on how to use the puffer. Make sure you use the puffer the right way.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694373",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A spacer may be used with the puffer (inhaler) for easy use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695186",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using more than 1 type of puffer (inhaler), ask your doctor which puffer to use first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695599",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rinse out mouth after each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3973682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Combivent&reg; puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake puffer (inhaler) for 10 seconds before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3973683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prepare puffer (inhaler) before first use or when puffer has not been used for more than 24 hours. Spray 3 test sprays into the air.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3973684",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Combivent&reg; Respimat&reg; puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3973685",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Prepare before first use or when puffer has not been used for more than 21 days. Spray towards the ground until mist is seen. Once the mist is seen, repeat 3 more times. If it has been more than 3 days since it has been used, spray once at the ground.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3973682",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Combivent&reg; puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away the puffer (inhaler) after the most number of sprays have been used, even if it feels like there is more drug in the can.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s3973684",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Combivent&reg; Respimat&reg; puffer (inhaler):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3973703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away after 3 months from first use or after the most number of sprays have been used, whichever comes first, even if it feels like there is more drug in the can.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10770 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35349=[""].join("\n");
var outline_f34_33_35349=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184255\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184256\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319002\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016671\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016670\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016675\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016676\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016678\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016673\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016674\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016679\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016680\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?27/51/28469?source=related_link\">",
"      Ipratropium and albuterol: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35350="Fexofenadine: Drug information";
var content_f34_33_35350=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fexofenadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/43/38580?source=see_link\">",
"    see \"Fexofenadine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/37/3670?source=see_link\">",
"    see \"Fexofenadine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra&reg;;",
"     </li>",
"     <li>",
"      Allegra&reg; Allergy 12 Hour [OTC];",
"     </li>",
"     <li>",
"      Allegra&reg; Allergy 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Allegra&reg; Children's Allergy ODT [OTC];",
"     </li>",
"     <li>",
"      Allegra&reg; Children's Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F171101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F171074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     <b>",
"      Seasonal allergic rhinitis, idiopathic urticaria, allergic rhinitis (OTC labeling):",
"     </b>",
"     Oral: 60 mg twice daily",
"     <b>",
"      or",
"     </b>",
"     180 mg once daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F171090\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/37/3670?source=see_link\">",
"      see \"Fexofenadine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Chronic idiopathic urticaria:",
"     </b>",
"     Oral:  Children 6 months to &lt;2 years: 15 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic idiopathic urticaria, seasonal allergic rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: 30 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Allergic rhinitis (OTC labeling):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: Oral: 30 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F171075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Chronic idiopathic urticaria, seasonal allergic rhinitis:",
"     </b>",
"     Oral: Use caution; adjust dose for renal impairment.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F171076\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6 months to &lt;2 years: Initial: 15 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2-11 years: Initial: 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults: Initial: 60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not effectively removed by hemodialysis.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15881420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, need for adjustment not likely since undergoes minimal hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg;: 6 mg/mL (300 mL) [contains propylene glycol; raspberry cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Children's Allergy: 6 mg/mL (120 mL) [contains propylene glycol, sodium 18 mg/5 mL; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 30 mg, 60 mg, 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Allergy 12 Hour: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Allergy 24 Hour: 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Children's Allergy: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Children's Allergy ODT: 30 mg [contains phenylalanine 5.3 mg/tablet, sodium 5 mg/tablet; orange cream flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating tablet and suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F171050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, tablet: Administer with water only; do not administer with fruit juices. Shake suspension well before use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally disintegrating tablet: Take on an empty stomach. Do not remove from blister pack until administered. Using dry hands, place immediately on tongue. Tablet will dissolve within seconds, and may be swallowed with or without liquid (do not administer with fruit juices). Do not split or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F171049\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms associated with seasonal allergic rhinitis; treatment of chronic idiopathic urticaria",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     OTC labeling: Relief of symptoms associated with allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fexofenadine may be confused with fesoterodine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegra&reg; may be confused with Viagra&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Allegra [U.S, Canada, and multiple international markets] may be confused with Allegro brand name for fluticasone [Israel] and frovatriptan [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F171099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (5% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Vomiting (children 6 months to 5 years: 4% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (1% to 3%), somnolence (1% to 3%), dizziness (2%), fever (2%), pain (2%), drowsiness (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3% to 4%), nausea (2%), dyspepsia (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (3%), back pain (2% to 3%), pain in extremities (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Otitis media (2% to 4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory:  Upper respiratory tract infection (3% to 4%), cough (2% to 4%), rhinorrhea (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Hypersensitivity reactions (anaphylaxis, angioedema, chest tightness, dyspnea, flushing, pruritus, rash, urticaria); insomnia, nervousness, sleep disorders, paroniria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F171053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fexofenadine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F171036\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &lt;6 months of age; orally disintegrating tablet not recommended for use in children &lt;6 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orally disintegrating tablet: Contains phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F171096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein, SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Fexofenadine. Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Carbonate; Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the bioavailability of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F171066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase CNS depression. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Fruit juice (apple, grapefruit, orange) may decrease bioavailability of fexofenadine by ~36%. Management: Administer with water only, avoid fruit juice.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease fexofenadine levels.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies fexofenadine as pregnancy category C. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Information related to the use of fexofenadine during pregnancy is limited; therefore, other agents are preferred.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F171079\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12874091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if fexofenadine is excreted in breast milk. The manufacturer recommends that caution be exercised when administering fexofenadine to nursing women.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F6030683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain phenylalanine and/or sodium. Take suspension and tablets with water only; do not administer with fruit juices.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F171055\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Allegra Allergy Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/5 mL (120 mL): $10.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Allegra Allergy Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (12): $10.87",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Allegra Allergy Childrens Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (6): $6.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Allegra Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (12): $9.59",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (45): $24.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fexofenadine HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (500): $699.35",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (100): $41.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (KLS Aller-Fex Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (120): $40.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Wal-Fex Allergy Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     60 mg (12): $10.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (30): $19.99",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F171045\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of symptoms",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F171057\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alerfedine (AR);",
"     </li>",
"     <li>",
"      Allegra (BB, BM, BR, BS, BZ, CO, CR, DO, EC, GT, GY, HN, IN, JM, KP, MX, NI, NL, PA, PE, PR, PY, SR, SV, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Allegra 180 (CN);",
"     </li>",
"     <li>",
"      Allemax (PE);",
"     </li>",
"     <li>",
"      Bosnum (HK, TH);",
"     </li>",
"     <li>",
"      Fe Min (TW);",
"     </li>",
"     <li>",
"      Fenafex (TH);",
"     </li>",
"     <li>",
"      Fexet (PH);",
"     </li>",
"     <li>",
"      Fexodine (HK, PH);",
"     </li>",
"     <li>",
"      Fexofast (TH);",
"     </li>",
"     <li>",
"      Fexofin (MY);",
"     </li>",
"     <li>",
"      Fexon (KP);",
"     </li>",
"     <li>",
"      Fexoral (PH);",
"     </li>",
"     <li>",
"      Fexotabs (AU);",
"     </li>",
"     <li>",
"      Fexotene (TH);",
"     </li>",
"     <li>",
"      Fynadin (TW);",
"     </li>",
"     <li>",
"      Neofex (PH);",
"     </li>",
"     <li>",
"      Raltiva (CL);",
"     </li>",
"     <li>",
"      Rhinogan (PH);",
"     </li>",
"     <li>",
"      Sizzle (PK);",
"     </li>",
"     <li>",
"      Tefodine (AU);",
"     </li>",
"     <li>",
"      Telfast (AT, AU, BE, BF, BG, BJ, CH, CI, CZ, DE, DK, EE, ES, ET, FI, FR, GB, GH, GM, GN, HK, ID, IE, IL, IT, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, NO, NZ, PH, PL, PT, RU, SC, SD, SE, SG, SL, SN, TH, TN, TR, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Tofexo (TH);",
"     </li>",
"     <li>",
"      Vifas (TH);",
"     </li>",
"     <li>",
"      Xergic (AU, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F171035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fexofenadine is an active metabolite of terfenadine and like terfenadine it competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the gastrointestinal tract, blood vessels and respiratory tract; it appears that fexofenadine does not cross the blood-brain barrier to any appreciable degree, resulting in a reduced potential for sedation",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F171052\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Antihistaminic effect: &ge;12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 70%, primarily albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Minimal (Hepatic ~5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 14.4 hours (31% to 72% longer in renal impairment)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: ODT: 2 hours (4 hours with high-fat meal); Tablet: ~2.6 hours; Suspension: ~1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (~80%) and urine (~11%) as unchanged drug",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/33/35350/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Day JH, Briscoe M, Welsh A, et al, &ldquo;Onset of Action, Efficacy and Safety of a Single Dose of 60 mg and 120 mg Fexofenadine HCl for Ragweed Allergy Using Controlled Antigen Exposure in an Environmental Exposure Unit (EEU),&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1996, 97(1 Pt 3):434.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Fexofenadine,&rdquo;",
"      <i>",
"       Med Lett Drugs Ther",
"      </i>",
"      , 1996, 38(986):95-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/33/35350/abstract-text/8906132/pubmed\" id=\"8906132\" target=\"_blank\">",
"        8906132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, Bergman JN, Watson WT, et al, &ldquo;The Clinical Pharmacology of Fexofenadine in Children,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1996, 98(6 Pt 1):1062-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/33/35350/abstract-text/8977506/pubmed\" id=\"8977506\" target=\"_blank\">",
"        8977506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8445 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.66.252.144-2A34E2F131-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35350=[""].join("\n");
var outline_f34_33_35350=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171069\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171070\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171101\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171074\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171090\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171075\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171076\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15881420\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171032\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171050\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171049\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171108\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171099\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171053\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171036\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171096\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171041\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171066\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171056\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171079\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12874091\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6030683\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171055\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171045\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171057\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171035\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171052\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8445\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8445|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?37/43/38580?source=related_link\">",
"      Fexofenadine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?3/37/3670?source=related_link\">",
"      Fexofenadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35351="Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions";
var content_f34_33_35351=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chronic obstructive pulmonary disease: Prognostic factors and comorbid conditions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35351/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35351/contributors\">",
"     Scott T Weiss, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35351/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35351/contributors\">",
"     James K Stoller, MS, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35351/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35351/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/33/35351/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of clinical factors are thought to influence the natural history and prognosis of patients with chronic obstructive pulmonary disease (COPD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. These factors and the impact of acute exacerbations on disease outcome will be reviewed here.",
"   </p>",
"   <p>",
"    The diagnosis and management of COPD are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=see_link\">",
"     \"Management of acute exacerbations of chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of factors have been identified as prognostic indicators for COPD. In addition to the forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), other predictors of accelerated lung function decline, diminished physical function,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mortality in patients with COPD include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/3-13\">",
"     3-13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Airways responsiveness",
"     </li>",
"     <li>",
"      Cigarette smoking",
"     </li>",
"     <li>",
"      Low body-mass index (BMI &le;21)",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Increased airway bacterial load",
"     </li>",
"     <li>",
"      Decreased exercise capacity",
"     </li>",
"     <li>",
"      Peak oxygen consumption (VO",
"      <sub>",
"       2",
"      </sub>",
"      ), measured by cardiopulmonary exercise testing",
"     </li>",
"     <li>",
"      Elevated C-reactive protein (&gt;3",
"      <span class=\"nowrap\">",
"       mg/L)",
"      </span>",
"     </li>",
"     <li>",
"      Male gender",
"     </li>",
"     <li>",
"      Chest computed tomography showing presence of emphysema",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20085935\">",
"    <span class=\"h2\">",
"     Forced expiratory volume in one second",
"    </span>",
"    &nbsp;&mdash;&nbsp;The forced expiratory volume in one second (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ) is the parameter most commonly used to assess the course of COPD and to predict future changes in lung function and survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/14\">",
"     14",
"    </a>",
"    ]. The change in FEV",
"    <sub>",
"     1",
"    </sub>",
"    over time has been assessed in several studies and is affected by smoking status, but is also highly variable among individual patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a three-year study, the changes in the FEV",
"      <sub>",
"       1",
"      </sub>",
"      measured after administration of bronchodilator were assessed in 2163 subjects with COPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/15\">",
"       15",
"      </a>",
"      ]. The overall rate of decline was 33 mL per year, although almost 40 percent of the subjects had a decline of more than 40 mL per year. A high variability in the rate of decline in FEV",
"      <sub>",
"       1",
"      </sub>",
"      was noted, with higher rates in current smokers (54 mL per year), patients with bronchodilator reversibility, and patients with emphysema on computed tomography (CT).",
"     </li>",
"     <li>",
"      In the United States Lung Health Study, the rate of decline in post-bronchodilator FEV",
"      <sub>",
"       1",
"      </sub>",
"      was assessed in 5887 smokers with mild to moderate COPD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/18\">",
"       18",
"      </a>",
"      ]. The unadjusted annual decline was 53.1",
"      <span class=\"nowrap\">",
"       mL/year",
"      </span>",
"      at year 5 and 53.9",
"      <span class=\"nowrap\">",
"       mL/year",
"      </span>",
"      by year 12, by which time 46 percent were still active smokers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The postbronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    has also been used to predict survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/14\">",
"     14",
"    </a>",
"    ]. Among 200 patients with COPD, who were followed for 15 years, after controlling for age, the postbronchodilator FEV",
"    <sub>",
"     1",
"    </sub>",
"    was the best predictor of survival (",
"    <a class=\"graphic graphic_table graphicRef61524 \" href=\"mobipreview.htm?19/5/19548\">",
"     table 1",
"    </a>",
"    ). However, a wide individual variability in prognosis was noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     BODE index",
"    </span>",
"    &nbsp;&mdash;&nbsp;A multidimensional index (the BODE index) was developed to assess an individual's risk of death from COPD. The four factors included in the index are weight (BMI), airway obstruction (FEV",
"    <sub>",
"     1",
"    </sub>",
"    ), dyspnea (Medical Research Council dyspnea score), and exercise capacity (six-minute walk distance) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The BODE index is superior to unidimensional assessment based on the FEV",
"    <sub>",
"     1",
"    </sub>",
"    value alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/3,11\">",
"     3,11",
"    </a>",
"    ]. The utility of the BODE index is not confined to assessing the risk of death; it can also predict hospitalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with COPD have a stable BODE index over time, as demonstrated in a longitudinal study of 751 patients who were followed for a median of 64 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/16\">",
"     16",
"    </a>",
"    ]. A statistically significant increase in the BODE index was noted in 14 percent; these patients had more severe obstruction at baseline than those with a stable BODE index.",
"   </p>",
"   <p>",
"    A modified BODE (mBODE) index uses an alternate dyspnea questionnaire (ie, UCSD SOBQ) and is a better predictor of mortality than its separate components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link&amp;anchor=H15#H15\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Body mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Body mass index (BMI) is an independent risk factor in COPD. Decreasing body mass is associated with increasing mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Further weight loss increases mortality risk, whereas weight gain improves prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The fat-free mass index (FFMI) provides information beyond that provided by the BMI.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The FFMI can identify a subgroup of patients with an increased mortality risk despite a normal BMI. This was illustrated by a prospective cohort study of 1898 patients with COPD who were followed for a mean of seven years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/26\">",
"       26",
"      </a>",
"      ]. Both BMI and FFMI were predictors of mortality. Among patients with a normal BMI, FFMI was a predictor of mortality (26 percent had an FFMI lower than the tenth percentile).",
"     </li>",
"     <li>",
"      The FFMI is a better predictor of disease severity. While both BMI and FFMI correlate with the six-minute walk test, only FFMI correlates with the degree of chronic dyspnea, the FEV",
"      <sub>",
"       1",
"      </sub>",
"      , the",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio, or the stage of disease, according to one observational study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Bronchodilator response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histamine-induced airway hyperresponsiveness is a predictor of mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/5\">",
"     5",
"    </a>",
"    ]. Conversely, it is uncertain whether bronchodilation due to a beta-agonist predicts mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H200428268\">",
"    <span class=\"h2\">",
"     Types of COPD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only a few studies have focused on prognosis of specific types of COPD. In one study of 609 patients with severe emphysema (mean FEV",
"    <sub>",
"     1",
"    </sub>",
"    27 percent of predicted), the following factors predicted mortality: advanced age (&ge;70 years), supplemental oxygen use, total lung capacity (&lt;140 percent of predicted), residual volume (&ge;262 percent of predicted), maximal workload during cardiopulmonary exercise testing (&le;25 W for females, &le;40 W for males), BODE index (&ge;7), and increased emphysema",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood flow to the lower lung zones [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Acute exacerbations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with COPD are frequently hospitalized for acute exacerbations, most commonly in association with respiratory infections. The effect of these exacerbations on survival is unclear, with estimates varying widely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/29-36\">",
"     29-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 1016 patients hospitalized with COPD exacerbation complicated by hypercapnia (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &gt;50 mmHg at admission), the in-hospital, 60-day, 90-day, one-year, and two-year mortality rate was 11, 20, 33, 43, and 49 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/31\">",
"     31",
"    </a>",
"    ]. Patient characteristics associated with death at six months included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic health status",
"     </li>",
"     <li>",
"      Nutritional status",
"     </li>",
"     <li>",
"      Coexisting cardiac disease",
"     </li>",
"     <li>",
"      Severity of the acute illness (determined by the Acute Physiologic And Chronic Health Evaluation [APACHE] score and the",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FIO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratio)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Interestingly, the presence of heart failure or cor pulmonale was associated with a longer survival time after adjustment for other variables. This may be the result of the relatively good response of these disorders to acute therapy.",
"   </p>",
"   <p>",
"    Subsequent studies have identified additional factors associated with poor outcome due to COPD exacerbation. Decreased levels of serum albumin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/29\">",
"     29",
"    </a>",
"    ], low BMI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/29\">",
"     29",
"    </a>",
"    ], advanced pulmonary disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/35\">",
"     35",
"    </a>",
"    ], and nonrespiratory organ dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/35\">",
"     35",
"    </a>",
"    ] are predictive of long-term mortality. In contrast, advanced age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/35\">",
"     35",
"    </a>",
"    ], prolonged hospital length of stay before ICU admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/35\">",
"     35",
"    </a>",
"    ], severe respiratory dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/35,36\">",
"     35,36",
"    </a>",
"    ], and severe nonrespiratory organ dysfunction are associated with in-hospital mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypercapnia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercapnia induced by an acute exacerbation of COPD does not predict increased mortality compared to eucapnia. In a five-year observational study of 85 patients admitted to the hospital with a COPD exacerbation, survival was similar among eucapnic patients (33 percent) and acutely hypercapnic patients (28 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/32\">",
"     32",
"    </a>",
"    ]. In contrast, patients with chronic hypercapnia had a decreased five-year survival (11 percent) (",
"    <a class=\"graphic graphic_figure graphicRef58903 \" href=\"mobipreview.htm?42/51/43837\">",
"     figure 1",
"    </a>",
"    ). All three groups had similar levels of pulmonary function, as measured by FEV",
"    <sub>",
"     1",
"    </sub>",
"    and FVC. Only 24 percent of the patients who became hypercapnic during the acute illness subsequently developed chronic hypercapnia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute respiratory failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute respiratory failure due to a COPD exacerbation does not appear to be associated with diminished long-term survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. In an observational study of 36 patients with acute respiratory failure due to an acute exacerbation of COPD, two-year survival was 72 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/33\">",
"     33",
"    </a>",
"    ]. Compared to controls with similar baseline pulmonary function, there was no difference in two-year mortality.",
"   </p>",
"   <p>",
"    A common clinical question is whether recurrent episodes of acute respiratory failure and mechanical ventilation affect the prognosis of COPD. Unfortunately, little data exists to answer this question.",
"   </p>",
"   <p>",
"    A retrospective cohort study of 74 patients with severe COPD (mean FEV",
"    <sub>",
"     1",
"    </sub>",
"    0.74 L) complicated by acute respiratory failure and ICU admission found an in-hospital mortality of 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/36\">",
"     36",
"    </a>",
"    ]. In this population, the cumulative mortality at one, two, and three years was 48, 58, and 64 percent, respectively. The degree of hypercarbia and higher APACHE II scores were correlated with in-hospital mortality; however, clinical factors independently associated with long-term survival could not be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMORBID DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;COPD has been linked to comorbid conditions such as cardiovascular diseases (eg, hypertension, coronary heart disease, stroke), diabetes mellitus, renal insufficiency, osteoporosis, psychiatric illness (eg, depression and anxiety), and cognitive dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/37-49\">",
"     37-49",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5189?source=see_link&amp;anchor=H2#H2\">",
"     \"Smoking and cardiovascular risk in diabetes mellitus\", section on 'Health hazards of smoking'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H23#H23\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Cigarette smoking'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=see_link&amp;anchor=H4872547#H4872547\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Cigarette smoking'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A potential association between COPD and renal insufficiency was evaluated in a series of 356 older adults (mean age 75.4 years) with COPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/45\">",
"     45",
"    </a>",
"    ]. Renal insufficiency (glomerular filtration rate [GFR] &lt;60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m2) was detected in 43 percent, compared with 23 percent of older adults without COPD. In addition, approximately half of the patients with COPD and a reduced GFR had a normal serum creatinine. This latter group of patients with &ldquo;covert&rdquo; renal insufficiency was more likely to have a low serum albumin and low muscle mass.",
"   </p>",
"   <p>",
"    A three-year observational study, the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study, examined the prevalence of depression among 2118 subjects with COPD, 335 smokers without COPD, and 243 nonsmokers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/50\">",
"     50",
"    </a>",
"    ]. Depression was more prevalent among subjects with COPD (26 percent), than smokers without COPD (12 percent) or nonsmokers (7 percent) and was associated with worse health and functional status. Additional studies are needed to determine the optimal methods for the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/51,52\">",
"     51,52",
"    </a>",
"    ] and treatment of depression in patients with COPD, although comprehensive pulmonary rehabilitation programs appear helpful. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link&amp;anchor=H22#H22\">",
"     \"Clinical manifestations and diagnosis of depression\", section on 'Screening for depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=see_link&amp;anchor=H16#H16\">",
"     \"Pulmonary rehabilitation in COPD\", section on 'Psychological support'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16601?source=see_link\">",
"     \"Depression in adults: Supportive psychotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cognition impairment was evaluated in a survey of 4150 older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35351/abstract/40\">",
"     40",
"    </a>",
"    ]. The adjusted mean cognition scores of those with severe COPD were significantly lower than those with nonsevere or absent COPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/59/5043?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=see_link\">",
"       \"Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The natural history and prognosis of COPD are variable and factors influencing this variability are incompletely understood. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors, such as genetic predisposition, severity of disease, environmental exposures, comorbidities, and, to a lesser degree, acute exacerbations, appear to influence prognosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short-term (ie, in-hospital) survival for patients with COPD and respiratory failure is determined by the overall severity of acute illness, rather than the degree of respiratory failure. In comparison, long-term survival is primarily influenced by the severity of COPD and the presence of comorbid conditions. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Acute exacerbations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute respiratory failure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      COPD is associated with a number of comorbid conditions, such as cardiovascular diseases (eg, hypertension, coronary heart disease, stroke), diabetes mellitus, renal insufficiency, osteoporosis, psychiatric illness (eg, depression and anxiety), and cognitive dysfunction. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Comorbid diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/1\">",
"      Dolan S, Varkey B. Prognostic factors in chronic obstructive pulmonary disease. Curr Opin Pulm Med 2005; 11:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/2\">",
"      Centers for Disease Control and Prevention (CDC). Deaths from chronic obstructive pulmonary disease--United States, 2000-2005. MMWR Morb Mortal Wkly Rep 2008; 57:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/3\">",
"      Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/4\">",
"      Heffner JE, Mularski RA, Calverley PM. COPD performance measures: missing opportunities for improving care. Chest 2010; 137:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/5\">",
"      Hospers JJ, Postma DS, Rijcken B, et al. Histamine airway hyper-responsiveness and mortality from chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/6\">",
"      Diaz PT, King MA, Pacht ER, et al. Increased susceptibility to pulmonary emphysema among HIV-seropositive smokers. Ann Intern Med 2000; 132:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/7\">",
"      Wilkinson TM, Patel IS, Wilks M, et al. Airway bacterial load and FEV1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/8\">",
"      Berry MJ, Adair NE, Rejeski WJ. Use of peak oxygen consumption in predicting physical function and quality of life in COPD patients. Chest 2006; 129:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/9\">",
"      Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/10\">",
"      Drummond MB, Blackford AL, Benditt JO, et al. Continuous oxygen use in nonhypoxemic emphysema patients identifies a high-risk subset of patients: retrospective analysis of the National Emphysema Treatment Trial. Chest 2008; 134:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/11\">",
"      de Torres JP, Cote CG, L&oacute;pez MV, et al. Sex differences in mortality in patients with COPD. Eur Respir J 2009; 33:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/12\">",
"      Kohansal R, Martinez-Camblor P, Agust&iacute; A, et al. The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/13\">",
"      Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010; 138:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/14\">",
"      Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979; 119:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/15\">",
"      Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med 2011; 365:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/16\">",
"      Casanova C, de Torres JP, Aguirre-Ja&iacute;me A, et al. The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort. Am J Respir Crit Care Med 2011; 184:1015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/17\">",
"      Nishimura M, Makita H, Nagai K, et al. Annual change in pulmonary function and clinical phenotype in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/18\">",
"      Drummond MB, Hansel NN, Connett JE, et al. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/19\">",
"      Ong KC, Earnest A, Lu SJ. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 2005; 128:3810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/20\">",
"      Martinez FJ, Han MK, Andrei AC, et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med 2008; 178:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/21\">",
"      Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The National Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989; 139:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/22\">",
"      Gray-Donald K, Gibbons L, Shapiro SH, et al. Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996; 153:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/23\">",
"      Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/24\">",
"      Landbo C, Prescott E, Lange P, et al. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/25\">",
"      Prescott E, Almdal T, Mikkelsen KL, et al. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 2002; 20:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/26\">",
"      Vestbo J, Prescott E, Almdal T, et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 2006; 173:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/27\">",
"      Ischaki E, Papatheodorou G, Gaki E, et al. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 2007; 132:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/28\">",
"      Martinez FJ, Foster G, Curtis JL, et al. Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 2006; 173:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/29\">",
"      Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005; 26:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/30\">",
"      Patil SP, Krishnan JA, Lechtzin N, Diette GB. In-hospital mortality following acute exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 2003; 163:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/31\">",
"      Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 1996; 154:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/32\">",
"      Costello R, Deegan P, Fitzpatrick M, McNicholas WT. Reversible hypercapnia in chronic obstructive pulmonary disease: a distinct pattern of respiratory failure with a favorable prognosis. Am J Med 1997; 102:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/33\">",
"      Martin TR, Lewis SW, Albert RK. The prognosis of patients with chronic obstructive pulmonary disease after hospitalization for acute respiratory failure. Chest 1982; 82:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/34\">",
"      Hudson LD. Survival data in patients with acute and chronic lung disease requiring mechanical ventilation. Am Rev Respir Dis 1989; 140:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/35\">",
"      Seneff MG, Wagner DP, Wagner RP, et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. JAMA 1995; 274:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/36\">",
"      Breen D, Churches T, Hawker F, Torzillo PJ. Acute respiratory failure secondary to chronic obstructive pulmonary disease treated in the intensive care unit: a long term follow up study. Thorax 2002; 57:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/37\">",
"      Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/38\">",
"      Light RW, Merrill EJ, Despars JA, et al. Prevalence of depression and anxiety in patients with COPD. Relationship to functional capacity. Chest 1985; 87:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/39\">",
"      Incalzi RA, Gemma A, Marra C, et al. Chronic obstructive pulmonary disease. An original model of cognitive decline. Am Rev Respir Dis 1993; 148:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/40\">",
"      Hung WW, Wisnivesky JP, Siu AL, Ross JS. Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/41\">",
"      Omachi TA, Katz PP, Yelin EH, et al. Depression and health-related quality of life in chronic obstructive pulmonary disease. Am J Med 2009; 122:778.e9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/42\">",
"      Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/43\">",
"      Ferguson GT, Calverley PM, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/44\">",
"      Schneider C, Jick SS, Bothner U, Meier CR. COPD and the risk of depression. Chest 2010; 137:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/45\">",
"      Incalzi RA, Corsonello A, Pedone C, et al. Chronic renal failure: a neglected comorbidity of COPD. Chest 2010; 137:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/46\">",
"      Katz PP, Julian LJ, Omachi TA, et al. The impact of disability on depression among individuals with COPD. Chest 2010; 137:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/47\">",
"      Watz H, Waschki B, Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010; 138:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/48\">",
"      Feary JR, Rodrigues LC, Smith CJ, et al. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/49\">",
"      Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-exposed cohort. Am J Respir Crit Care Med 2011; 183:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/50\">",
"      Hanania NA, M&uuml;llerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/51\">",
"      Arimura Y, Yamazaki S, Yanagi S, et al. Clinical usefulness of the two-question assessment tool for depressive symptoms in Japanese patients with chronic obstructive pulmonary disease. Lung 2013; 191:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35351/abstract/52\">",
"      Julian LJ, Gregorich SE, Earnest G, et al. Screening for depression in chronic obstructive pulmonary disease. COPD 2009; 6:452.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1439 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-211.167.112.17-380DEE3FB3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35351=[""].join("\n");
var outline_f34_33_35351=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20085935\">",
"      Forced expiratory volume in one second",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BODE index",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Body mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Bronchodilator response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H200428268\">",
"      Types of COPD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Acute exacerbations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypercapnia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute respiratory failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMORBID DISEASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1439\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1439|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/51/43837\" title=\"figure 1\">",
"      Kaplan Meier curves in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1439|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/5/19548\" title=\"table 1\">",
"      FEV1 and survival in COPD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?22/50/23329?source=related_link\" title=\"calculator 1\">",
"      Calculator: BODE Index for COPD survival prediction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/14/30954?source=related_link\">",
"      Chronic obstructive pulmonary disease: Definition, clinical manifestations, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/13/16601?source=related_link\">",
"      Depression in adults: Supportive psychotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/5/23641?source=related_link\">",
"      Management of acute exacerbations of chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/13/1236?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/59/5043?source=related_link\">",
"      Patient information: Chronic obstructive pulmonary disease (COPD), including emphysema (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38840?source=related_link\">",
"      Pulmonary rehabilitation in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/4/5189?source=related_link\">",
"      Smoking and cardiovascular risk in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35352="Imatinib: Pediatric drug information";
var content_f34_33_35352=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Imatinib: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"    see \"Imatinib: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/49/3862?source=see_link\">",
"    see \"Imatinib: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Gleevec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F181930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Gleevec&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1019099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antineoplastic Agent, Tyrosine Kinase Inhibitor",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1019131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=see_link\">",
"      see \"Imatinib: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     For concurrent use with a strong CYP3A4 enzyme-inducing agent (eg, rifampin, phenytoin), imatinib dosage should be increased by at least 50%. The optimal duration of therapy for CML is not yet determined; discontinuing treatment is not recommended after achieving remission due to the potential for relapse (NCCN CML guidelines v1.2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;2 years:",
"     <b>",
"      Note:",
"     </b>",
"     May be administered once daily or in 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ph+ CML (chronic phase, newly diagnosed): 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day; maximum: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ph+ CML (chronic phase and recurrent after stem cell transplant or resistant to interferon): 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Note:",
"     </b>",
"     Doses &le;600 mg should be administered once daily; 800 mg doses should be administered as 400 mg/dose twice a day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ph+ CML:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Chronic phase: 400 mg once daily; may be increased to 600 mg daily, if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6-12 months, or loss of previous hematologic or cytogenetic response; ranges up to 800 mg/day (400 mg twice daily) have also been used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Accelerated phase or blast crisis: 600 mg once daily; may be increased to 800 mg daily (400 mg/dose twice daily), if tolerated, for disease progression, lack of hematologic response after 3 months, lack of cytogenetic response after 6-12 months, or loss of previous hematologic or cytogenetic response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ph+ ALL (relapsed or refractory): 600 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GIST (adjuvant treatment following complete resection): 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     GIST (unresectable and/or metastatic malignant): 400 mg/day; may be increased up to 800 mg/day (400 mg/dose twice daily), if tolerated, for disease progression;",
"     <b>",
"      Note:",
"     </b>",
"     Significant improvement (progression-free survival, objective response rate) was demonstrated in patients with KIT exon 9 mutation with 800 mg (versus 400 mg), although overall survival (OS) was not impacted. The higher dose did not demonstrate a difference in time to progression or OS patients with Kit exon 11 mutation or wild-type status (Debiec-Rychter, 2006; Heinrich, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ASM with eosinophilia: Initiate at 100 mg once daily; titrate up to a maximum of 400 mg once daily (if tolerated) for insufficient response to lower dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ASM without D816V c-Kit mutation or c-Kit mutation status unknown: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DFSP: 400 mg/dose twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HES/CEL: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase: Initiate at 100 mg once daily; titrate up to a maximum of 400 mg once daily (if tolerated) if insufficient response to lower dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     MDS/MPD: 400 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment with concomitant strong CYP3A4 inducers:",
"     </b>",
"     Avoid concomitant use of strong CYP3A4 inducers (eg, dexamethasone, carbamazepine, phenobarbital, phenytoin, rifampin); if concomitant use cannot be avoided, increase imatinib dose by at least 50% with careful monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Mild impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     40-59 mL/minute): Maximum recommended dose: 600 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Moderate impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     20-39 mL/minute): Decrease recommended starting dose by 50%; dose may be increased as tolerated; maximum recommended dose: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Severe impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;20 mL/minute): Use caution; a dose of 100 mg/day has been tolerated in severe impairment (Gibbons, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hepatic impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Mild-to-moderate impairment: No adjustment necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Severe impairment: Manufacturer&rsquo;s FDA-approved labeling: Reduce dose by 25%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     <i>",
"      NCCN Soft tissue Sarcoma guidelines (v.1.2009)",
"     </i>",
"     : GIST: Reduce dose by 25% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hepatotoxicity (during therapy) or other nonhematologic adverse reactions:",
"     </b>",
"     Withhold treatment until toxicity resolves; may resume if appropriate (depending on initial severity of adverse event)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     Hepatotoxicity (during therapy): If elevations of bilirubin &gt;3 times upper limit of normal (ULN) or liver transaminases &gt;5 times ULN occur, withhold treatment until bilirubin &lt;1.5 times ULN or transaminases &lt;2.5 times ULN. Resume treatment at a reduced dose as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If initial dose 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, reduce dose to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If initial dose 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, reduce dose to 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If initial dose 400 mg, reduce dose to 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If initial dose 600 mg, reduce dose to 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     If initial dose 800 mg, reduce dose to 600 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for hematologic adverse reactions:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Chronic phase CML (initial dose: 260-340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in children) or 400 mg/day in adults), ASM, MDS/MPD, and HES/CEL (initial dose: 400 mg/day), or GIST (initial dose: 400 mg): If ANC &lt;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Withhold until ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; resume treatment at previous dose. For recurrent neutropenia or thrombocytopenia, withhold until recovery and reinstitute treatment at a reduced dose as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Children &ge;2 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If initial dose 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, reduce dose to 200 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     If initial dose 340 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day, reduce dose to 260 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Adults: If initial dose 400 mg, reduce dose to 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     CML (accelerated phase or blast crisis) and PH+ ALL: Adults (initial dose: 600 mg): If ANC &lt;0.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;10 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, establish whether cytopenia is related to leukemia (bone marrow aspirate or biopsy). If unrelated to leukemia, reduce dose to 400 mg. If cytopenia persists for an additional 2 weeks, further reduce dose to 300 mg. If cytopenia persists for 4 weeks and is still unrelated to leukemia, withhold treatment until ANC &ge;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;20 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L, then resume treatment at 300 mg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     ASM-associated with eosinophilia and HES/CEL with FIP1L1-PDGFR&alpha; fusion kinase (starting dose: 100 mg/day): If ANC &lt;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L: Withhold until ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; resume treatment at previous dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DFSP (initial dose: 800 mg/day): If ANC &lt;1 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and/or platelets &lt;50 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L , withhold until ANC &ge;1.5 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L and platelets &ge;75 x 10",
"     <sup>",
"      9",
"     </sup>",
"     /L; resume treatment at reduced dose of 600 mg/day. If depression in neutrophils or platelets recurs, withhold until recovery and reinstitute treatment with a further dose reduction to 400 mg/day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F181906\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gleevec&reg;: 100 mg, 400 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F181892\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1019138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Should be administered orally with a meal and a large glass of water. Tablets may be dispersed in water or apple juice (using ~50 mL for 100 mg tablet, ~200 mL for 400 mg tablet); stir until tablet dissolves and use immediately. For daily dosing &ge;800 mg, the 400 mg tablets should be used to reduce iron exposure (tablets are coated with ferric oxide). Avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1019120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at controlled room temperature of 25&deg;C (77&deg;F); protect from moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1019100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Newly-diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (FDA approved in ages &ge;2 years and adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recurrent Ph+ CML in chronic phase following stem cell transplant or in patients resistant to interferon alpha therapy (FDA approved in ages &ge;2 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ph+ CML in blast crisis, accelerated phase, or chronic phase after failure of interferon therapy  (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ph+ acute lymphoblastic leukemia (ALL) (relapsed or refractory), aggressive systemic mastocytosis (ASM) without D816V c-Kit mutation (or c-Kit mutation status unknown), dermatofibrosarcoma protuberans (DFSP) (unresectable, recurrent, and metastatic), hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL), myelodysplastic/myeloproliferative disease (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Has also been used in the treatment of desmoid tumors (soft tissue sarcoma); poststem cell transplant (allogeneic) follow-up treatment in CML",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3401645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Imatinib may be confused with axitinib, dasatinib, erlotinib, gefitinib, nilotinib, ponatinib, SORAfenib, SUNItinib, vandetanib",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F181964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: Chest pain; edema/fluid retention (includes aggravated edema, anasarca, ascites, palpitation, pericardial effusion, peripheral edema, pulmonary edema, and superficial edema); facial edema, flushing, hypotension (children and adolescents), pleural effusion (children and adolescents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, CNS/cerebral hemorrhage, depression, dizziness, fatigue, fever, headache, hypoesthesia, insomnia, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Dermatologic: Alopecia, dermatitis, dry skin, erythema, photosensitivity reaction, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Albumin decreased, hyperglycemia, hypocalcemia, hypokalemia (more common in children and adolescents), hypoproteinemia, LDH increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distension, abdominal pain, anorexia, appetite decreased, constipation, diarrhea, dyspepsia, flatulence, gastritis, gastroesophageal reflux, gastrointestinal hemorrhage, nausea, stomatitis/mucositis, taste disturbance, vomiting, weight gain/loss, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hematologic: Anemia, hemorrhage, leukopenia, lymphopenia, neutropenia, neutropenic fever, pancytopenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hepatic: Alkaline phosphatase increased, ALT increased, AST increased, bilirubin increased, transaminases increased (children and adolescents)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, back pain, bone pain, joint swelling, limb pain, muscle cramps, musculoskeletal pain, myalgia, paresthesia, peripheral neuropathy, rigors, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision, conjunctival hemorrhage, conjunctivitis, dry eyes, lacrimation increased, periorbital edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal: Serum creatinine increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, epistaxis, hypoxia, nasopharyngitis, pharyngitis, pharyngolaryngeal pain, pneumonia, pneumonitis (children and adolescents), rhinitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, flu-like syndrome, infection (more common in children and adolescents), night sweats",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acute febrile neutropenic dermatosis (Sweet&rsquo;s syndrome), anaphylactic shock, angina, angioedema, aplastic anemia, arrhythmia, arthritis, ascites, atrial fibrillation, avascular necrosis, bullous eruption, cardiac arrest, cardiac tamponade, cardiogenic shock, cataract, cellulitis, cerebral edema, diverticulitis, embolism, eosinophilia, erythema multiforme, exanthematous pustulosis (acute generalized), exfoliative dermatitis, fungal infection, gastric ulcer, gastrointestinal obstruction, gastrointestinal perforation, glaucoma, gout, growth retardation (children), hearing loss, heart failure (severe), hematoma, hematemesis, hematuria, hemolytic anemia, hemorrhagic corpus luteum, hemorrhagic ovarian cyst, hepatic failure, hepatic necrosis, hepatitis, hepatotoxicity, herpes simplex, herpes zoster, hip osteonecrosis, hypercalcemia, hyperkalemia, hyperuricemia, hypertension, hypomagnesemia, hyponatremia, hypophosphatemia, hypothyroidism, ileus, inflammatory bowel disease, interstitial lung disease, interstitial pneumonitis, intracranial pressure increased, left ventricular dysfunction, leukocytoclastic vasculitis, lichen planus, lichenoid keratosis, lymphadenopathy, macular edema, melena, memory impairment, menorrhagia, MI, migraine, myopathy, optic neuritis, ovarian cyst (hemorrhagic), palmar-plantar erythrodysesthesia syndrome, pancreatitis, papilledema, pericarditis, psoriasis, pulmonary fibrosis, pulmonary hemorrhage, pulmonary hypertension, Raynaud's phenomenon, renal failure, respiratory failure, respiratory tract (lower) infection, restless leg syndrome, retinal hemorrhage, rhabdomyolysis, sciatica, scleral hemorrhage, seizure, sepsis, skin pigment changes, Stevens-Johnson syndrome, subdural hematoma, syncope, tachycardia, thrombocythemia, thrombosis, toxic epidermal necrolysis, tumor hemorrhage (GIST), tumor lysis syndrome, tumor necrosis, urinary tract infection, vitreous hemorrhage",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1019104\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to imatinib or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F8106837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with pre-existing hepatic and/or renal impairment; may require dosage adjustment. Use caution in thyroidectomy patients (receiving levothyroxine thyroid replacement therapy); hypothyroidism has been reported; monitor TSH levels. May cause GI irritation. Opportunistic infections may be associated with use. Use with caution in patients receiving concurrent therapy with drugs which alter cytochrome P450 activity or require metabolism by these isoenzymes (avoid concomitant use of strong CYP3A4 inducers). Hazardous agent; use appropriate precautions for handling and disposal.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1019105\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause fluid retention, weight gain, and edema which may lead to significant complications, including pleural effusion, pericardial effusion, pulmonary edema, and ascites. Use with caution in patients where fluid accumulation may be poorly tolerated, such as cardiovascular disease (HF or hypertension) and pulmonary disease. Severe HF and left ventricular dysfunction (LVD) have been reported (rare), usually in patients with comorbidities and/or risk factors. Carefully monitor patients with pre-existing cardiac disease or risk factors for heart failure. With initiation of imatinib treatment, cardiogenic shock and/or LVD have been reported in patients with hypereosinophilic syndrome and cardiac involvement (reversible with systemic steroids, circulatory support, and temporary cessation of imatinib). Patients with high eosinophil levels and an abnormal echocardiogram or abnormal serum troponin level may benefit from prophylactic systemic steroids with the initiation of imatinib.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Severe bullous dermatologic reactions (including erythema multiforme and Stevens-Johnson syndrome) have been reported. Successful resumption at a lower dose (with corticosteroids and/or antihistamine) has been described; however, some patients may experience recurrent reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause hepatotoxicity (either as monotherapy or in combination with chemotherapy); may be severe; monitor; interruption of therapy or dose reductions may be necessary. Transaminase and bilirubin elevations and acute liver failure have been observed with imatinib in combination with chemotherapy.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause severe hemorrhage. Hematologic toxicity (anemia, neutropenia, and thrombocytopenia) may occur.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F181952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     BCRP, CYP2C9 (weak), CYP2D6 (moderate), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F181900\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetaminophen: May enhance the hepatotoxic effect of Imatinib. Imatinib may increase the serum concentration of Acetaminophen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Imatinib may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with strong CYP3A4 inducers when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fludarabine: Imatinib may diminish the myelosuppressive effect of Fludarabine. Imatinib may decrease the serum concentration of Fludarabine. More specifically, imatinib may decrease the formation of fludarabine active metabolite F-ara-ATP  Management: Due to the risk for impaired fludarabine response, consider discontinuing imatinib therapy at least 5 days prior to initiating fludarabine conditioning therapy in CML patients undergoing HSCT.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibuprofen: May decrease the serum concentration of Imatinib. Specifically, ibuprofen may decrease intracellular concentrations of imatinib, leading to decreased clinical response. Management: Consider using an alternative to ibuprofen in patients who are being treated with imatinib.  Available evidence suggests other NSAIDs do not interact in a similar manner.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivabradine.  Management: In patients with a resting heart rate over 60 beats per minute receiving a moderate CYP3A4 inhibitor, ivabradine initiation at an adult dose of 2.5 mg twice daily may be considered.  Monitor heart rate closely under these circumstances.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lansoprazole: May enhance the dermatologic adverse effect of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ranolazine.  Management: Limit the ranolazine adult dose to a maximum of 500 mg twice daily in patients concurrently receiving moderate CYP3A4 inhibitors (e.g., diltiazem, verapamil, erythromycin, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Imatinib. Management: Avoid concurrent use of imatinib with the rifamycin derivatives when possible.  If such a combination must be used, increase imatinib dose by at least 50% and monitor the patient's clinical response closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Imatinib may decrease the metabolism of Simvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Imatinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: BCRP/ABCG2 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Imatinib may enhance the anticoagulant effect of Warfarin. Imatinib may decrease the metabolism of Warfarin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1019119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Food may reduce gastrointestinal irritation. Avoid grapefruit juice (may increase imatinib plasma concentration).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F181902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F181916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated teratogenic effects and fetal loss. Women of childbearing potential are advised not to become pregnant (female patients and female partners of male patients); highly effective contraception is recommended. Case reports of pregnancies while on therapy (both males and females) include reports of spontaneous abortion, minor abnormalities (hypospadias, pyloric stenosis, and small intestine rotation) at or shortly after birth, and other congenital abnormalities including skeletal malformations, hypoplastic lungs, exomphalos, kidney abnormalities, hydrocephalus, cerebellar hypoplasia, and cardiac defects.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Retrospective case reports of women with CML in complete hematologic response (CHR) with cytogenic response (partial or complete) who interrupted imatinib therapy due to pregnancy, demonstrated a loss of response in some patients while off treatment. At 18 months after treatment reinitiation following delivery, CHR was again achieved in all patients and cytogenic response was achieved in some patients. Cytogenetic response rates may not be at as high as compared to patients with 18 months of uninterrupted therapy (Ault, 2006; Pye, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1019140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC (weekly for first month, biweekly for second month, then periodically thereafter), liver function tests [at baseline and monthly or as clinically indicated; more frequently (at least weekly) in patients with moderate-to-severe hepatic impairment (Ramanathan, 2008)], renal function, serum electrolytes, including calcium, phosphorus, potassium, and sodium levels; thyroid function tests (in thyroidectomy patients); fatigue, weight, and edema/fluid status; consider echocardiogram and serum troponin levels in patients with HES/CEL and in patients with MDS/MPD or ASM with high eosinophil levels.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Monitor for signs/symptoms of HF in patients at risk for cardiac failure or patients with pre-existing cardiac disease. Baseline evaluation of left ventricular ejection fraction may be considered prior to initiation of imatinib therapy in patients with known underlying heart disease or in elderly patients.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1019122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits Bcr-Abl tyrosine kinase, the constitutive abnormal gene product of the Philadelphia chromosome in chronic myeloid leukemia (CML). Inhibition of this enzyme blocks proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as in fresh leukemic cells in Philadelphia chromosome positive CML. Also inhibits tyrosine kinase for platelet-derived growth factor (PDGF), stem cell factor (SCF), c-kit, and cellular events mediated by PDGF and SCF.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1019124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~95% to albumin and alpha",
"     <sub>",
"      1",
"     </sub>",
"     -acid glycoprotein (parent drug and metabolite)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP3A4 (minor metabolism via CYP1A2, CYP2D6, CYP2C9, CYP2C19); primary metabolite (active): N-demethylated piperazine derivative (CGP74588); severe hepatic impairment (bilirubin &gt;3-10 times ULN) increases AUC by 45% to 55% for imatinib and its active metabolite, respectively",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Parent drug: ~18 hours; N-desmethyl metabolite: ~40 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Parent drug: ~15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-4 hours (adults and children)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (68% primarily as metabolites, 20% as unchanged drug); urine (&le;13% primarily as metabolites, 5% as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1019144\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/49/3862?source=see_link\">",
"      see \"Imatinib: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid chronic use of acetaminophen or aspirin unless approved by prescriber. Take exactly as directed; do not alter or discontinue dose without consulting prescriber. Take with food or a large glass of water. If you have difficulty swallowing tablets, tablet may be dissolved in water or apple juice (using ~50 mL for 100 mg tablet or ~200 mL for 400 mg tablet), stir until dissolved and use immediately. Avoid grapefruit juice. Maintain adequate hydration unless instructed to restrict fluid intake. You will be required to have regularly scheduled laboratory tests while on this medication. You will be more susceptible to infection (avoid crowds or contagious people and do not receive any vaccination unless approved by prescriber). You may experience headache, dizziness, or fatigue (use caution when driving or engaging in tasks requiring alertness until response to drug is known); loss of appetite, nausea, vomiting, or mouth sores (small frequent meals, frequent mouth care, chewing gum, or sucking lozenges may help); constipation (increased exercise, fluids, fruit, or fiber may help); or diarrhea. Report immediately any chest pain, palpitations, or swelling of extremities; unusual cough, respiratory difficulty, or wheezing; weight gain &gt;5 lb; skin rash; muscle or bone pain, tremors, or cramping; persistent fatigue or weakness; easy bruising or unusual bleeding (eg, tarry stools, blood in vomitus, stool, urine, or mouth); persistent GI problems or pain; or other adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F12807779\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     An oral suspension may be prepared by placing tablets (whole, do not crush) in a glass of water or apple juice. Use ~50 mL for 100 mg tablet, or ~200 mL for 400 mg tablet. Stir until tablets are disintegrated, then administer immediately. To ensure the full dose is administered, rinse the glass and administer residue.",
"    </p>",
"    <div class=\"reference\">",
"     Gleevec&reg; prescribing information, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 2012.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Carpenter PA, Snyder DS, Flowers ME, et al, &ldquo;Prophylactic Administration of Imatinib After Hematopoietic Cell Transplantation for High-Risk Philadelphia Chromosome-Positive Leukemia,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2007, 109(7):2791-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/33/35352/abstract-text/17119111/pubmed\" id=\"17119111\" target=\"_blank\">",
"        17119111",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons J, Egorin MJ, Ramanathan RK, et al, \"Phase I and Pharmacokinetic Study of Imatinib Mesylate in Patients With Advanced Malignancies and Varying Degrees of Renal Dysfunction: A Study by the National Cancer Institute Organ Dysfunction Working Group,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2008, 26(4):570-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/33/35352/abstract-text/18235116/pubmed\" id=\"18235116\" target=\"_blank\">",
"        18235116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network (NCCN)&reg; &ldquo;Practice Guidelines in Oncology&trade;: Soft Tissue Sarcoma Version 1.2009.&rdquo; Available at file://www.nccn.org/professionals/physician_gls/PDF/sarcoma.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12618 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-24348CF07F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35352=[""].join("\n");
var outline_f34_33_35352=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181929\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181930\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019099\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019131\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181906\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181892\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019138\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019120\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019100\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3401645\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181964\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019104\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106837\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019105\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181952\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181900\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019119\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181902\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181916\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019140\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019122\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019124\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1019144\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12807779\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12618\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12618|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/1/17434?source=related_link\">",
"      Imatinib: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/49/3862?source=related_link\">",
"      Imatinib: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35353="Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)";
var content_f34_33_35353=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35353/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/33/35353/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic granulomatosis with polyangiitis (Churg-Strauss), abbreviated EGPA, which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral blood eosinophilia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. CSS is classified as a vasculitis of the small and medium sized arteries, although the vasculitis is often not apparent in the initial phases of the disease.",
"   </p>",
"   <p>",
"    The most commonly involved organ is the lung, followed by the skin. CSS, however, can affect any organ system, including the cardiovascular, gastrointestinal, renal, and central nervous systems. Vasculitis of extrapulmonary organs is largely responsible for the morbidity and mortality associated with EGPA.",
"   </p>",
"   <p>",
"    The diagnosis of EGPA is typically suspected based on the clinical findings (ie, eosinophilia",
"    <span class=\"nowrap\">",
"     &ge;1500/microL,",
"    </span>",
"    asthma, and allergic rhinitis). A positive antineutrophil cytoplasmic antibody test is present in 40 to 60 percent, but is neither sensitive nor specific. The diagnosis is generally confirmed by a biopsy of an affected tissue, such as lung, skin, or peripheral nerve [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef76251 \" href=\"mobipreview.htm?26/50/27435\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The treatment and prognosis of EGPA will be reviewed here. The epidemiology, pathogenesis, clinical features, and diagnosis of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27177?source=see_link\">",
"     \"Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASSESSING VASCULITIS SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two scoring systems have been developed to assess vasculitis disease activity in patients with EGPA and other vasculitides: the \"five factors score\" and the Birmingham Vasculitis Activity Score (BVAS). These scoring systems are used to guide initial therapy.",
"   </p>",
"   <p>",
"    The \"five-factors score\" (FFS) is based on the presence or absence of the following five clinical factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac involvement",
"     </li>",
"     <li>",
"      Gastrointestinal disease (bleeding, perforation, infarction, or pancreatitis)",
"     </li>",
"     <li>",
"      Renal insufficiency (plasma creatinine concentration &gt;1.58",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [141",
"      <span class=\"nowrap\">",
"       micromol/L])",
"      </span>",
"     </li>",
"     <li>",
"      Proteinuria (&gt;1",
"      <span class=\"nowrap\">",
"       g/day)",
"      </span>",
"     </li>",
"     <li>",
"      Central nervous system involvement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of each factor is given one point. The FFS score ranges from 0 to 2: a score of 0 is given when none of the factors are present, a score of 1 for one factor, and a score of 2 for two or more factors. This scoring system has also been correlated with prognosis. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The Birmingham Vasculitis Activity Score (BVAS) is a research tool that is seldom used in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/7\">",
"     7",
"    </a>",
"    ]. It has largely been applied to patients with granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis, but has also been used in EGPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. The score includes both general symptoms (arthralgia, arthritis, and fever) and involvement of eight major organ systems (skin, mucous membranes,",
"    <span class=\"nowrap\">",
"     ear/nose/throat,",
"    </span>",
"    cardiovascular, pulmonary, gastrointestinal, renal, nervous system) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/7\">",
"     7",
"    </a>",
"    ]. At each site, persistent symptoms or manifestations (eg, sensorineural deafness, pulmonary nodule, alveolar hemorrhage) are given one point and new or worse symptoms are given two points. The score ranges from 0 (complete remission) to a maximum of 68. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H3#H3\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Assessment of disease activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIATING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary therapy for EGPA is systemic glucocorticoids. An additional immunosuppressive agent is typically added in patients with more advanced or refractory disease and in those whose disease flares with tapering of systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/9\">",
"     9",
"    </a>",
"    ]. Choosing among these agents is largely dependent on the disease severity and response to treatment. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Assessing vasculitis severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Asthma is additionally managed according to current guidelines, as described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"     \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of severe asthma in adolescents and adults\", section on 'Adjusting controller therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypertension should be managed in a standard fashion, but is sometimes difficult to control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=see_link\">",
"     \"Overview of hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Systemic glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic glucocorticoid therapy is the mainstay of treatment for EGPA. For patients with evidence of systemic vasculitis, treatment is initiated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or the equivalent) at a dose of 0.5 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. The higher dose is used for patients with more severe vasculitis (eg, impending respiratory failure, cardiac involvement, glomerulonephritis, neuropathy). With acute multiorgan disease, intravenous glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    1 g daily for three days) is used for initial therapy, followed by oral glucocorticoid therapy as noted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The majority of patients with EGPA achieve a remission with glucocorticoid therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/11\">",
"     11",
"    </a>",
"    ]. In a study of 72 patients without poor-prognosis factors (ie, no cardiac, renal, or central nervous system involvement) followed for five years or longer, 93 percent achieved a remission with glucocorticoid therapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/11\">",
"     11",
"    </a>",
"    ]. However, patients with involvement of the heart, kidney, gastrointestinal tract, or central nervous system will usually require additional immunosuppressive therapy as described below.",
"   </p>",
"   <p>",
"    Once disease manifestations have come under control, the glucocorticoid dose is gradually tapered over approximately 12 to 18 months, as tolerated. A portion of patients will need long-term low dose oral glucocorticoid therapy (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or less). In the study of 72 patients described above, almost 80 percent of those who achieved a remission required long-term low-dose glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In EGPA, late relapses of systemic vasculitis after a successful response to treatment are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/12\">",
"     12",
"    </a>",
"    ]. However, premature withdrawal of treatment can result in recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    is typically used in combination with glucocorticoids for patients with severe, multiorgan disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5,13-20\">",
"     5,13-20",
"    </a>",
"    ]. The decision to add cyclophosphamide is based on the severity of disease in terms of number of organ systems involved and degree of impairment. The five factors score (FFS) is used to quantitate the extent of disease and guide therapy (",
"    <a class=\"graphic graphic_table graphicRef50118 \" href=\"mobipreview.htm?6/40/6795\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Assessing vasculitis severity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in patients with a FFS of 2 or greater, as this score is associated with greater mortality among patients who are treated with glucocorticoids alone, compared with those who also receive cyclophosphamide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/17,19\">",
"       17,19",
"      </a>",
"      ]. In a meta-analysis of 277 patients with EGPA, microscopic polyangiitis, and polyarteritis and an FFS of 2 (",
"      <a class=\"graphic graphic_table graphicRef50118 \" href=\"mobipreview.htm?6/40/6795\">",
"       table 2",
"      </a>",
"      ), survival was significantly prolonged among patients treated with cyclophosphamide and glucocorticoids rather than glucocorticoids alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      We also suggest addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      for patients with a \"five factors score\" of 1, particularly in the presence of cardiac or central nervous system involvement [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5,18,20\">",
"       5,18,20",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef50118 \" href=\"mobipreview.htm?6/40/6795\">",
"       table 2",
"      </a>",
"      ). This suggestion is based on higher mortality among patients with a FFS of 1, compared with patients with a FFS of 0 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, in a series of patients with a FFS of 1, a lower mortality was noted among those who were treated with cyclophosphamide compared with a separate group in which only some of the patients received cyclophosphamide (7 versus 26 percent mortality, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An alternative regimen for patients with an FFS of 1, but milder, nonorgan-threatening disease, would be initial treatment with glucocorticoids plus either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/9,21\">",
"       9,21",
"      </a>",
"      ]. The use of an alternative induction regimen was evaluated in a study of 100 patients with early systemic ANCA-positive vasculitides (including EGPA) that compared glucocorticoids plus methotrexate with glucocorticoids plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/21\">",
"       21",
"      </a>",
"      ]. The remission success rate was similar at six months (90 and 94 percent, respectively). However, the methotrexate regimen was less successful for patients with more extensive disease or pulmonary involvement. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Methotrexate'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Some experts would also use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      in patients with an FFS of 0 and a positive ANCA, as these patients tend to develop renal involvement, peripheral neuropathy, and biopsy evidence of vasculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    may be administered orally every day or intravenously once a month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/18\">",
"     18",
"    </a>",
"    ]. Insufficient data is available for EGPA to make a clear recommendation regarding this choice. Extrapolating from granulomatosis with polyangiitis (Wegener&rsquo;s), outcomes with daily and monthly regimens were similar; a slightly greater risk of bladder toxicity with the daily regimen and a slightly greater risk of relapse with the monthly regimen have been noted. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H10#H10\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dosing and monitoring considerations for daily and monthly administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy remains controversial. When used to treat granulomatosis with polyangiitis, typically a six month regimen is used. However, in a preliminary study of patients with EGPA, those receiving 6 pulses of cyclophosphamide had more relapses than those receiving 12 pulses (94 percent versus 41 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/20\">",
"     20",
"    </a>",
"    ]. Further data is needed to clarify whether the benefits of 12 pulses of cyclophosphamide outweigh the additional risks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MAINTENANCE AND GLUCOCORTICOID SPARING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once remission is induced with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and glucocorticoid therapy (which usually occurs within six to twelve months), patients are switched to maintenance therapy with less toxic immunosuppressive drugs, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , in combination with a tapering dose of glucocorticoids.",
"   </p>",
"   <p>",
"    For patients whose disease is not severe enough to require",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , but requires long-term therapy with moderate to high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (eg, more than 10 mg daily), an immunosuppressive agent is often added for a glucocorticoid sparing effect. The data in support of this comes from clinical experience and extrapolation from the management of granulomatosis with polyangiitis (Wegener&rsquo;s). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Maintenance immunosuppressive therapy is typically continued for 12 to 18 months. Longer term or indefinite maintenance therapy may be warranted in patients with multiple relapses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with EGPA,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (AZA) is typically used after induction of remission with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or as a glucocorticoid-sparing agent in patients requiring long-term treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at doses greater than 15 mg per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/11,22,23\">",
"     11,22,23",
"    </a>",
"    ]. Analysis of the thiopurine methyltransferase (TPMT) gene prior to the administration of AZA may help predict those individuals at risk for severe toxicity. When deficiency of the TPMT enzyme is found, we choose an alternate immunosuppressive agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , although data regarding the use of these agents is limited. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Pharmacogenetics and TPMT testing'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different regimens have been reported for initiation of AZA: starting with the target dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    lean body weight versus starting at 25 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for the first week to test for drug hypersensitivity and then increasing by 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day every four to six weeks up to the target dose. In general, we favor going directly to the target dose in order to avoid a relapse during the time that the patient is on suboptimal doses. The direct approach was used successfully in a trial of patients with granulomatosis with polyangiitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/24\">",
"     24",
"    </a>",
"    ]. A lower target dose is indicated in patients with renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link&amp;anchor=H6#H6\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Azathioprine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H19#H19\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Dosing and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following the pattern established for granulomatosis with polyangiitis, the timing of initiation of maintenance AZA is based on whether the patient was on daily or monthly dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . For patients on daily dosing, the switch is immediate; for those on monthly dosing, AZA is begun approximately two weeks after the last dose of cyclophosphamide. This is delayed further if the white blood cell count is below 4000",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or the absolute neutrophil count is below 1500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link&amp;anchor=H9#H9\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Initiation of maintenance therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is sometimes used in EGPA to maintain a remission after induction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or as a glucocorticoid-sparing agent. However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    is generally preferred over methotrexate because it is difficult to monitor for methotrexate pneumonitis in a patient with other causes of dyspnea, such as asthma and pulmonary eosinophilia.",
"   </p>",
"   <p>",
"    Data regarding the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for maintenance of remission in EGPA are limited. In a case series of 25 patients with EGPA, methotrexate was associated with relapse rate of 48 percent, when used for maintenance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/25\">",
"     25",
"    </a>",
"    ]. On the other hand, the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose was decreased by an average of 50 percent in these patients.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    is occasionally used as an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    to induce a remission in patients with a five factors score (FFS) of 1 and mild disease. This is discussed in the section on initiating therapy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cyclophosphamide'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The dosing regimen for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    comes from the larger experience using this medication in patients with Wegener's granulomatosis. The typical dose is 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per week (maximum dose 15 mg), given orally. If tolerated, the dose is increased in 2.5 mg increments each week to a dose of 20 to 25 mg per week. Patients are also treated with daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (2.5 to 5 mg) once per week given 24 hours after methotrexate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=see_link&amp;anchor=H5#H5\">",
"     \"Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'Methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    should be avoided in patients with an estimated creatinine clearance less than 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and is contraindicated during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids are typically used to help control upper and lower respiratory tract disease. Asthma management follows the guidelines outlined separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=see_link&amp;anchor=H15#H15\">",
"     \"An overview of asthma management\", section on 'Pharmacologic treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of severe asthma in adolescents and adults\", section on 'Adjusting controller therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second line treatment options may be considered when patients have disease refractory to the above-described conventional therapy or have therapy-limiting side effects. The data in support of these agents are limited to case reports and small case series.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report described successful use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil plus oral glucocorticoids to treat a patient with EGPA manifest by asthma, chronic rhinosinusitis, cutaneous vasculitis, and a positive ANCA (pANCA with antibodies to myeloperoxidase [MPO]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/26\">",
"     26",
"    </a>",
"    ]. Dosing and potential side effects of mycophenolate are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intravenous immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case series have reported improvement in disease control in patients with refractory disease after addition of high-dose intravenous immune globulin to glucocorticoids with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/6,27,28\">",
"     6,27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=see_link\">",
"     \"General principles in the use of immune globulin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    , an agent that is used in the treatment of the hypereosinophilic syndrome, was found to be beneficial as a glucocorticoid-sparing agent in a patient with EGPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/29\">",
"     29",
"    </a>",
"    ]. Hydroxyurea has relatively few side effects compared to other chemotherapeutic agents, although hematological toxicity and gastrointestinal side effects may occur at higher doses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25898?source=see_link\">",
"     \"Treatment of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few case reports have described some improvement in EGPA after treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , an anti-CD20 monoclonal antibody [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/30-33\">",
"     30-33",
"    </a>",
"    ]. However, rituximab appeared to cause immediate and severe bronchospasm in two patients with ANCA-negative EGPA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of biologic agents in the rheumatic diseases\", section on 'B-cell depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Interferon-alpha",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several patients with disease unresponsive to glucocorticoids and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    have improved with a regimen of glucocorticoids and interferon-alpha [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/8,23\">",
"     8,23",
"    </a>",
"    ]. This medication has also been used as a second line agent for patients with the hypereosinophilic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25898?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of the hypereosinophilic syndromes\", section on 'Interferon alfa'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Anti-IgE therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case report described a patient with EGPA and nonallergic asthma, whose asthma was refractory to systemic and inhaled glucocorticoid and long-acting beta agonists; asthma control improved with anti-IgE (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    ) therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/35\">",
"     35",
"    </a>",
"    ]. Another report described similar results with anti-IgE in two patients whose EGPA was not controlled by systemic glucocorticoid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/36\">",
"     36",
"    </a>",
"    ]. Omalizumab may have a pro-apoptotic effect on eosinophils.",
"   </p>",
"   <p>",
"    Conversely, a temporal association between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/46/38629?source=see_link\">",
"     omalizumab",
"    </a>",
"    use and the development of EGPA has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/37\">",
"     37",
"    </a>",
"    ]. Further studies of safety and efficacy are needed before this approach can be recommended. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=see_link\">",
"     \"Anti-IgE therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Anti-IL-5 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparations of anti-interleukin (IL)-5 antibodies appear to have a glucocorticoid sparing effect in patients with hypereosinophilic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25898?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment of the hypereosinophilic syndromes\", section on 'Anti-IL-5'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of mepolizumab, a humanized monoclonal antibody to IL-5, has been assessed in patients with EGPA as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 10 patients with refractory or relapsing EGPA (defined by a Birmingham Vasculitis Activity Score [BVAS] of &gt;3), mepolizumab was administered in nine infusions, 750 mg once every 4 weeks, followed by maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      and glucocorticoids (tapered dosage to",
"      <span class=\"nowrap\">",
"       &lt;7.5mg/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/38\">",
"       38",
"      </a>",
"      ]. Eight patients achieved a BVAS of 0 and a glucocorticoid dose less than 7.5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      One additional patient achieved a BVAS of 0, but was not able to decrease the glucocorticoid dose below 7.5",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"      Another patient achieved a remission, but was subsequently excluded from the study due to nonadherence. After switching to methotrexate, two major and five minor relapses occurred over a median follow-up of 10 months. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Assessing vasculitis severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mepolizumab was administered monthly for four doses to seven patients with EGPA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/39\">",
"       39",
"      </a>",
"      ]. The patients who were all on systemic glucocorticoid therapy had a decrease in peripheral eosinophil counts and were able to decrease their",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      dose by 60 percent. By 20 weeks after discontinuation of mepolizumab, peripheral eosinophils had increased to premepolizumab levels, and asthma exacerbations had necessitated an increase in systemic glucocorticoids almost to the premepolizumab level.",
"     </li>",
"     <li>",
"      In a case report, EGPA, manifest by asthma, mononeuritis multiplex, and pulmonary opacities with 60 percent eosinophils on bronchoalveolar lavage, was refractory to high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , but responded to intravenous administration of mepolizumab (750",
"      <span class=\"nowrap\">",
"       mg/month)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=see_link&amp;anchor=H20#H20\">",
"       \"Alternative and experimental agents for the treatment of asthma\", section on 'Anti-IL-5 antibodies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Plasma exchange",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma exchange occasionally has been used in conjunction with other therapies, but a meta-analysis involving 140 patients with glomerulonephritis due to EGPA or microscopic polyangiitis found that it added no benefit to treatment with glucocorticoids, with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=see_link\">",
"     \"Indications for therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     PREVENTION OF TREATMENT RELATED COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predominant complications of the immunosuppressive and glucocorticoid therapy described above are opportunistic infections and glucocorticoid-related osteoporosis, cataracts, and adrenal suppression; appropriate prophylaxis can help to prevent some of these complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We suggest Pneumocystis prophylaxis for patients who are on a combination of high-dose glucocorticoid (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    20",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    or more) and another immunosuppressive agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prevention of other complications of chronic systemic glucocorticoid therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mercaptoethane sulfonate (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/0/41989?source=see_link\">",
"     MESNA",
"    </a>",
"    ) is typically used to reduce bladder toxicity during infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=see_link&amp;anchor=H19#H19\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\", section on 'Prevention of drug-induced cystitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Analysis of the thiopurine methyltransferase (TPMT) gene prior to the administration of AZA may help predict those individuals at risk for severe toxicity. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Azathioprine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring responsiveness to treatment and the development of recurrence is best achieved by following symptoms, the eosinophil count, spirometry, and any previously abnormal laboratory parameters. Radiographic manifestations may remain stable or may rapidly regress with glucocorticoid treatment. Renal function should be monitored by urinalysis and measurement of serum creatinine. We typically reassess patients at three month intervals, sooner if they experience any change in clinical status.",
"   </p>",
"   <p>",
"    Persistence of ANCA positivity in EGPA may be a marker of an underlying disease process, but does not appear to adequately reflect disease activity and, thus, cannot be used by itself to determine changes in therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=see_link&amp;anchor=H8#H8\">",
"     \"Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis\", section on 'ANCA titers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SPECIAL CONSIDERATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Upper airway involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nasal and otologic complications of EGPA typically require intranasal glucocorticoids and intermittent courses of antibiotics and systemic glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Some patients will also require more long-term systemic glucocorticoid therapy and sometimes also immunosuppressive therapy. In addition, surgical approaches, such as functional endoscopic sinus surgery for nasal polypectomy or myringotomy with ventilation tube placement for refractory otitis, may be necessary. When possible, we try to manage the upper airway complications of EGPA with local therapy and intermittent courses of systemic glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=see_link&amp;anchor=H21#H21\">",
"     \"Management of chronic rhinosinusitis\", section on 'CRS with nasal polyposis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of leukotriene modifying agents (LTMA) in the management of asthma and nasal polyposis in patients with EGPA is unclear, due to the reports of EGPA developing in the context of LTMA therapy. In patients with asthma, nasal polyposis, and EGPA who have not previously taken an LTMA, we often add an LTMA to the regimen, as described for patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    exacerbated respiratory disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link&amp;anchor=H6#H6\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Association with medications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=see_link&amp;anchor=H21#H21\">",
"     \"Aspirin exacerbated respiratory disease\", section on 'Leukotriene modifying agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of vasculitis during pregnancy is complicated due to adverse fetal effects of immunosuppressive medications. As examples,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    are teratogenic and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is an abortifacient. Systemic glucocorticoids are relatively safer, but may not control active vasculitis. Approaches to the treatment of vasculitis during pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=see_link&amp;anchor=H28#H28\">",
"     \"Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis\", section on 'Management in pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of patients with EGPA has improved significantly since the widespread use of systemic glucocorticoids. Prior to the use of glucocorticoids, for example, the disease was uniformly fatal, with 50 percent of untreated patients dying within three months of the onset of vasculitis. In comparison, most modern clinical series suggest a survival rate of greater than 70 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most deaths result from complications of the vasculitic phase of the disease, and are most commonly due to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cardiac failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      myocardial infarction",
"     </li>",
"     <li>",
"      Cerebral hemorrhage",
"     </li>",
"     <li>",
"      Renal failure",
"     </li>",
"     <li>",
"      Gastrointestinal bleeding",
"     </li>",
"     <li>",
"      Status asthmaticus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence or absence of the features that make up the \"five-factor score\" has been used to predict survival in EGPA (ie, cardiac involvement, gastrointestinal disease [bleeding, perforation, infarction, or pancreatitis], renal insufficiency [plasma creatinine concentration &gt;1.6",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (141",
"    <span class=\"nowrap\">",
"     micromol/L)],",
"    </span>",
"    proteinuria [&gt;1",
"    <span class=\"nowrap\">",
"     g/day],",
"    </span>",
"    central nervous system involvement) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5,19\">",
"     5,19",
"    </a>",
"    ]. One large series reported the following 5-year mortality figures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      12 percent when none of the five prognostic factors was present",
"     </li>",
"     <li>",
"      26 percent when one factor was present",
"     </li>",
"     <li>",
"      46 percent when three or more factors were present",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of the \"five factors\", cardiac involvement and gastrointestinal disease appear to be the strongest indicators of poor prognosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35353/abstract/46\">",
"     46",
"    </a>",
"    ]. The role of ANCA measurements in predicting outcome is not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) abbreviated EGPA, which was previously called the Churg-Strauss syndrome (CSS) or allergic granulomatosis and angiitis, is a multisystem disorder characterized by allergic rhinitis, asthma, and prominent peripheral blood eosinophilia. It is classified as a vasculitis of small and medium sized arteries, although the vasculitis is often not apparent in the initial phases of the disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=see_link\">",
"       \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The first step in the management of EGPA is to assess the severity of disease. A frequently used system is the \"five-factors score\" (FFS) based on the presence or absence of five clinical factors: cardiac involvement, gastrointestinal disease, renal insufficiency (plasma creatinine concentration &gt;1.6",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [141",
"      <span class=\"nowrap\">",
"       micromol/L]),",
"      </span>",
"      proteinuria (&gt;1",
"      <span class=\"nowrap\">",
"       g/day),",
"      </span>",
"      or central nervous system involvement. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Assessing vasculitis severity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all patients with EGPA and evidence of systemic vasculitis, we recommend systemic glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      doses of 0.5 to 1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day are typically administered for 6 to 12 weeks, or until disease remission is attained, and then gradually tapered. Patients with fulminant disease may require initial therapy with intravenous glucocorticoids. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with severe disease manifest by a FFS of 2, we recommend addition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      to systemic glucocorticoid therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients with a FFS of 1 (especially with cardiac or central nervous system involvement), we suggest addition of cyclophosphamide to systemic glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      After induction of remission with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , we recommend a transition to maintenance therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      to sustain the remission (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      is an alternative agent that can be used if azathioprine is not tolerated or is not effective. These drugs are preferred to long-term cyclophosphamide therapy, which is associated with significantly greater toxicity. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Maintenance and glucocorticoid sparing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest continuing maintenance immunosuppressive therapy for 12 to 18 months. Longer term or indefinite maintenance therapy may be warranted in patients with multiple relapses. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Maintenance and glucocorticoid sparing therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to maintenance therapy with an immunosuppressive agent, we recommend concurrent glucocorticoid therapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The glucocorticoid is gradually tapered to the lowest dose required for control of symptoms and signs of active EGPA. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Systemic glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/1\">",
"      Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/2\">",
"      Sinico RA, Bottero P. Churg-Strauss angiitis. Best Pract Res Clin Rheumatol 2009; 23:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/3\">",
"      Pagnoux C, Guilpain P, Guillevin L. Churg-Strauss syndrome. Curr Opin Rheumatol 2007; 19:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/4\">",
"      Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/5\">",
"      Guillevin L, Lhote F, Gayraud M, et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996; 75:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/6\">",
"      Danieli MG, Cappelli M, Malcangi G, et al. Long term effectiveness of intravenous immunoglobulin in Churg-Strauss syndrome. Ann Rheum Dis 2004; 63:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/7\">",
"      Stone JH, Hoffman GS, Merkel PA, et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/8\">",
"      Metzler C, Schnabel A, Gross WL, Hellmich B. A phase II study of interferon-alpha for the treatment of refractory Churg-Strauss syndrome. Clin Exp Rheumatol 2008; 26:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/9\">",
"      Bosch X, Guilabert A, Espinosa G, Mirapeix E. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007; 298:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/10\">",
"      Liou HH, Liu HM, Chiang IP, et al. Churg-Strauss syndrome presented as multiple intracerebral hemorrhage. Lupus 1997; 6:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/11\">",
"      Ribi C, Cohen P, Pagnoux C, et al. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients. Arthritis Rheum 2008; 58:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/12\">",
"      Sabl&eacute;-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/13\">",
"      Cottin V, Khouatra C, Dubost R, et al. Persistent airflow obstruction in asthma of patients with Churg-Strauss syndrome and long-term follow-up. Allergy 2009; 64:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/14\">",
"      Neumann T, Manger B, Schmid M, et al. Cardiac involvement in Churg-Strauss syndrome: impact of endomyocarditis. Medicine (Baltimore) 2009; 88:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/15\">",
"      Guillevin L, Jarrousse B, Lok C, et al. Longterm followup after treatment of polyarteritis nodosa and Churg-Strauss angiitis with comparison of steroids, plasma exchange and cyclophosphamide to steroids and plasma exchange. A prospective randomized trial of 71 patients. The Cooperative Study Group for Polyarteritis Nodosa. J Rheumatol 1991; 18:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/16\">",
"      Hellmich B, Gross WL. Recent progress in the pharmacotherapy of Churg-Strauss syndrome. Expert Opin Pharmacother 2004; 5:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/17\">",
"      Bourgarit A, Le Toumelin P, Pagnoux C, et al. Deaths occurring during the first year after treatment onset for polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: a retrospective analysis of causes and factors predictive of mortality based on 595 patients. Medicine (Baltimore) 2005; 84:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/18\">",
"      Gayraud M, Guillevin L, Cohen P, et al. Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides. Br J Rheumatol 1997; 36:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/19\">",
"      Gayraud M, Guillevin L, le Toumelin P, et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44:666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/20\">",
"      Cohen P, Pagnoux C, Mahr A, et al. Churg-Strauss syndrome with poor-prognosis factors: A prospective multicenter trial comparing glucocorticoids and six or twelve cyclophosphamide pulses in forty-eight patients. Arthritis Rheum 2007; 57:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/21\">",
"      De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52:2461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/22\">",
"      Lhote F, Cohen P, Guilpain P, Guillevin L. [Churg-Strauss syndrome]. Rev Prat 2008; 58:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/23\">",
"      Tatsis E, Schnabel A, Gross WL. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 1998; 129:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/24\">",
"      Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N Engl J Med 2008; 359:2790.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/25\">",
"      Metzler C, Hellmich B, Gause A, et al. Churg Strauss syndrome--successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin Exp Rheumatol 2004; 22:S52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/26\">",
"      Assaf C, Mewis G, Orfanos CE, Geilen CC. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br J Dermatol 2004; 150:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/27\">",
"      Hamilos DL, Christensen J. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. J Allergy Clin Immunol 1991; 88:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/28\">",
"      Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Ann Allergy Asthma Immunol 2004; 92:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/29\">",
"      Lee RU, Stevenson DD. Hydroxyurea in the treatment of Churg-Strauss syndrome. J Allergy Clin Immunol 2009; 124:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/30\">",
"      Saech J, Owczarczyk K, Owczarzyk K, et al. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 2010; 69:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/31\">",
"      Jones RB, Ferraro AJ, Chaudhry AN, et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/32\">",
"      Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/33\">",
"      Cartin-Ceba R, Keogh KA, Specks U, et al. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant 2011; 26:2865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/34\">",
"      Bouldouyre MA, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009; 68:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/35\">",
"      Giavina-Bianchi P, Giavina-Bianchi M, Agondi R, Kalil J. Three months' administration of anti-IgE to a patient with Churg-Strauss syndrome. J Allergy Clin Immunol 2007; 119:1279; author reply 1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/36\">",
"      Pabst S, Tiyerili V, Groh&eacute; C. Apparent response to anti-IgE therapy in two patients with refractory \"forme fruste\" of Churg-Strauss syndrome. Thorax 2008; 63:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/37\">",
"      Winchester DE, Jacob A, Murphy T. Omalizumab for asthma. N Engl J Med 2006; 355:1281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/38\">",
"      Moosig F, Gross WL, Herrmann K, et al. Targeting interleukin-5 in refractory and relapsing Churg-Strauss syndrome. Ann Intern Med 2011; 155:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/39\">",
"      Kim S, Marigowda G, Oren E, et al. Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/40\">",
"      Kahn JE, Grandpeix-Guyodo C, Marroun I, et al. Sustained response to mepolizumab in refractory Churg-Strauss syndrome. J Allergy Clin Immunol 2010; 125:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/41\">",
"      Guillevin L, Cevallos R, Durand-Gasselin B, et al. Treatment of glomerulonephritis in microscopic polyangiitis and Churg-Strauss syndrome. Indications of plasma exchanges, Meta-analysis of 2 randomized studies on 140 patients, 32 with glomerulonephritis. Ann Med Interne (Paris) 1997; 148:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/42\">",
"      Cohen P, Guillevin L, Baril L, et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin Exp Rheumatol 1995; 13:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/43\">",
"      Birck R, Schmitt WH, Kaelsch IA, van der Woude FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/44\">",
"      Bacciu A, Bacciu S, Mercante G, et al. Ear, nose and throat manifestations of Churg-Strauss syndrome. Acta Otolaryngol 2006; 126:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/45\">",
"      Ishiyama A, Canalis RF. Otological manifestations of Churg-Strauss syndrome. Laryngoscope 2001; 111:1619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/46\">",
"      Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999; 78:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35353/abstract/47\">",
"      Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115:284.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4346 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-210.101.131.231-9685F97C73-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35353=[""].join("\n");
var outline_f34_33_35353=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASSESSING VASCULITIS SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIATING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MAINTENANCE AND GLUCOCORTICOID SPARING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intravenous immune globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Interferon-alpha",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Anti-IL-5 antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      PREVENTION OF TREATMENT RELATED COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SPECIAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Upper airway involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4346|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/50/27435\" title=\"table 1\">",
"      Diagnostic criteria Churg Strauss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/40/6795\" title=\"table 2\">",
"      Churg Strauss five factor score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33354?source=related_link\">",
"      Alternative and experimental agents for the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/46/17130?source=related_link\">",
"      Anti-IgE therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/34/27177?source=related_link\">",
"      Clinical features and diagnosis of eosinophilic granulomatosis with polyangiitis (Churg-Strauss)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/11/28857?source=related_link\">",
"      General principles in the use of immune globulin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/19/12597?source=related_link\">",
"      Indications for therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/32/34314?source=related_link\">",
"      Initial immunosuppressive therapy in granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/23/6521?source=related_link\">",
"      Maintenance immunosuppressive therapy in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/4/30794?source=related_link\">",
"      Management of chronic rhinosinusitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/36/32330?source=related_link\">",
"      Overview of hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9130?source=related_link\">",
"      Relapsing disease in granulomatosis with polyangiitis (Wegener&rsquo;s) and microscopic polyangiitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/18/25898?source=related_link\">",
"      Treatment of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35354="Pathogenesis of acute myeloid leukemia";
var content_f34_33_35354=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of acute myeloid leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35354/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35354/contributors\">",
"     Wendy Stock, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35354/contributors\">",
"     Michael J Thirman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35354/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35354/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/33/35354/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/33/35354/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/33/35354/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute myeloid leukemia (AML) develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. These changes alter normal hematopoietic growth and differentiation, resulting in an accumulation of large numbers of abnormal, immature myeloid cells in the bone marrow and peripheral blood. These cells are capable of dividing and proliferating, but cannot differentiate into mature hematopoietic cells (ie, neutrophils).",
"   </p>",
"   <p>",
"    This topic will review the cell of origin and the multistep and multi-causal pathogenesis of AML. More detailed descriptions of the molecular basis of AML and the genetic abnormalities seen in AML are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link\">",
"     \"Molecular genetics of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link\">",
"     \"Prognosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91823159\">",
"    <span class=\"h2\">",
"     Normal counterpart",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leukemia is a heterogenous group of diseases characterized by clonal cells that exhibit maturation defects that correspond to stages in hematopoietic differentiation. Hematopoietic stem cells are multipotent and have the capacity to differentiate into the cells of all 10 blood lineages &mdash; erythrocytes, platelets, neutrophils, eosinophils, basophils, monocytes, T and B lymphocytes, natural killer cells, and dendritic cells. In order to sustain hematopoiesis, stem cells are part of a developmental hierarchy capable of three basic functions:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maintenance in a non-cycling state (ie, not actively progressing through the cell cycle)",
"     </li>",
"     <li>",
"      Self-renewal, allowing production of additional stem cells",
"     </li>",
"     <li>",
"      Production of committed progenitor cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These progenitor cells commit to subsets of myeloid and lymphoid lineages, and ultimately to single developmental pathways, resulting in the expression of the terminally differentiated stage of each cell type (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"mobipreview.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"     \"Overview of hematopoiesis and stem cell function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Normal hematopoiesis is a dynamic, highly regulated process controlled by the combined effects of growth factors that permit cellular proliferation, and nuclear transcription factors that activate specific genetic programs, resulting in commitment to a specific lineage and in terminal differentiation (",
"    <a class=\"graphic graphic_figure graphicRef76779 \" href=\"mobipreview.htm?11/3/11327\">",
"     figure 1",
"    </a>",
"    ). Many of the regulatory growth factors and a number of specific transcription factors have been identified that play critical roles in lineage commitment, and in the subsequent development of the mature lymphoid and myeloid (erythroid,",
"    <span class=\"nowrap\">",
"     granulocytic/monocytic,",
"    </span>",
"    and megakaryocytic) lineages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of genes encoding these transcription factors are involved in recurring chromosomal translocations seen in AML, suggesting that the AML variants arise because the translocations result in significant alterations in regulatory processes controlling growth and differentiation programs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/5\">",
"     5",
"    </a>",
"    ]. The novel fusion genes created by these translocations will be reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link\">",
"     \"Molecular genetics of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clonality",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML is a clonal process that develops from a single transformed hematopoietic progenitor cell.",
"   </p>",
"   <p>",
"    Studies of isoenzyme restriction in leukemic myeloblasts of females heterozygous for the A and B isoforms of glucose 6-phosphate dehydrogenase (G6PD) have demonstrated the clonal origin of AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The G6PD locus is on a portion of the X chromosome that undergoes inactivation in XX somatic cells (Lyonization). Approximately one-half of the cells in normal somatic tissue will have randomly inactivated one or the other of the X chromosomes, allowing expression of the A and B isoforms in approximately equal amounts. Cells of clonal origin, however, express only one type of G6PD.In each of the G6PD heterozygous females with AML, both types of enzyme were found in normal tissues, but only a single type was observed in the leukemic myeloblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Similar conclusions were reached using X-linked recombinant DNA probes, standard cytogenetics, and fluorescence in situ hybridization (FISH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=see_link\">",
"     \"Cytogenetic and molecular genetic diagnostic tools\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/21/6489?source=see_link&amp;anchor=H4#H4\">",
"     \"General aspects of cytogenetic analysis in hematologic malignancies\", section on 'Definition of clonality'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Leukemic stem cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML is a heterogenous disease with leukemic cells of different subtypes resembling normal cells at various stages of maturation. However, there is growing information to support that all leukemias, including AML, appear to be maintained by a pool of self-renewing malignant cells. Based on their ability to serially transfer the disease upon xenotransplantation into immunodeficient mice, it has been hypothesized that limited numbers of cells within the bulk population of leukemic cells have the capacity to function as stem cells that maintain the potential for unlimited self-renewal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/12\">",
"     12",
"    </a>",
"    ]. These leukemic stem cells (LSC, also leukemia-initiating cells) may be more immature than the majority of circulating leukemic cells, and are thought to have originated from cells with existing self-renewal capacity or from progenitors that have re-acquired this stem cell-like property.",
"   </p>",
"   <p>",
"    According to this hypothesis, the majority of leukemia cells do not have unlimited self-renewal and exhibit some features of partial differentiation depending on the genetic aberration present. However, xenotransplantation of human leukemia cells might not be the best experimental system to examine leukemia stem cell capacity. When lymphomas and leukemias of mouse origin are transplanted into histocompatible mice, a very high frequency (at least 1 in 10) of these cells can transfer the disease to recipient mice suggesting that the low frequency of leukemia-initiating cells observed in xenotransplantation studies may reflect the limited ability of human tumor cells to adapt to growth in a foreign (mouse) milieu [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2186046\">",
"    <span class=\"h2\">",
"     Stage of leukemic transformation",
"    </span>",
"   </p>",
"   <p>",
"    Two models have been proposed to explain the heterogeneity of AML observed at the molecular, cytogenetic, phenotypic, and clinical level.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Transformation to leukemia occurring at one of several developmental stages",
"     </li>",
"     <li>",
"      Transformation to leukemia occurring within primitive multipotent cells",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is no universal agreement as to which of these two models best reflects the truth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Transformation at one of several developmental stages",
"    </span>",
"    &nbsp;&mdash;&nbsp;This model proposes that any cell type within the stem",
"    <span class=\"nowrap\">",
"     cell/progenitor",
"    </span>",
"    cell hierarchy, from primitive multipotent stem cell to lineage-committed progenitor cell, is susceptible to leukemic transformation, resulting in the expansion of abnormal cells that exhibit different stages of differentiation. For AML, this model predicts that the phenotype of the leukemic stem cells restricted to the granulocytic-monocytic series differs from that of cells with involvement of erythroid, megakaryocytic, and granulocytic-monocytic lineages (",
"    <a class=\"graphic graphic_algorithm graphicRef52024 \" href=\"mobipreview.htm?34/9/34968\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The correlation between specific cytogenetic and molecular genetic aberrations and the morphologic appearance of leukemic cells might suggest that the transforming event occurs at different stages of myeloid differentiation. This hypothesis is underscored by the French-American-British (FAB) classification for AML, which distinguishes different subtypes of AML based upon the stage of apparent differentiation (",
"    <a class=\"graphic graphic_table graphicRef63050 \" href=\"mobipreview.htm?15/48/16141\">",
"     table 1",
"    </a>",
"    ). Support for this model includes flow",
"    <span class=\"nowrap\">",
"     cytometric/molecular",
"    </span>",
"    analyses of the leukemic cell in acute promyelocytic leukemia (APL) that suggest that the leukemic cell arises in a committed lineage-restricted,",
"    <span class=\"nowrap\">",
"     CD34+/CD38+",
"    </span>",
"    progenitor cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Transformation within primitive multipotent cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;A second model proposes that mutations responsible for leukemic transformation and progression occur only in primitive multipotent stem cells, with disease heterogeneity resulting from a variable ability of these primitive stem cells to differentiate and acquire specific phenotypic lineage markers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hematopoietic stem cells express a characteristic cell surface antigen (CD34), and can be further subdivided by the expression of additional cell surface antigens, including CD38 and HLA-DR (",
"    <a class=\"graphic graphic_figure graphicRef77910 \" href=\"mobipreview.htm?1/33/1567\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       CD34+/CD38-/HLA-DR-",
"      </span>",
"      cells are multipotential hematopoietic stem cells, give rise to mixed-lineage granulocytic-erythroid- megakaryocytic colonies in culture, can repopulate immune deficient mice with normal hematopoietic cells in vivo, and demonstrate self-renewal capacity, as assessed by their ability to be serially transplanted into secondary recipient mice. There are data to suggest that, in some cases of AML, the leukemic stem cell may be quite similar to normal hematopoietic stem cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       CD34+/CD38+/HLA-DR+",
"      </span>",
"      cells define a committed population of myeloid progenitor cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/20\">",
"       20",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=see_link\">",
"       \"Overview of hematopoiesis and stem cell function\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cytogenetic and FISH studies of sorted stem cell compartments from patients with AML evolving from a prior myelodysplastic syndrome and patients with de novo AML have shown that the characteristic cytogenetic abnormality from both groups was present in the",
"    <span class=\"nowrap\">",
"     CD34+/CD38-",
"    </span>",
"    multipotential stem cell compartment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Similar findings were noted in patients with the 5q- syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/24\">",
"     24",
"    </a>",
"    ] and monosomy 7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/25\">",
"     25",
"    </a>",
"    ], myelodysplastic disorders with differing risks of leukemic transformation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=see_link&amp;anchor=H359933#H359933\">",
"     \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\", section on 'MDS with isolated del(5q)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More compelling evidence comes from studies in which purified stem cell subpopulations from normal subjects and those with AML were transplanted into mice with severe combined immunodeficiency disease (SCID) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/26\">",
"     26",
"    </a>",
"    ]. These experiments have detected approximately one SCID mouse leukemia-initiating cell (SL-IC) in 10(5) AML cells, which can repopulate immune deficient mice with leukemic cells phenotypically identical to those of the AML patient from which they were derived [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/23,26,27\">",
"     23,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using a non-obese diabetic",
"    <span class=\"nowrap\">",
"     (NOD)/SCID",
"    </span>",
"    mouse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/28\">",
"     28",
"    </a>",
"    ], SL-ICs were found to reside only in the",
"    <span class=\"nowrap\">",
"     CD34+/CD38-",
"    </span>",
"    fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/12\">",
"     12",
"    </a>",
"    ]. This was consistent regardless of the AML subtype, lineage markers, or percentage of leukemic blast cells expressing the CD34 antigen. The SL-ICs also demonstrated self-renewal capacity, a requirement for maintenance of the leukemic clone. The uniformity of the leukemic stem cell phenotype strongly suggests that the leukemia initiating transformation and progression-associated genetic events occur in primitive cells and not in committed progenitors. Similar conclusions about the site of the leukemia initiating transformation have been made in acute lymphoblastic leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence for the second model derives from the use of a retroviral gene transfer system to express",
"    <span class=\"nowrap\">",
"     AML1/ETO,",
"    </span>",
"    a fusion gene linked to the pathogenesis of AML, in normal human hematopoietic stem and progenitor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/30\">",
"     30",
"    </a>",
"    ]. When this fusion gene was expressed in more mature progenitor cells, the result was growth arrest and abrogated colony formation in primary clonogenic assays. On the other hand,",
"    <span class=\"nowrap\">",
"     AML1/ETO",
"    </span>",
"    expression in stem cells resulted in their preferential expansion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    self-renewal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H10#H10\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Cooperating mutations in AML'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Further supporting evidence comes from studies of clonal hematopoiesis in AML, which indicate that, although the majority of cells derived from the leukemic clone can undergo differentiation to cells of the granulocytic-monocytic lineage, they also may differentiate into cells of the erythroid",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    megakaryocytic pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/9-11,32\">",
"     9-11,32",
"    </a>",
"    ]. Such multi-lineage involvement has been noted more frequently in elderly patients, in those whose AML arose following a documented prior myelodysplastic disorder, or following treatment for another malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/11,32\">",
"     11,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Protection by stromal cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML cells develop in the bone marrow where interaction with the microenvironment may foster chemoresistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. As an example, two studies in mouse models of APL demonstrated that dislodgement of leukemic cells from their stromal environment via interruption of CXCR4 signaling resulted in an increased sensitivity of the leukemic cells to chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TWO-HIT HYPOTHESIS OF LEUKEMOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Progression to acute leukemia may require a series of genetic events beginning with clonal expansion of a transformed leukemic stem cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. The specific mutational event(s) required for this progression are not currently well defined. Single nucleotide polymorphism (SNP) studies have been performed on tumor samples from adults and children with AML as a genomic screen to locate previously unidentified genes that many play a role in the pathobiology of AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/42,43\">",
"     42,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"two-hit hypothesis\" of leukemogenesis implies that AML is the consequence of at least two mutations, one conferring a proliferative advantage (class I mutations) and another impairing hematopoietic differentiation (class II mutations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/44\">",
"     44",
"    </a>",
"    ]. Type I mutations include those of FLT3-ITD, K-RAS mutations, and KIT mutations, while mutations in CEBPA are type II abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H9#H9\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Important insights have been obtained from human leukemias and mouse models:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In chronic phase chronic myeloid leukemia (CML), all leukemic cells contain t(9;22), resulting in formation of the",
"      <span class=\"nowrap\">",
"       BCR/ABL",
"      </span>",
"      fusion gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/46\">",
"       46",
"      </a>",
"      ], whose product is of critical significance in the pathogenesis of CML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/47\">",
"       47",
"      </a>",
"      ]. As the disease progresses, additional cytogenetic abnormalities are acquired [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/48\">",
"       48",
"      </a>",
"      ], which are often accompanied by loss of important tumor suppressor genes such as p53 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/49\">",
"       49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H8#H8\">",
"       \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'The BCR-ABL1 fusion protein'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=see_link&amp;anchor=H7228199#H7228199\">",
"       \"Cellular and molecular biology of chronic myeloid leukemia\", section on 'Progression to acute phase CML'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A variety of clonality studies have shown that patients with AML in clinical remission may still have clonal, rather than polyclonal, hematopoiesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/9,50-52\">",
"       9,50-52",
"      </a>",
"      ]. Such clonal remission may represent the presence of a \"preleukemic stem cell\" that has undergone an initial transforming event but has not acquired the additional mutation(s) essential to progression to overt leukemia. In these cases, it is presumed that the transformed, overtly leukemic cell probably represented a subclone of the original \"preleukemic stem cell\" which secondarily acquired the additional genetic mutations required for the definitive block in differentiation and manifestation of the leukemic phenotype. Although some studies suggest that \"clonal\" remissions may be the result of skewed Lyonization (preferential inactivation of one X chromosome over another) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/53,54\">",
"       53,54",
"      </a>",
"      ], more carefully controlled studies suggest that clonal remissions do occur following treatment for AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On average, AML clones have 8 to 10 mutations found within the coding regions of the genome. The accumulation of these lesions in a step-wise process within a hematopoietic stem cell was demonstrated in a study that compared gene mutations found in de novo AML with patient-matched residual non-leukemic hematopoietic stem cells in long-term survivors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/57\">",
"       57",
"      </a>",
"      ]. Identification of individual cells containing subsets of these mutations allowed for the identification of mutations that occurred early and late in the process. This finding suggests not only that several hits are required for the development of AML, but also that relapsed disease can represent the further replication of the original dominant clone, the emergence of a minor clone present at diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/58\">",
"       58",
"      </a>",
"      ], or further evolution of a preleukemic clone after treatment (",
"      <a class=\"graphic graphic_figure graphicRef84023 \" href=\"mobipreview.htm?36/48/37639\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In one study of seven patients with AML that had evolved from MDS, approximately 85 percent of bone marrow cells were clonal at the time of MDS diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/59\">",
"       59",
"      </a>",
"      ]. Whole genome sequencing of paired skin and bone marrow samples identified 11 recurrently mutated genes. Genotyping of bone marrow samples from the same patients collected at the time of AML diagnosis identified those mutations that were present at the time of MDS diagnosis (ie, NPM1, RUNX1, SMC3, STAG2, TP53, U2AF1, UMODL1, and ZSWIM4) and those that developed subsequently (ie, CDH23, PTPN11, WT1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A retrospective study that compared mutational analyses of paired diagnostic and relapse leukemia samples from 69 children with AML reported that 38 percent of patients had a change in their mutation status between diagnosis and relapse. Patients whose AML demonstrated a type",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    mutation at relapse had a shorter time to relapse. Consistent with the two-hit theory, expression of a chimeric protein represents only one of the genetic modifications necessary for the development of cancer and leukemia, and that the affected cell requires additional mutational events in order to express the transformed phenotype. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link&amp;anchor=H7#H7\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on '8;21 translocation in AML'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a number of examples indicate that the presence of cells with the",
"    <span class=\"nowrap\">",
"     RUNX1/RUNX1T1",
"    </span>",
"    fusion transcript may not be sufficient, in itself, to result in AML:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transgenic mice expressing",
"      <span class=\"nowrap\">",
"       RUNX1/RUNX1T1",
"      </span>",
"      were healthy throughout their lifespan, developing AML only after exposure to an alkylating mutagen [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/60\">",
"       60",
"      </a>",
"      ], or in cooperation with Wilms tumor gene (WT1) overexpression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Remission bone marrow samples from patients with de novo AML (FAB -M2) with t(8;21)(q22;q22) and the",
"      <span class=\"nowrap\">",
"       RUNX1/RUNX1T1",
"      </span>",
"      fusion transcript have been found to harbor the aberrant fusion transcript for as many as eight years following cessation of all chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       RUNX1/RUNX1T1",
"      </span>",
"      fusion transcript has been detected in bone marrow samples from patients in remission following allogeneic bone marrow transplantation for AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In five children who developed AML with t(8;21) at 3 to 12 years of age, in whom archived blood samples for metabolic studies (Guthrie cards) were available,",
"      <span class=\"nowrap\">",
"       RUNX1/RUNX1T1",
"      </span>",
"      sequences were detected at birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/64\">",
"       64",
"      </a>",
"      ]. Of interest, similar observations were made in three children developing acute lymphoblastic leukemia at ages 3 to 5 years of age with t(12;21) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above,",
"    <span class=\"nowrap\">",
"     RUNX1/RUNX1T1",
"    </span>",
"    is not immediately leukemogenic in either animals or man, and may require a \"second hit\" for the development of AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. However, the presence of an alternatively spliced isoform",
"    <span class=\"nowrap\">",
"     AML1/ETO9a",
"    </span>",
"    has been shown to be present in the majority of patients with t(8;21) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/68\">",
"     68",
"    </a>",
"    ]. Expression of this alternative isoform leads to the rapid development of leukemia in a mouse model, and coexpression of",
"    <span class=\"nowrap\">",
"     RUNX1/RUNX1T1",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     AML1/ETO9a",
"    </span>",
"    results in the substantially earlier onset of AML and blocks myeloid cell maturation at a more immature stage. These early results suggest that fusion proteins from alternatively spliced isoforms resulting from a chromosomal translocation may work together to induce this malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91823203\">",
"    <span class=\"h1\">",
"     MECHANISMS OF GENETIC DAMAGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic changes associated with leukemogenesis can occur following chemotherapy, ionizing radiation, chemical exposure, and infection with retroviruses. In addition, certain familial disorders are associated with an increased incidence of AML.",
"   </p>",
"   <p>",
"    While environmental and hereditary conditions serve as excellent models for obtaining insights into the molecular pathogenesis of AML, it must be emphasized that the vast majority of patients with de novo AML show no evidence of any of these risk factors, and the etiologic factors contributing to the development of AML remain unknown. Interestingly, in a series of 127 patients with a previous primary malignancy and secondary AML, 30 percent did not receive any chemotherapy or radiation treatment prior to the development of AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemotherapy-induced AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of MDS and AML following chemotherapy for a variety of malignancies (eg, breast cancer, Hodgkin lymphoma) is an unfortunate complication of curative treatment strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/70\">",
"     70",
"    </a>",
"    ], such as dose-intensive therapy with or without hematopoietic cell transplantation and growth factor support [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. This identification of an increasing incidence of therapy-related AML (t-AML) in an attempt to improve cure rates emphasizes the critical importance of understanding the underlying pathogenetic mechanisms for development of t-AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=see_link\">",
"     \"Malignancy after hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=see_link&amp;anchor=H7#H7\">",
"     \"Second malignancies after treatment of classical Hodgkin lymphoma\", section on 'Acute leukemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8202?source=see_link&amp;anchor=H541709410#H541709410\">",
"     \"Patterns of relapse and long-term complications of therapy in breast cancer survivors\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    T-AML typically develops following alkylating agent-induced damage, at a median of three to five years following therapy for the primary malignancy and is usually associated with an antecedent myelodysplastic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/77\">",
"     77",
"    </a>",
"    ]. This latency period suggests that multiple mutational events are involved in the development of the malignant phenotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clonal chromosomal abnormalities have been reported in the majority of cases of t-AML. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"      </a>",
"      .) The most frequently reported abnormalities involve complete loss or interstitial deletions of the long arm of chromosomes 7",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      5.",
"     </li>",
"     <li>",
"      Other therapy-related leukemias are associated with rearrangements of the MLL gene in chromosome band 11q23 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/78\">",
"       78",
"      </a>",
"      ]. AML associated with 11q23 often develops after treatment with drugs that target DNA-topoisomerase II (eg, epipodophyllotoxins, anthracyclines) with a very short latency of 12 to 18 months following treatment, and are not typically associated with an antecedent myelodysplastic syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/79-81\">",
"       79-81",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H15#H15\">",
"       \"Molecular genetics of acute myeloid leukemia\", section on 'Involvement of the MLL locus'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link&amp;anchor=H16#H16\">",
"       \"Cytogenetics in acute myeloid leukemia\", section on 'Following DNA topoisomerase II inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Accelerated telomere loss may precede the development of",
"      <span class=\"nowrap\">",
"       t-MDS/AML",
"      </span>",
"      after autologous hematopoietic cell transplantation (HCT) resulting in genetic instability and thereby contributing to the leukemic transformation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/82,83\">",
"       82,83",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic polymorphisms of a number of drug-metabolizing enzymes may alter the risk of t-AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/76,84,85\">",
"     76,84,85",
"    </a>",
"    ]. As an example, polymorphisms in genes that encode glutathione S-transferases (GST), which detoxify potentially mutagenic chemotherapeutic agents, may increase susceptibility to t-AML as well as MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/84,86,87\">",
"     84,86,87",
"    </a>",
"    ]. In one study, relative to de novo AML, the GSTP1 codon 105 Val allele occurred more often among patients with t-AML with prior exposure to chemotherapy, particularly those with exposure to known GSTP1 substrates (odds ratio 4.3; 95% CI 1.4-13), and not among those t-AML patients with prior exposure to radiotherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation shares with alkylating agents the ability to damage DNA, usually by inducing double strand breaks that may cause the mutations, deletions, or translocations required for hematopoietic stem cell transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/70,88\">",
"     70,88",
"    </a>",
"    ]. As examples, an increased incidence of AML, which may have been directly proportional to the radiation exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/89\">",
"     89",
"    </a>",
"    ], has been noted in atomic bomb survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/90\">",
"     90",
"    </a>",
"    ] as well as in radiologists and radiologic technologists chronically exposed to high levels of radiation in the period before 1950 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ionizing radiation used in the treatment of malignancies (eg, Hodgkin lymphoma, breast cancer, uterine cancer, lung cancer) has also been linked to the development of AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/92\">",
"     92",
"    </a>",
"    ]. This risk appears to be quite low when radiation alone is used as treatment, and is associated with age of the patient, and doses of more than 20 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Whether irradiation adds to the risk of t-AML associated with chemotherapy remains controversial. Although some studies suggest that the risk of development of AML is significantly increased when the two modalities are combined, other studies demonstrated that high doses of radiotherapy confined to small volumes in combination with chemotherapy did not significantly increase leukemogenic risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/95-98\">",
"     95-98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unknown whether ionizing radiation used for medical examination such as CT scans results in an increased risk of leukemia in adults. However, there is epidemiologic evidence that exposure to x-rays and gamma rays during childhood is associated with a small absolute increase in the incidence of leukemia. In a cohort study of individuals who had CT scans when they were younger than 22 years of age, compared with those who received a cumulative radiation dose &lt;5 mGy, the risk of subsequent leukemia was tripled for those who received a cumulative radiation dose &ge;30 mGy, which is equivalent to approximately 5 to 10 head CTs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/99\">",
"     99",
"    </a>",
"    ]. Radiation risk in children is compounded with their longer lifespan following exposure so that there is a longer time over which radiation-induced cancers can occur.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Chemical exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to high levels of benzene has been associated with a higher risk of developing AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. Relatively low-level exposure to benzene by petroleum distribution workers has been associated with an increased risk of developing myelodysplastic syndrome, but not AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/102\">",
"     102",
"    </a>",
"    ]. The risk of developing a myeloid malignancy after benzene exposure appears to be dose-related and it is unknown whether there is any safe threshold for benzene exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/103\">",
"     103",
"    </a>",
"    ]. A potential association between formaldehyde exposure and AML has been controversial, with conflicting data from meta-analyses of epidemiologic studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/104-106\">",
"     104-106",
"    </a>",
"    ]. Except for special groups exposed to high levels of benzene or radiation, the reported risks associated with occupation and chemicals have generally been less than twofold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/107\">",
"     107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of RAS mutations in patients with AML has been associated with specific occupational exposure to chemicals, suggesting that these exposures may induce genetic damage culminating in acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/108\">",
"     108",
"    </a>",
"    ]. In a case-control study, cigarette smoking was associated with only a modest increase in leukemic risk; however, a twofold increase in risk for AML was noted in study subjects over the age of 60 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/109\">",
"     109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Polymorphisms resulting in inactivation of NAD(P)H:quinone oxidoreductase 1 (NQO1, originally called DT-diaphorase), an enzyme which detoxifies quinones and reduces oxidative stress, have been associated with an increased risk of de novo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/110\">",
"     110",
"    </a>",
"    ] and therapy-related acute leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/111\">",
"     111",
"    </a>",
"    ], as well as a greater risk of benzene-induced hematotoxicity and leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/112\">",
"     112",
"    </a>",
"    ]. For de novo AML, the most significant effect of low or null NQO1 activity was observed among patients with chromosomal translocations and inversions (odds ratio: 2.4), and was especially high for those with inv(16) (odds ratio: 8.1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic polymorphisms in the microsomal epoxide hydrolase (HYL1) gene, an enzyme involved in benzene metabolism, have also been associated with an increased incidence of AML. Data from one study suggest that smoking",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    exposure to a carcinogen that is activated by HYL1, such as benzene, may be important in subsets of patients with AML, such as males with t(8;21) or",
"    <span class=\"nowrap\">",
"     -7/del(7q)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/113,114\">",
"     113,114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AML often have infections at the time of diagnosis, some of which are severe. However, there are limited data regarding whether infections play a role in the pathogenesis of AML. A large population-based retrospective registry study from Sweden suggested that a personal history of infection was associated with an increased risk of developing AML or myelodysplastic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/115\">",
"     115",
"    </a>",
"    ]. While interesting, further study is needed to confirm these results and to study potential mechanisms. Studies have also suggested that chronic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    use might increase the risk of developing AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/116,117\">",
"     116,117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a number of animal models, retroviruses have been demonstrated to play an important role in leukemogenesis, and the human T-lymphotropic virus type I (HTLV-I) is associated with adult T-cell leukemia-lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/118\">",
"     118",
"    </a>",
"    ]. In AML, however, despite extensive investigation, there has been no clear association of a retrovirus with leukemogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/119\">",
"     119",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H26#H26\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Animal models of AML'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9945?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Familial leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients diagnosed with AML do not have a familial predisposition towards the development of myelodysplastic syndrome or leukemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/120\">",
"     120",
"    </a>",
"    ]. However, rare pedigrees with multiple cases of AML have been described and termed familial leukemia. Familial leukemia can occur in the context of a medical syndrome in which AML is one component of the overall disease, or it can occur as an isolated leukemia not specifically associated with co-morbid conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/121,122\">",
"     121,122",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A rare constitutional trisomy 8 syndrome associated with a characteristic facial and skeletal muscle dysmorphism, and the development of hematologic disorders, including aplastic anemia, myelodysplasia, and acute and chronic myeloid leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/123\">",
"       123",
"      </a>",
"      ]. Potential chromosome 8 genes associated with the development of AML are reviewed in detail in subsequent sections of this topic review, and include the ETO gene, involved in the t(8;21)(q22;q22) translocation and the MOZ gene, involved in FAB",
"      <span class=\"nowrap\">",
"       M4/M5",
"      </span>",
"      leukemias with a t(8;16)(p11;p13) translocation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/124,125\">",
"       124,125",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Down syndrome (trisomy 21) there is a 10- to 18-fold increased risk for leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/126-128\">",
"       126-128",
"      </a>",
"      ]. In individuals under the age of three, the leukemia is most frequently AML of the FAB-M7 (megakaryoblast) subtype. In studies of children with Down syndrome-associated transient myeloproliferative disorder or acute megakaryoblastic leukemia, almost all had acquired mutations in GATA-1, a transcription factor which, among other functions, plays an important role in megakaryocyte development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/129-137\">",
"       129-137",
"      </a>",
"      ]. The trisomy 21 abnormality appears to be associated with expansion of erythroid and megakaryocytic precursors independent of GATA-1 mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/136,137\">",
"       136,137",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4458?source=see_link&amp;anchor=H9#H9\">",
"       \"Megakaryocyte biology and the production of platelets\", section on 'GATA-1 transcription factor'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical features and diagnosis of Down syndrome\", section on 'Hematologic disorders'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over the age of three, the development of ALL is more common. From the study of atypical karyotypes, it has been possible to narrow down the critical region for leukemia. This region includes the AML1 locus on 21q22.3, which encodes the alpha subunit of core-binding factor (CBF), and is the site of recurrent t(8;21)(q22;q22) translocations in AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/124,138\">",
"     124,138",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H6#H6\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Involvement of core binding factor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Familial disorders leading to AML",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inherited disorders associated with defective DNA repair have also been associated with a high incidence of hematologic malignancies, including AML. These and other familial disorders include (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H7#H7\">",
"     \"Molecular genetics of acute myeloid leukemia\", section on 'Familial platelet disorder with predisposition to AML'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/122\">",
"     122",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bloom's syndrome, in which AML, ALL, lymphoma or other malignancies occur in about 25 percent of affected individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/139,140\">",
"       139,140",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fanconi's anemia, in which approximately 52 percent of patients develop AML or myelodysplasia by the age of 40 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/141\">",
"       141",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26842?source=see_link&amp;anchor=H4#H4\">",
"       \"Inherited aplastic anemia in children\", section on 'Fanconi anemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Neurofibromatosis, which results from mutations in the neurofibromin tumor suppressor gene on chromosome 17q11.2 and is associated with the development of juvenile CML, ALL, lymphomas, and a disproportionately high rate of MDS evolving into AML in young patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/142,143\">",
"       142,143",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Li-Fraumeni syndrome, which occurs as a consequence of dominantly inherited germline mutations of the p53 tumor suppressor genes, and is associated with the development of multiple types of tumors, occasionally including leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/144\">",
"       144",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=see_link\">",
"       \"Li-Fraumeni syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Wiskott-Aldrich syndrome, an X-linked immunodeficiency syndrome associated with the occasional development of lymphomas, AML, and ALL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/145\">",
"       145",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36313?source=see_link\">",
"       \"Wiskott-Aldrich syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Kostmann's syndrome (infantile agranulocytosis), which has been associated with mutations in the G-CSF receptor on chromosome 1p35-p34.3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/146-148\">",
"       146-148",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link\">",
"       \"Congenital neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diamond Blackfan anemia (congenital hypoplastic anemia) and growth retardation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Emberger syndrome, an autosomal dominant disorder characterized by severe lymphedema and a predisposition to MDS and AML, has been associated with mutations in the hematopoietic transcription factor GATA2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/150\">",
"       150",
"      </a>",
"      ]. GATA2 mutations have also been described in two other syndromes with a tendency to develop MDS and AML: monocytopenia and mycobacterial infection (MonoMAC) syndrome and a related syndrome of defects in dendritic cells, monocytes, and B and NK lymphoid cells (DCML) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/151,152\">",
"       151,152",
"      </a>",
"      ]. In addition, GATA2 mutations have been reported in families that show a predisposition to MDS and AML but lack any preceding hematopoietic abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/153\">",
"       153",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=see_link&amp;anchor=H3663155#H3663155\">",
"       \"Mendelian susceptibility to mycobacterial diseases (MSMD)\", section on 'GATA2 deficiency (MonoMAC syndrome)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Familial platelet disorder with predisposition to myelodysplasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      acute myeloid leukemia",
"      <span class=\"nowrap\">",
"       (FPD/AML)",
"      </span>",
"      is an autosomal dominant disorder characterized by qualitative and quantitative platelet defects, a decrement in megakaryocyte colony formation, an increased incidence of AML, and RUNX1 mutations. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=see_link&amp;anchor=H7#H7\">",
"       \"Molecular genetics of acute myeloid leukemia\", section on 'Familial platelet disorder with predisposition to AML'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several families have been reported in which multiple siblings have developed childhood onset of myelodysplasia with bone marrow monosomy for chromosome 7, followed by evolution to AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/154\">",
"     154",
"    </a>",
"    ]. The inheritance pattern is autosomal recessive. Autosomal dominant patterns of inheritance of leukemia have also been reported, with a variety of morphologic and cytogenetic subtypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/155-158\">",
"     155-158",
"    </a>",
"    ]. Some are associated with an antecedent myelodysplastic syndrome, while others appear to arise as de novo AML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ROLE OF HEMATOPOIETIC GROWTH FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using in vitro clonogenic assays, leukemic cells have been shown to proliferate in response to many of the endogenous hematopoietic growth factors critical for normal hematopoiesis, including granulocyte, granulocyte-monocyte, macrophage, and stem cell colony-stimulating factors (G-CSF, GM-CSF, M-CSF, SCF), interleukin 3, and Flt3 ligand (flt3-L) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/159-164\">",
"     159-164",
"    </a>",
"    ], with combinations of these factors producing a synergistic growth response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Mutations in the G-CSF receptor gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mutations in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) receptor gene have been described in patients with severe congenital neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/147\">",
"     147",
"    </a>",
"    ]. A number of patients with severe congenital neutropenia with documented nonsense mutations in the G-CSF receptor have developed AML, supporting the notion that defective signaling function by the aberrant receptor increased the susceptibility to AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/165\">",
"     165",
"    </a>",
"    ]. It is also possible that mutations in the G-CSF receptor predispose to the myelodysplastic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/166\">",
"     166",
"    </a>",
"    ], or to AML via a resistance to apoptosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/167\">",
"     167",
"    </a>",
"    ], allowing more time for a \"second hit\" mutation to occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a substantial number of patients with AML, autonomous growth has been reported to occur as a result of autocrine or paracrine stimulation by a number of factors, including G-CSF, GM-CSF, IL-1b, and IL-6 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/168,169\">",
"     168,169",
"    </a>",
"    ]. Several investigators have noted that the presence of autonomous growth characteristics by AML cells grown in vitro correlates with lower remission rates, and poor survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/170,171\">",
"     170,171",
"    </a>",
"    ]. In a multivariate analysis, expression by leukemic blasts of c-mpl, the receptor for thrombopoietin, correlated with a significantly decreased remission duration in patients with AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/172\">",
"     172",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several explanations for these observations have been proposed. One possibility is that the acquisition of autonomous growth capability allows AML cells to become more aggressive, by making them independent of stromal cell production of essential growth factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/171\">",
"     171",
"    </a>",
"    ]. Others have suggested that autonomous production of growth factors, such as GM-CSF, may reduce the cytotoxicity of chemotherapy agents, by altering intracellular drug metabolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/173\">",
"     173",
"    </a>",
"    ]. Some data suggest that exogenously administered, as well as endogenously produced, hematopoietic growth factors not only stimulate in vitro growth and proliferation, but also inhibit apoptosis of AML cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/174,175\">",
"     174,175",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of in vitro data demonstrating the growth-promoting effects of a variety of cytokines on AML cells, one of the controversies in the treatment of AML has centered on the use of hematopoietic growth factors during or following induction chemotherapy. The desired goal of reducing the toxicity of treatment and the duration of cytopenia with exogenous administration of G-CSF or GM-CSF has been tempered by concerns about their leukemogenic potential. A number of large, randomized clinical trials in AML demonstrate variable clinical efficacy of these growth factors with respect to significant decreases in morbidity and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/176\">",
"     176",
"    </a>",
"    ]. While different conclusions have been reached regarding clinical efficacy, there is consensus about the safety and lack of increased leukemogenic potential of these growth factors when they are administered following induction or consolidation chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=see_link&amp;anchor=H17#H17\">",
"     \"Induction therapy for acute myeloid leukemia in younger adults\", section on 'Growth factors'",
"    </a>",
"    .) Although similar theoretical arguments have been made against the use of growth factors in MDS, they appear to be safe and have a role in the treatment of selected patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H2104237#H2104237\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H727300840\">",
"    <span class=\"h2\">",
"     Exogenous growth factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The therapeutic use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) may result in an increased risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), although the magnitude of the risk appears to be small, and may be dose-related. Initial suggestions of this association came from retrospective analyses and prospective trials mostly involving its use in breast cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/177,178\">",
"     177,178",
"    </a>",
"    ]. A systemic review which included data from 12,104 patients enrolled in randomized controlled clinical trials of cancer chemotherapy with G-CSF reported the following at a median follow-up time of 54 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/179\">",
"     179",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated relative risk for",
"      <span class=\"nowrap\">",
"       AML/MDS",
"      </span>",
"      among patients assigned to receive G-CSF was 1.9 with an absolute increase in risk of 0.4 percent.",
"     </li>",
"     <li>",
"      The estimated relative risk for mortality among patients assigned to receive G-CSF was 0.9 with an estimated absolute decrease of 3.4 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite a suggested increased risk of",
"    <span class=\"nowrap\">",
"     AML/MDS",
"    </span>",
"    among patients receiving G-CSF, patients who received G-CSF demonstrated superior survival. By its nature, this analysis of randomized trials avoids many of the potential biases that confound the earlier retrospective studies; however, this study design cannot differentiate between an increase in rates of",
"    <span class=\"nowrap\">",
"     AML/MDS",
"    </span>",
"    due to the use of G-CSF versus an increase due to the use of dose-intensified systemic chemotherapy. Further studies are required to address this issue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link&amp;anchor=H13#H13\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Therapy-related myeloid neoplasms (t-MDS/t-AML)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     HETEROGENEITY AMONG THE ACUTE MYELOID LEUKEMIAS",
"    </span>",
"    &nbsp;&mdash;&nbsp;AML is classified using the WHO classification system based upon a combination of morphology, immunophenotype, genetics, and clinical features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/180\">",
"     180",
"    </a>",
"    ]. Cases of AML categorized as AML, not otherwise specified (NOS) are further subclassified by morphology that is similar to that used in the previous French, American, and British (FAB) classification system (",
"    <a class=\"graphic graphic_table graphicRef63050 \" href=\"mobipreview.htm?15/48/16141\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/181\">",
"     181",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some FAB AML subgroups correlate with selected pathologic or clinical features, such as [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/181,182\">",
"     181,182",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Megakaryoblastic differentiation with marrow fibrosis &mdash; FAB M7",
"     </li>",
"     <li>",
"      Monocytic differentiation with soft tissue infiltrates &mdash; FAB M4",
"     </li>",
"     <li>",
"      Promyelocytic differentiation with disseminated intravascular coagulation &mdash; FAB M3",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, these features give few insights into the pathobiology of AML. The current WHO classification system incorporates biologic and genetic data, including sophisticated immunophenotyping and the recurring chromosomal abnormalities to make the AML classification scheme more relevant to clinical decision-making. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39720?source=see_link\">",
"     \"Classification of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The investigation of recurring chromosome translocations that result in the creation of novel fusion genes has provided great insight into potential mechanisms of leukemogenesis and has led to important clinical observations (",
"    <a class=\"graphic graphic_table graphicRef51764 \" href=\"mobipreview.htm?19/30/19948\">",
"     table 2",
"    </a>",
"    ). Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The association of FAB-M3 morphology in acute promyelocytic leukemia (APL) with t(15;17)(q22;q11-12) and the PML-RAR fusion gene involving the retinoic acid receptor gene on chromosome 17 (",
"      <a class=\"graphic graphic_picture graphicRef73965 \" href=\"mobipreview.htm?32/41/33424\">",
"       picture 1",
"      </a>",
"      ). This observation provided an explanation for the highly effective treatment of APL with all-trans retinoic acid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=see_link\">",
"       \"Molecular biology of acute promyelocytic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A subgroup of FAB-M2 AML with prominent Auer rods, vacuoles, and myeloblast granules has t(8;21)(q22;q22) and the",
"      <span class=\"nowrap\">",
"       AML1/ETO",
"      </span>",
"      fusion gene (",
"      <a class=\"graphic graphic_picture graphicRef80200 \" href=\"mobipreview.htm?13/33/13842\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A subgroup of FAB-M4 AML with atypical eosinophilic myeloblast granules (M4Eo) has inv(16)(p13q22) and the",
"      <span class=\"nowrap\">",
"       CBFb/MYH11",
"      </span>",
"      fusion gene (",
"      <a class=\"graphic graphic_picture graphicRef71045 \" href=\"mobipreview.htm?18/62/19424\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These three AML variants are associated with a favorable prognosis (",
"    <a class=\"graphic graphic_table graphicRef60295 \" href=\"mobipreview.htm?17/14/17643\">",
"     table 3",
"    </a>",
"    ), with the latter two responding well to consolidation treatment containing high doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/183\">",
"     183",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=see_link&amp;anchor=H8#H8\">",
"     \"Prognosis of acute myeloid leukemia\", section on 'Karyotype'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=see_link\">",
"     \"Cytogenetics in acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The fusion genes created as a result of the latter two translocations contain components of the core-binding factor complex (AML1 and CBFb), which may render these leukemia cells more sensitive to the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/53/20314?source=see_link\">",
"     cytarabine",
"    </a>",
"    . These fusion genes, and other AML-associated chromosomal translocations are reviewed in detail separately. Since specific recurring chromosomal abnormalities have prognostic relevance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/33/35354/abstract/184-186\">",
"     184-186",
"    </a>",
"    ], most AML trials stratify treatment based on the presenting cytogenetic abnormalities and known response to treatment of a specific subtype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=see_link\">",
"       \"Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91823097\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute myeloid leukemia (AML) develops as the consequence of a series of genetic changes in a hematopoietic precursor cell. These changes alter normal hematopoietic growth and differentiation, resulting in an accumulation of large numbers of abnormal, immature myeloid cells in the bone marrow and peripheral blood. These cells are capable of dividing and proliferating, but cannot differentiate into mature hematopoietic cells (ie, neutrophils).",
"     </li>",
"     <li>",
"      AML is a heterogenous group of diseases characterized by clonal cells that exhibit maturation defects that correspond to stages in hematopoietic differentiation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Cell of origin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Heterogeneity among the acute myeloid leukemias'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All leukemias, including AML, appear to be maintained by a pool of self-renewing malignant cells. These leukemic stem cells (also leukemia-initiating cells) may be more immature than the majority of circulating leukemic cells, and are thought to have originated from cells with existing self-renewal capacity or from progenitors that have re-acquired this stem cell-like property. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Leukemic stem cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The \"two-hit hypothesis\" of leukemogenesis implies that AML is the consequence of at least two mutations, one conferring a proliferative advantage (class I mutations) and another impairing hematopoietic differentiation (class II mutations). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Two-hit hypothesis of leukemogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Leukemogenic mutations can occur following chemotherapy, ionizing radiation, chemical exposure, and infection with retroviruses. In addition, certain familial disorders are associated with an increased incidence of AML. (See",
"      <a class=\"local\" href=\"#H91823203\">",
"       'Mechanisms of genetic damage'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/1\">",
"      Godin IE, Garcia-Porrero JA, Coutinho A, et al. Para-aortic splanchnopleura from early mouse embryos contains B1a cell progenitors. Nature 1993; 364:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/2\">",
"      Botnick LE, Hannon EC, Hellman S. Nature of the hemopoietic stem cell compartment and its proliferative potential. Blood Cells 1979; 5:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/3\">",
"      Orkin SH. Transcription factors and hematopoietic development. J Biol Chem 1995; 270:4955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/4\">",
"      Tenen DG, Hromas R, Licht JD, Zhang DE. Transcription factors, normal myeloid development, and leukemia. Blood 1997; 90:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/5\">",
"      Rabbitts TH. Chromosomal translocations in human cancer. Nature 1994; 372:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/6\">",
"      Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: expression in cells restricted to granulocytic and monocytic differentiation. N Engl J Med 1979; 301:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/7\">",
"      Fialkow PJ, Singer JW, Adamson JW, et al. Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood 1981; 57:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/8\">",
"      Ferraris AM, Canepa L, Mareni C, et al. Reexpression of normal stem cells in erythroleukemia during remission. Blood 1983; 62:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/9\">",
"      Fearon ER, Burke PJ, Schiffer CA, et al. Differentiation of leukemia cells to polymorphonuclear leukocytes in patients with acute nonlymphocytic leukemia. N Engl J Med 1986; 315:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/10\">",
"      Kein&auml;nen M, Griffin JD, Bloomfield CD, et al. Clonal chromosomal abnormalities showing multiple-cell-lineage involvement in acute myeloid leukemia. N Engl J Med 1988; 318:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/11\">",
"      van Lom K, Hagemeijer A, Smit EM, L&ouml;wenberg B. In situ hybridization on May-Gr&uuml;nwald Giemsa-stained bone marrow and blood smears of patients with hematologic disorders allows detection of cell-lineage-specific cytogenetic abnormalities. Blood 1993; 82:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/12\">",
"      Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/13\">",
"      Kelly PN, Dakic A, Adams JM, et al. Tumor growth need not be driven by rare cancer stem cells. Science 2007; 317:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/14\">",
"      Turhan AG, Lemoine FM, Debert C, et al. Highly purified primitive hematopoietic stem cells are PML-RARA negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood 1995; 85:2154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/15\">",
"      McCulloch EA. Stem cells in normal and leukemic hemopoiesis (Henry Stratton Lecture, 1982). Blood 1983; 62:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/16\">",
"      Bonnet D. Normal and leukaemic stem cells. Br J Haematol 2005; 130:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/17\">",
"      Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/18\">",
"      Terstappen LW, Huang S, Safford M, et al. Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells. Blood 1991; 77:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/19\">",
"      Stubbs MC, Armstrong SA. Therapeutic implications of leukemia stem cell development. Clin Cancer Res 2007; 13:3439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/20\">",
"      Huang S, Terstappen LW. Formation of haematopoietic microenvironment and haematopoietic stem cells from single human bone marrow stem cells. Nature 1992; 360:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/21\">",
"      Mehrotra B, George TI, Kavanau K, et al. Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood 1995; 86:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/22\">",
"      Haase D, Feuring-Buske M, K&ouml;nemann S, et al. Evidence for malignant transformation in acute myeloid leukemia at the level of early hematopoietic stem cells by cytogenetic analysis of CD34+ subpopulations. Blood 1995; 86:2906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/23\">",
"      Levis M, Murphy KM, Pham R, et al. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells. Blood 2005; 106:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/24\">",
"      Nilsson L, Astrand-Grundstr&ouml;m I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. Blood 2000; 96:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/25\">",
"      Miura I, Kobayashi Y, Takahashi N, et al. Involvement of natural killer cells in patients with myelodysplastic syndrome carrying monosomy 7 revealed by the application of fluorescence in situ hybridization to cells collected by means of fluorescence-activated cell sorting. Br J Haematol 2000; 110:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/26\">",
"      Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/27\">",
"      Sutherland H, Blair A, Vercauteren S, Zapf R. Detection and clinical significance of human acute myeloid leukaemia progenitors capable of long-term proliferation in vitro. Br J Haematol 2001; 114:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/28\">",
"      Bhatia M, Wang JC, Kapp U, et al. Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci U S A 1997; 94:5320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/29\">",
"      Cox CV, Evely RS, Oakhill A, et al. Characterization of acute lymphoblastic leukemia progenitor cells. Blood 2004; 104:2919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/30\">",
"      Mulloy JC, Cammenga J, MacKenzie KL, et al. The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/31\">",
"      Tonks A, Pearn L, Tonks AJ, et al. The AML1-ETO fusion gene promotes extensive self-renewal of human primary erythroid cells. Blood 2003; 101:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/32\">",
"      Fialkow PJ, Singer JW, Raskind WH, et al. Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med 1987; 317:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/33\">",
"      Konopleva M, Konoplev S, Hu W, et al. Stromal cells prevent apoptosis of AML cells by up-regulation of anti-apoptotic proteins. Leukemia 2002; 16:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/34\">",
"      Colmone A, Amorim M, Pontier AL, et al. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 2008; 322:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/35\">",
"      Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. Blood 2009; 114:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/36\">",
"      Ustun C, Miller JS, Munn DH, et al. Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood 2011; 118:5084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/37\">",
"      Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113:6215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/38\">",
"      Nervi B, Ramirez P, Rettig MP, et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113:6206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/39\">",
"      Jacobs A. Leukaemia Research Fund annual guest lecture 1990. Genetics lesions in preleukaemia. Leukemia 1991; 5:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/40\">",
"      Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/41\">",
"      Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/42\">",
"      Radtke I, Mullighan CG, Ishii M, et al. Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A 2009; 106:12944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/43\">",
"      Walter MJ, Payton JE, Ries RE, et al. Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 2009; 106:12950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/44\">",
"      Reilly JT. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis? Br J Haematol 2005; 128:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/45\">",
"      Bachas C, Schuurhuis GJ, Hollink IH, et al. High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. Blood 2010; 116:2752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/46\">",
"      Kurzrock R, Gutterman JU, Talpaz M. The molecular genetics of Philadelphia chromosome-positive leukemias. N Engl J Med 1988; 319:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/47\">",
"      Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/48\">",
"      Rubin CM, Larson RA, Anastasi J, et al. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 1990; 76:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/49\">",
"      Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A 1991; 88:6293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/50\">",
"      Fialkow PJ, Janssen JW, Bartram CR. Clonal remissions in acute nonlymphocytic leukemia: evidence for a multistep pathogenesis of the malignancy. Blood 1991; 77:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/51\">",
"      Bartram CR, Ludwig WD, Hiddemann W, et al. Acute myeloid leukemia: analysis of ras gene mutations and clonality defined by polymorphic X-linked loci. Leukemia 1989; 3:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/52\">",
"      Busque L, Gilliland DG. Clonal evolution in acute myeloid leukemia. Blood 1993; 82:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/53\">",
"      Gale RE, Mein CA, Linch DC. Quantification of X-chromosome inactivation patterns in haematological samples using the DNA PCR-based HUMARA assay. Leukemia 1996; 10:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/54\">",
"      Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age. Blood 1996; 88:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/55\">",
"      Jowitt SN, Liu Yin JA, Saunders MJ, Lucas GS. Clonal remissions in acute myeloid leukaemia are commonly associated with features of trilineage myelodysplasia during remission. Br J Haematol 1993; 85:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/56\">",
"      Jinnai I, Nagai K, Yoshida S, et al. Incidence and characteristics of clonal hematopoiesis in remission of acute myeloid leukemia in relation to morphological dysplasia. Leukemia 1995; 9:1756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/57\">",
"      Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012; 481:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/58\">",
"      Parkin B, Ouillette P, Li Y, et al. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Blood 2013; 121:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/59\">",
"      Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/60\">",
"      Yuan Y, Zhou L, Miyamoto T, et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci U S A 2001; 98:10398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/61\">",
"      Nishida S, Hosen N, Shirakata T, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood 2006; 107:3303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/62\">",
"      Nucifora G, Larson RA, Rowley JD. Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. Blood 1993; 82:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/63\">",
"      Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88:2183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/64\">",
"      Wiemels JL, Xiao Z, Buffler PA, et al. In utero origin of t(8;21) AML1-ETO translocations in childhood acute myeloid leukemia. Blood 2002; 99:3801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/65\">",
"      Hjalgrim LL, Madsen HO, Melbye M, et al. Presence of clone-specific markers at birth in children with acute lymphoblastic leukaemia. Br J Cancer 2002; 87:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/66\">",
"      Kuchenbauer F, Schnittger S, Look T, et al. Identification of additional cytogenetic and molecular genetic abnormalities in acute myeloid leukaemia with t(8;21)/AML1-ETO. Br J Haematol 2006; 134:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/67\">",
"      Krejci O, Wunderlich M, Geiger H, et al. p53 signaling in response to increased DNA damage sensitizes AML1-ETO cells to stress-induced death. Blood 2008; 111:2190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/68\">",
"      Yan M, Kanbe E, Peterson LF, et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/69\">",
"      Pagana L, Pulsoni A, Tosti ME, et al. Clinical and biological features of acute myeloid leukaemia occurring as second malignancy: GIMEMA archive of adult acute leukaemia. Br J Haematol 2001; 112:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/70\">",
"      Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992; 19:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/71\">",
"      DeCillis A, Anderson S, Wickerham DL, et al. Acute myeloid leukemia in NSABP-25. Proc ASCO 1995; 14:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/72\">",
"      Miller JS, Arthur DC, Litz CE, et al. Myelodysplastic syndrome after autologous bone marrow transplantation: an additional late complication of curative cancer therapy. Blood 1994; 83:3780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/73\">",
"      Stone RM, Neuberg D, Soiffer R, et al. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1994; 12:2535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/74\">",
"      Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol 1994; 12:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/75\">",
"      Seedhouse C, Russell N. Advances in the understanding of susceptibility to treatment-related acute myeloid leukaemia. Br J Haematol 2007; 137:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/76\">",
"      Guillem V, Tormo M. Influence of DNA damage and repair upon the risk of treatment related leukemia. Leuk Lymphoma 2008; 49:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/77\">",
"      Le Beau MM, Albain KS, Larson RA, et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986; 4:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/78\">",
"      Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/79\">",
"      Albain KS, Le Beau MM, Ullirsch R, Schumacher H. Implication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation. Genes Chromosomes Cancer 1990; 2:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/80\">",
"      Pedersen-Bjergaard J, Philip P. Two different classes of therapy-related and de-novo acute myeloid leukemia? Cancer Genet Cytogenet 1991; 55:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/81\">",
"      Super HJ, McCabe NR, Thirman MJ, et al. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II. Blood 1993; 82:3705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/82\">",
"      Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009; 27:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/83\">",
"      Calado RT, Regal JA, Hills M, et al. Constitutional hypomorphic telomerase mutations in patients with acute myeloid leukemia. Proc Natl Acad Sci U S A 2009; 106:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/84\">",
"      Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci U S A 2001; 98:11592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/85\">",
"      Bolufer P, Collado M, Barragan E, et al. Profile of polymorphisms of drug-metabolising enzymes and the risk of therapy-related leukaemia. Br J Haematol 2007; 136:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/86\">",
"      Chen H, Sandler DP, Taylor JA, et al. Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect. Lancet 1996; 347:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/87\">",
"      Dahabreh IJ, Giannouli S, Gota V, Voulgarelis M. GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis. Int J Cancer 2010; 126:1716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/88\">",
"      Little JB. Cellular, molecular, and carcinogenic effects of radiation. Hematol Oncol Clin North Am 1993; 7:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/89\">",
"      Ishimaru T, Otake M, Ischimaru M. Dose-response relationship of neutrons and gamma rays to leukemia incidence among atomic bomb survivors in Hiroshima and Nagasaki by type of leukemia, 1950--1971. Radiat Res 1979; 77:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/90\">",
"      Bizzozero OJ Jr, Johnson KG, Ciocco A. Radiation-related leukemia in Hiroshima and Nagasaki, 1946-1964. I. Distribution, incidence and appearance time. N Engl J Med 1966; 274:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/91\">",
"      Yoshinaga S, Mabuchi K, Sigurdson AJ, et al. Cancer risks among radiologists and radiologic technologists: review of epidemiologic studies. Radiology 2004; 233:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/92\">",
"      Shuryak I, Sachs RK, Hlatky L, et al. Radiation-induced leukemia at doses relevant to radiation therapy: modeling mechanisms and estimating risks. J Natl Cancer Inst 2006; 98:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/93\">",
"      Kaldor JM, Day NE, Band P, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987; 39:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/94\">",
"      Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol Oncol Clin North Am 1996; 10:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/95\">",
"      Valagussa P, Santoro A, Fossati-Bellani F, et al. Second acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 1986; 4:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/96\">",
"      Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987; 316:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/97\">",
"      van Leeuwen FE, Somers R, Taal BG, et al. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol 1989; 7:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/98\">",
"      Andrieu JM, Ifrah N, Payen C, et al. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. J Clin Oncol 1990; 8:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/99\">",
"      Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012; 380:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/100\">",
"      Brandt L, Nilsson PG, Mitelman F. Occupational exposure to petroleum products in men with acute non-lymphocytic leukaemia. Br Med J 1978; 1:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/101\">",
"      Austin H, Delzell E, Cole P. Benzene and leukemia. A review of the literature and a risk assessment. Am J Epidemiol 1988; 127:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/102\">",
"      Schnatter AR, Glass DC, Tang G, et al. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst 2012; 104:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/103\">",
"      Irons RD, Gross SA, Le A, et al. Integrating WHO 2001-2008 criteria for the diagnosis of Myelodysplastic Syndrome (MDS): a case-case analysis of benzene exposure. Chem Biol Interact 2010; 184:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/104\">",
"      Hauptmann M, Stewart PA, Lubin JH, et al. Mortality from lymphohematopoietic malignancies and brain cancer among embalmers exposed to formaldehyde. J Natl Cancer Inst 2009; 101:1696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/105\">",
"      Beane Freeman LE, Blair A, Lubin JH, et al. Mortality from lymphohematopoietic malignancies among workers in formaldehyde industries: the National Cancer Institute Cohort. J Natl Cancer Inst 2009; 101:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/106\">",
"      Bachand AM, Mundt KA, Mundt DJ, Montgomery RR. Epidemiological studies of formaldehyde exposure and risk of leukemia and nasopharyngeal cancer: a meta-analysis. Crit Rev Toxicol 2010; 40:85.",
"     </a>",
"    </li>",
"    <li>",
"     Linet MS. The Leukemias: Epidemiologic Aspects, Oxford University Press, New York 1985.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/108\">",
"      Taylor JA, Sandler DP, Bloomfield CD, et al. ras oncogene activation and occupational exposures in acute myeloid leukemia. J Natl Cancer Inst 1992; 84:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/109\">",
"      Sandler DP, Shore DL, Anderson JR, et al. Cigarette smoking and risk of acute leukemia: associations with morphology and cytogenetic abnormalities in bone marrow. J Natl Cancer Inst 1993; 85:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/110\">",
"      Smith MT, Wang Y, Kane E, et al. Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 2001; 97:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/111\">",
"      Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C--&gt;T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999; 94:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/112\">",
"      Rothman N, Smith MT, Hayes RB, et al. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C--&gt;T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res 1997; 57:2839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/113\">",
"      Lebailly P, Willett EV, Moorman AV, et al. Genetic polymorphisms in microsomal epoxide hydrolase and susceptibility to adult acute myeloid leukaemia with defined cytogenetic abnormalities. Br J Haematol 2002; 116:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/114\">",
"      Moorman AV, Roman E, Cartwright RA, Morgan GJ. Smoking and the risk of acute myeloid leukaemia in cytogenetic subgroups. Br J Cancer 2002; 86:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/115\">",
"      Kristinsson SY, Bj&ouml;rkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011; 29:2897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/116\">",
"      Ross JA, Blair CK, Cerhan JR, et al. Nonsteroidal anti-inflammatory drug and acetaminophen use and risk of adult myeloid leukemia. Cancer Epidemiol Biomarkers Prev 2011; 20:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/117\">",
"      Walter RB, Milano F, Brasky TM, White E. Long-term use of acetaminophen, aspirin, and other nonsteroidal anti-inflammatory drugs and risk of hematologic malignancies: results from the prospective Vitamins and Lifestyle (VITAL) study. J Clin Oncol 2011; 29:2424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/118\">",
"      Poiesz BJ, Ruscetti FW, Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 1980; 77:7415.",
"     </a>",
"    </li>",
"    <li>",
"     Gallo R, Ruscetti F, Collins S, et al. Human myeloid leukemia cells: Studies on oncornaviral related information and in vitro growth and differentiation. In: Hematopoietic Cell Differentiation, Golde D, Cline M, Metcalf D, et al. (Eds), Academic Press, Orlando 1979. Vol 10, p.335.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/120\">",
"      Goldin LR, Kristinsson SY, Liang XS, et al. Familial aggregation of acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol 2012; 30:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/121\">",
"      Horwitz M. The genetics of familial leukemia. Leukemia 1997; 11:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/122\">",
"      Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia--a review. Br J Haematol 2008; 140:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/123\">",
"      Secker-Walker LM, Fitchett M. Constitutional and acquired trisomy 8. Leuk Res 1995; 19:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/124\">",
"      Nucifora G, Rowley JD. AML1 and the 8;21 and 3;21 translocations in acute and chronic myeloid leukemia. Blood 1995; 86:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/125\">",
"      Borrow J, Stanton VP Jr, Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/126\">",
"      Evans DI, Steward JK. Down's syndrome and leukaemia. Lancet 1972; 2:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/127\">",
"      Rosner F, Lee SL. Down's syndrome and acute leukemia: myeloblastic or lymphoblastic? Report of forty-three cases and review of the literature. Am J Med 1972; 53:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/128\">",
"      Seibel NL, Sommer A, Miser J. Transient neonatal leukemoid reactions in mosaic trisomy 21. J Pediatr 1984; 104:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/129\">",
"      Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 2002; 32:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/130\">",
"      Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 2003; 102:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/131\">",
"      Xu G, Nagano M, Kanezaki R, et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 2003; 102:2960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/132\">",
"      Shimada A, Xu G, Toki T, et al. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood 2004; 103:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/133\">",
"      Gurbuxani S, Vyas P, Crispino JD. Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 2004; 103:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/134\">",
"      Li Z, Godinho FJ, Klusmann JH, et al. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 2005; 37:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/135\">",
"      Shimizu R, Engel JD, Yamamoto M. GATA1-related leukaemias. Nat Rev Cancer 2008; 8:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/136\">",
"      Chou ST, Opalinska JB, Yao Y, et al. Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood 2008; 112:4503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/137\">",
"      Tunstall-Pedoe O, Roy A, Karadimitris A, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood 2008; 112:4507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/138\">",
"      Korenberg JR, Chen XN, Schipper R, et al. Down syndrome phenotypes: the consequences of chromosomal imbalance. Proc Natl Acad Sci U S A 1994; 91:4997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/139\">",
"      German J, Bloom D, Passarge E, et al. Bloom's syndrome. VI. The disorder in Israel and an estimation of the gene frequency in the Ashkenazim. Am J Hum Genet 1977; 29:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/140\">",
"      Ellis NA, Groden J, Ye TZ, et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell 1995; 83:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/141\">",
"      Butturini A, Gale RP, Verlander PC, et al. Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 1994; 84:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/142\">",
"      Stiller CA, Chessells JM, Fitchett M. Neurofibromatosis and childhood leukaemia/lymphoma: a population-based UKCCSG study. Br J Cancer 1994; 70:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/143\">",
"      Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med 1994; 330:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/144\">",
"      Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 2011; 305:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/145\">",
"      Filipovich AH, Heinitz KJ, Robison LL, Frizzera G. The Immunodeficiency Cancer Registry. A research resource. Am J Pediatr Hematol Oncol 1987; 9:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/146\">",
"      Gilman PA, Jackson DP, Guild HG. Congenital agranulocytosis: prolonged survival and terminal acute leukemia. Blood 1970; 36:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/147\">",
"      Dong F, Brynes RK, Tidow N, et al. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med 1995; 333:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/148\">",
"      Beekman R, Valkhof MG, Sanders MA, et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood 2012; 119:5071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/149\">",
"      Halperin DS, Freedman MH. Diamond-blackfan anemia: etiology, pathophysiology, and treatment. Am J Pediatr Hematol Oncol 1989; 11:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/150\">",
"      Ostergaard P, Simpson MA, Connell FC, et al. Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome). Nat Genet 2011; 43:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/151\">",
"      Hsu AP, Sampaio EP, Khan J, et al. Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. Blood 2011; 118:2653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/152\">",
"      Dickinson RE, Griffin H, Bigley V, et al. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 2011; 118:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/153\">",
"      Hahn CN, Chong CE, Carmichael CL, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet 2011; 43:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/154\">",
"      Shannon KM, Turhan AG, Rogers PC, Kan YW. Evidence implicating heterozygous deletion of chromosome 7 in the pathogenesis of familial leukemia associated with monosomy 7. Genomics 1992; 14:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/155\">",
"      Gunz FW, Gunz JP, Vincent PC, et al. Thirteen cases of leukemia in a family. J Natl Cancer Inst 1978; 60:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/156\">",
"      Nissenblatt MJ, Bias W, Borgaonkar D, et al. Familial erythroleukemia: four cases of the Diguglielmo syndrome in close relatives. Johns Hopkins Med J 1982; 150:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/157\">",
"      Horwitz M, Sabath DE, Smithson WA, Radich J. A family inheriting different subtypes of acute myelogenous leukemia. Am J Hematol 1996; 52:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/158\">",
"      Olopade OI, Roulston D, Baker T, et al. Familial myeloid leukemia associated with loss of the long arm of chromosome 5. Leukemia 1996; 10:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/159\">",
"      Miyauchi J, Kelleher CA, Yang YC, et al. The effects of three recombinant growth factors, IL-3, GM-CSF, and G-CSF, on the blast cells of acute myeloblastic leukemia maintained in short-term suspension culture. Blood 1987; 70:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/160\">",
"      Delwel R, Salem M, Pellens C, et al. Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. Blood 1988; 72:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/161\">",
"      Vellenga E, Ostapovicz D, O'Rourke B, Griffin JD. Effects of recombinant IL-3, GM-CSF, and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1987; 1:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/162\">",
"      Ikeda H, Kanakura Y, Tamaki T, et al. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood 1991; 78:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/163\">",
"      Piacibello W, Fubini L, Sanavio F, et al. Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors. Blood 1995; 86:4105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/164\">",
"      Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res 2009; 15:4263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/165\">",
"      Dong F, Dale DC, Bonilla MA, et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia 1997; 11:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/166\">",
"      W&ouml;lfler A, Erkeland SJ, Bodner C, et al. A functional single-nucleotide polymorphism of the G-CSF receptor gene predisposes individuals to high-risk myelodysplastic syndrome. Blood 2005; 105:3731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/167\">",
"      Hunter MG, Avalos BR. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival. Blood 2000; 95:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/168\">",
"      Young DC, Griffin JD. Autocrine secretion of GM-CSF in acute myeloblastic leukemia. Blood 1986; 68:1178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/169\">",
"      Cozzolino F, Rubartelli A, Aldinucci D, et al. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proc Natl Acad Sci U S A 1989; 86:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/170\">",
"      L&ouml;wenberg B, van Putten WL, Touw IP, et al. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993; 328:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/171\">",
"      Hunter AE, Rogers SY, Roberts IA, et al. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood 1993; 82:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/172\">",
"      Wetzler M, Baer MR, Bernstein SH, et al. Expression of c-mpl mRNA, the receptor for thrombopoietin, in acute myeloid leukemia blasts identifies a group of patients with poor response to intensive chemotherapy. J Clin Oncol 1997; 15:2262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/173\">",
"      Koistinen P, Wang C, Curtis JE, McCulloch EA. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity. Leukemia 1991; 5:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/174\">",
"      Lotem J, Sachs L. Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor beta 1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 1992; 80:1750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/175\">",
"      Lisovsky M, Estrov Z, Zhang X, et al. Flt3 ligand stimulates proliferation and inhibits apoptosis of acute myeloid leukemia cells: regulation of Bcl-2 and Bax. Blood 1996; 88:3987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/176\">",
"      Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996; 14:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/177\">",
"      Hershman D, Neugut AI, Jacobson JS, et al. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy. J Natl Cancer Inst 2007; 99:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/178\">",
"      Relling MV, Boyett JM, Blanco JG, et al. Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment. Blood 2003; 101:3862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/179\">",
"      Lyman GH, Dale DC, Wolff DA, et al. Acute myeloid leukemia or myelodysplastic syndrome in randomized controlled clinical trials of cancer chemotherapy with granulocyte colony-stimulating factor: a systematic review. J Clin Oncol 2010; 28:2914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/180\">",
"      Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/181\">",
"      Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/182\">",
"      Rowley JD, Golomb HM, Dougherty C. 15/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia. Lancet 1977; 1:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/183\">",
"      Bloomfield CD, Lawrence D, Arthur DC, et al. Curative impact of intensification with high-dose cytarabine (HiDAC) in acute myeloid leukemia (AML) varies by cytogenetic group. Blood 1994; 84:111a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/184\">",
"      Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/185\">",
"      Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Cooperative Study Group. Cancer Genet Cytogenet 1988; 32:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/33/35354/abstract/186\">",
"      Sakurai M, Swansbury GJ. Fourth International Workshop on Chromosomes in Leukemia 1982: Overview of association between chromosome pattern and cell morphology, age, sex, and race. Cancer Genet Cytogenet 1984; 11:265.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4493 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-83254367CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35354=[""].join("\n");
var outline_f34_33_35354=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H91823097\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H91823159\">",
"      Normal counterpart",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clonality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Leukemic stem cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2186046\">",
"      Stage of leukemic transformation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Transformation at one of several developmental stages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Transformation within primitive multipotent cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Protection by stromal cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TWO-HIT HYPOTHESIS OF LEUKEMOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91823203\">",
"      MECHANISMS OF GENETIC DAMAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy-induced AML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Chemical exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Familial leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Familial disorders leading to AML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ROLE OF HEMATOPOIETIC GROWTH FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Mutations in the G-CSF receptor gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H727300840\">",
"      Exogenous growth factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HETEROGENEITY AMONG THE ACUTE MYELOID LEUKEMIAS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H91823097\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4493\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4493|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?34/9/34968\" title=\"algorithm 1\">",
"      Hematopoiesis regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4493|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/3/11327\" title=\"figure 1\">",
"      Hemat transcription factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/33/1567\" title=\"figure 2\">",
"      Stem cell properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/48/37639\" title=\"figure 3\">",
"      Tumor evolution in AML",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4493|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/41/33424\" title=\"picture 1\">",
"      AML FAB M3 Faggot cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/33/13842\" title=\"picture 2\">",
"      AML FAB M2 and t8 21",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?18/62/19424\" title=\"picture 3\">",
"      AML FAB M4EO",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4493|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/48/16141\" title=\"table 1\">",
"      FAB classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/30/19948\" title=\"table 2\">",
"      Cytogenetics in AML subsets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/14/17643\" title=\"table 3\">",
"      Prognostic factors AML",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/33/40474?source=related_link\">",
"      Cellular and molecular biology of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/50/39720?source=related_link\">",
"      Classification of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/15/26874?source=related_link\">",
"      Clinical features and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/45/9945?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/55/28536?source=related_link\">",
"      Cytogenetic and molecular genetic diagnostic tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/21/6489?source=related_link\">",
"      General aspects of cytogenetic analysis in hematologic malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30362?source=related_link\">",
"      Induction therapy for acute myeloid leukemia in younger adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/6/12391?source=related_link\">",
"      Li-Fraumeni syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/39/28280?source=related_link\">",
"      Malignancy after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/12/4297?source=related_link\">",
"      Mendelian susceptibility to mycobacterial diseases (MSMD)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/35/17976?source=related_link\">",
"      Molecular biology of acute promyelocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/17/25882?source=related_link\">",
"      Molecular genetics of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/34/25129?source=related_link\">",
"      Overview of hematopoiesis and stem cell function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/30/34275?source=related_link\">",
"      Patient information: Acute myeloid leukemia (AML) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/0/8202?source=related_link\">",
"      Patterns of relapse and long-term complications of therapy in breast cancer survivors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/55/36730?source=related_link\">",
"      Prognosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/26/35242?source=related_link\">",
"      Second malignancies after treatment of classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_33_35355="Down syndrome screening terms";
var content_f34_33_35355=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Glossary of Down syndrome screening terms",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Nuchal translucency (NT) measurement",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The width of the translucent space at the back of the fetal neck determined by ultrasound.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Combined test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       First trimester test based on sonographic and maternal serum measurements: NT, &beta;-human chorionic gonadotropin (&beta;-hCG: free or total), and pregnancy-associated plasma protein-A (PAPP-A), together with maternal age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Triple test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Second trimester test based on measurement of maternal serum alpha-fetoprotein (AFP), unconjugated estriol (uE",
"       <sub>",
"        3",
"       </sub>",
"       ), and &beta;-hCG (free or total), together with maternal age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Quadruple test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Second trimester test based on measurement of maternal serum AFP, uE",
"       <sub>",
"        3",
"       </sub>",
"       , &beta;-hCG, and inhibin-A, together with maternal age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Integrated test (full)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       The integration of measurements performed during the first and second trimesters into a single test result. Typically, the integrated test refers to the integration of NT and PAPP-A measurements in the first trimester with the quadruple test markers in the second trimester, together with maternal age.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Serum integrated test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A variation of the integrated test using maternal serum markers only: PAPP-A in the first trimester and the quadruple markers in the second trimester, together with maternal age.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35355=[""].join("\n");
var outline_f34_33_35355=null;
var title_f34_33_35356="Drugs assoc w SJS TEN";
var content_f34_33_35356=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drugs associated with Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            More Frequently",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Allopurinol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amithiozone (anti-tuberculosis agent)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Amoxicillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ampicillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barbiturates",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Carbamazepine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Hydantoins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lamotrigine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nevirapine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Phenylbutazone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Piroxicam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfadiazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfadoxine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulfasalazine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Trimethoprim-sulfamethoxazole (cotrimoxazole)",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Less Frequently",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cephalosporin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diclofenac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethambutol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fenbufen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoroquinolone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ibuprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ketoprofen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Naproxen",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pantoprazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Rifampin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sertraline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Sulindac",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tenoxicam",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Thiabendazole",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tiaprofenic acid",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Tramadol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vancomycin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Drugs are listed in alphabetical order within each column.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted and modified from: Roujeau, JC, Stern, RS, N Engl J Med 1994; 331:1272.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35356=[""].join("\n");
var outline_f34_33_35356=null;
var title_f34_33_35357="Asthma trigger questions";
var content_f34_33_35357=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment questions* for environmental and other factors that can make asthma worse",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Inhalant allergens",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Does the patient have symptoms year round? (If yes, ask the following questions. If no, see next set of questions) .",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Does the patient keep pets indoors? What type?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Does the patient have moisture or dampness in any room of his or her home (eg, basement)? (Suggests house-dust mites, molds).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Does the patient have mold visible in any part of his or her home? (Suggests molds).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Has the patient seen cockroaches or rodents in his or her home in the past month? (Suggests significant exposure).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Assume exposure to house dust mites unless patient lives in a semiarid region. However, if a patient living in a semiarid region uses a swamp cooler, exposure to house dust mites must still be assumed.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Do symptoms get worse at certain times of the year? (If yes, ask when symptoms occur).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Early spring? (Trees)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Late spring? (Grasses)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Late summer to autumn? (Weeds)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Summer and fall? (Alternaria, Cladosporium, mites)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cold months in temperate climates? (Animal dander)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Tobacco smoke",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient smoke?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does anyone smoke at home or work?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does anyone smoke at the child's daycare?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Indoor/outdoor pollutants and irritants",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Is a wood-burning stove or fireplace used in the patient's home?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Are there unvented stoves or heaters in the patient's home?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient have contact with other smells or fumes from perfumes, cleaning agents, or sprays?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Have there been recent renovations or painting in the home?",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Workplace exposures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient cough or wheeze during the week, but not on weekends when away from work?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Do the patient's eyes and nasal passages get irritated soon after arriving at work?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Do coworkers have similar symptoms?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            What substances are used in the patient's worksite? (Assess for sensitizers).",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Rhinitis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient have constant or seasonal nasal congestion, runny nose, and/or postnasal drip?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Gastroesophageal reflux disease (GERD)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient have heartburn?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does food sometimes come up into the patient's throat?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Has the patient had coughing, wheezing, or shortness of breath at night in the past&nbsp;four weeks?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the infant vomit, followed by cough, or have wheezy cough at night? Are symptoms worse after feeding?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Sulfite sensitivity",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient have wheezing, coughing, or shortness of breath after eating shrimp, dried fruit, or processed potatoes or after drinking beer or wine?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Medication sensitivities and contraindications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            What medications does the patient use now (prescription and nonprescription)?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient use eyedrops? What type?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient use any medications that contain beta-blockers?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Does the patient ever take aspirin or other nonsteroidal antiinflammatory drugs?",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Has the patient ever had symptoms of asthma after taking any of these medications?",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * These questions are examples and do not represent a standardized assessment or diagnostic instrument. The validity and reliability of these questions have not been assessed.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35357=[""].join("\n");
var outline_f34_33_35357=null;
var title_f34_33_35358="Pseudopolyps IBD Endosc";
var content_f34_33_35358=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76729&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Colonic pseudopolyps in inflammatory bowel disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 210px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy of pseudopolyps; these lesions are not specific to ulcerative colitis, although they are more common in this disorder than in Crohn's disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of James B McGee, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35358=[""].join("\n");
var outline_f34_33_35358=null;
var title_f34_33_35359="Saber sheath gross";
var content_f34_33_35359=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61119&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Saber sheath tracheal deformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Surgical specimens demonstrate a normal trachea (left) and a saber-sheath trachea (right) in cross-section.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Luis LG Fajardo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_33_35359=[""].join("\n");
var outline_f34_33_35359=null;
